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The ability of antimicrobials to prevent and treat infections caused by a range of microorganisms, 
including bacteria, is threatened by the emergence of drug-resistant microorganisms that is 
associated with high mortality rates globally. Novel nano-drug delivery systems, including lipid-
based drug delivery systems, represent an alternative therapeutic approach to combat antimicrobial 
resistance resulting from conventional dosage forms. Since bacteria are associated with an acidic 
environment and the bacterial envelope is made up of lipid bilayer, the application of pH-
responsive lipid-based nanomaterials for targeted antibiotic delivery is recognized as an active area 
of research. The aim of this study was to design and synthesize fatty acid-based pH-responsive 
lipids ( FAL, OLA-SPDA and DMGSAD-lipid) and explore their potential for the preparation of 
pH-responsive nano-based vancomycin (VCM) delivery systems to treat infectious diseases 
caused by methicillin-resistant Staphylococcus aureus (MRSA) infections. All the lipids were 
synthesized, and its structures were confirmed by FTIR, 1H NMR, 13C NMR and HR-MS. The 
nontoxic nature of the synthesized lipids was demonstrated by cell viability results above 75% on 
all tested mammalian cell lines using the MTT assay. After the synthesis and characterization, the 
novel fatty acid-based lipids were employed to formulate three pH-responsive lipid-based nano-
drug delivery systems (liposomes, micelles and lipid polymer hybrid nanoparticles) for efficient 
and targeted delivery of VCM for the treatment S. aureus and MRSA infections. These systems 
were characterised for their physicochemical properties (Zetasizer), in vitro drug release (dialysis 
bag), morphology (HR-TEM), in vitro cell viability studies (flow cytometry), in vitro cytotoxicity 
(MTT assay), in vitro antibacterial activity (broth dilution method) and in vivo antibacterial activity 
(mice skin infection model). 
The four formulated pH-responsive liposomes had a mean size ranging from 86.28 ± 11.76 to 282 
± 31.58 nm, with their respective PDI’s ranging from 0.151 ± 0.016 to 0.204 ± 0.014 at pH 7.4 
and 6.0 respectively. The ZP values were negative at physiological pH (7.4) and shifted towards 
positivity with a decrease in pH (6.0). The encapsulation efficiency (%EE) and loading capacity 
were in the range of 29.86 ± 4.5% and 44.27 ± 9.2%, The drug release profiles of all formulations 
at both pH 7.4 and 6.0 were sustained throughout the studied period of 72 h. Enhanced in vitro 
antibacterial activity at pH 6.0 was observed for the DOAPA-VAN-Liposome and DLAPA-VAN-
Liposome formulations. Flow cytometry studies indicated a high killing rate of MRSA cells using 
DOAPA-VAN-Lipo (71.98%) and DLAPA-VAN-Lipo (73.32%) using the MIC of 1.59 µg/ml. In 
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vivo studies showed reduced MRSA recovery from mice treated with liposome formulations 
(DOAPA-VAN-Lipo and DLAPA-VAN-Lipo) by 4- and 2-folds compared to bare VCM-treated 
mice respectively.  
The pH-responsive oleic acid-based dendritic lipid amphiphile self-assembled into stable micelles 
with particle size, PDI, ZP and %EE of 84.16 ± 0.184 nm, 0.199 ± 0.011 and -42.6 ± 1.98 mV and 
78.80 ± 3.26%, respectively. The micelles demonstrated pH-responsiveness with an increase in 
particle size to 141.1 ± 0.070 nm at pH 6.0. The drug release profiles of formulations at both pH 
7.4 and 6.0 were sustained throughout the studied period of 72 h. The in vitro antibacterial efficacy 
of VCM-OLA-SPDA-micelle against MRSA was 8-fold better when compared to bare VCM, and 
the formulation was 4-fold better at pH 6.0 when compared to the formulation’s MIC at pH 7.4. 
The MRSA viability assay showed that the micelles had a high percentage killing of 93.39% when 
compared to bare VCM (58.21%) at the same MIC (0.98 µg/ml). The in vivo mice skin infection 
model also demonstrated an enhanced antibacterial effect, showing 8-fold reduction in MRSA 
burden on skin treated with VCM-OLA-SPDA-micelles when compared with the skin sample 
treated with bare VCM. 
The optimized pH responsive lipid polymer hybrid nanoparticles (LPHNPs) formulations, 
RH40_VCM_LPHNPs had a particle size, PDI and ZP of 64.05 ± 0.64 nm, 0.277 ± 0.057 and 0.55 
± 0.14Vm, respectively, whereas SH15_VCM_LPHNPs displayed a size of 73.41 ± 0.468 nm, PDI 
of 0.487 ± 0.001 and ZP of -1.55 ± 0.184 Vm at pH 7.4. There was a significant change in particle 
size and ZP to 113.6 ± 0.20 nm and 9.44 ± 0.33 Vm for RH40_VCM_LPHNPs, respectively, 
whereas for SH15_VCM_LPHNPs, there was no change in is size but a significant change in 
surface charge switch to 9.83 ± 0.52 Vm at pH 6.0. The drug release profiles of formulations at 
both pH 7.4 and 6.0 were sustained throughout the studied period of 72 h. The VCM release profile, 
together with release kinetic study on LPHNPs, demonstrated the influence of pH on the high rate 
of VCM release at pH 6.0 as compared to pH 7.4. The LPHNPs a had better antibacterial activity 
against S. aureus and MRSA at both pH conditions when compared to bare VCM. Furthermore, 
the MIC of LPHNPs against MRSA was better by 8-fold at pH 6.0 than at 7.4.  
In summary, synthesized novel lipid materials showed superior biosafety profiles and potential in 
the development of lipid-based pH-responsive nanoantibiotic delivery systems against bacterial 
infections and other disease types characterized by low pH. The data from this study has resulted 
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1.1 Introduction  
This chapter provides a brief background to the study and highlights the status of infectious 
diseases, limitations associated with antibiotic therapy and the emergence of antimicrobial 
resistance. Furthermore, it provides details on alternative strategic solutions to enhance antibiotic 
therapy, which resulted in the proposed aims and objectives of the study. It also highlights the 
novelty and significance of the study. 
 
1.2 Background to the study  
For several decades in the history of infectious diseases, antimicrobial resistance (AMR) caused 
by pathogenic microorganisms such as bacteria, viruses, fungi and parasites has been the greatest 
threat to human health globally1. Since the late 1960s, infectious diseases were thought to be under 
control and some were almost completely eradicated2. Unfortunately, resistance to various 
antimicrobials gave rise to new threats, which continue to endanger the existence of the human 
population3. Antimicrobial resistance is a consequence of the evolutionary response of microbes 
and this process attenuates the impact of various treatment options such as antibacterial, 
antiparasitic, antiviral and antifungal drugs against the array of infections, thus, rendering them 
ineffective4. Therefore, AMR has been responsible for uncontainable infections and costly 
treatment associated with prolonged illnesses in infected patients and a subsequent increase in 
mortality rate1. Despite the scientific advancement and availability of new antimicrobial agents, 
the global rate of infection occurrence and the high number of deaths per year have been 
highlighted as the major threat on world economies and to the public healthcare system5, 6.  
 
Compared to any cause of death throughout human history, infectious diseases have been and 
continue to be the leading cause of death in both developing and developed countries as we 
continue to fight the known and unknown pathogens6. The severity of infectious diseases has been 
exacerbated by the emergence of new infections and the re-emergence of known infections7. The 
discovery of salvarsan in 1910 and penicillin in 1928 by Ehrlich and Fleming, respectively, were 
the earliest successful attempts to control infectious diseases8, 9. After this period, the development 
and introduction of more new antibiotics gave more hope into believing that the infectious disease 
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era will soon be phased out and the golden era of antibiotics, which existed between the 1930s to 
1960s, will rise above all infections10. Unfortunately, the extensive overuse of antibiotics resulted 
in the emergence of multidrug-resistant bacteria which made treatment less effective and 
completely inefficient10. In this regard, antibiotic resistance reduces the ability of current 
medicines to treat common infections11. For instance, antibiotics, which have played a significant 
role in preventing and treating infection in the clinical setting on patients who are receiving 
chemotherapy treatment, with chronic diseases such as diabetes and rheumatoid arthritis, are now 
rendered ineffective11, 12. The World Health Organization (WHO) projections on AMR, as shown 
in Figure 1, suggest that if no viable solutions are adopted by 2050, morbidity rates are estimated 
to be at 10 million and 28 million and people will experience severe poverty. Additionally, the 
global economy may also experience a possible loss of more than $100 trillion annually due to 
AMR13, 14.  
 
 




Pathogenic microorganisms have always evolved to resist the impact of new medicines applied 
against them. Among infectious diseases, bacterial infections are recognized as the major cause of 
death and with the emergence of AMR, they have become increasingly difficult to manage16. 
According to WHO and the Center for Disease Control and Prevention (CDC), over 2 million 
cases of infections are caused by antibiotic-resistant bacteria resulting to about 23 000 deaths, with 
over $20 billion excess healthcare cost and $35 billion societal costs annually in US alone17, 18. 
Methicillin-resistant Staphylococcus aureus is one of the most difficult bacterial pathogens to treat 
among the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.), which 
are responsible for nosocomial infections and deaths globally19. MRSA is one of the leading causes 
of nosocomial infections since their first report in the 1960s in the United Kingdom (UK) shortly 
after the introduction of methicillin20, 21. The virulence of MRSA strains has been associated with 
a rapid increase of life-threatening pneumonia, necrotizing fasciitis, endocarditis, osteomyelitis, 
severe sepsis, and toxinoses such as toxic shock syndrome, occurring in both healthcare and 
community settings20, 22.  
It was further reported that 13 to 74% of S. aureus infections reported are MRSA and the source 
of S. aureus infections around the world from both community-acquired (CA) and hospital-
acquired (HA) infection reported cases is changing 23, 24. Additionally, in all WHO regions, the 
prevalence of MRSA has been recorded to exceed 20% and above 80% in some regions25. For all 
the HA infections in Europe caused by the antibiotic-resistant bacterium, 44% were MRSA and 
contributed to over 20% excess mortality23. Whereas in the United States of America (USA) alone 
within the community setting, over 80,461 invasive MRSA infections and more than 11,285 
related deaths were recorded in 201124, 26. This resulted in the hospital/healthcare cost of about 1.4 
to 13.8 billion in the USA and 380 million annual loss in Europe in the fight against MRSA 
infections24. According to WHO report in 2014, even though the impact of MRSA infections in 
western countries is well document, the magnitude of MRSA infections in other regions like Africa 
is not known27. For example, whilst South Africa has a reported decline from 34 to 28% in 2011, 
in some part of Africa, cases of reported MRSA infections were exceeding 82%18, 28. Therefore, 




The continuous growth and unmonitored spread of MRSA prevalence from the nosocomial 
environment to communities in countries with intensified international mobility and lacking 
healthcare facilities to control of the infection are significantly contributing to the global spread of 
MRSA29. Even though vancomycin (VCM) has been the mainstay for the treatment of MRSA 
infections since 195830, 31, the extensive use of VCM for over 50 years and the emergence of 
MRSA isolates with reduced susceptibility to VCM indicate the risk of running out of effective 
antibiotics to treat MRSA infections32-35. These MRSA isolates are termed vancomycin-
intermediate resistant Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus 
aureus (VRSA). Although the total number of cases reported related to these MRSA isolates is 
currently low, new infections of this nature are being identified21, 36. Since VCM is often regarded 
as the last resort for S. aureus infections, their treatment becomes a daunting challenge. This 
phenomenon poses a serious threat as the number of VISA and VRSA incidences continues to rise. 
Collectively, these challenges advocate for new effective therapeutic approaches to be introduced 
or adopted to prevent, treat, and control the spread of these infectious diseases. Hence, there is a 
need for the development of new antimicrobial drugs or even novel effective approaches to treating 
microbial infections21, 35. 
 
Despite the great successes in using a conventional antibiotic therapeutic approach to treat bacterial 
infections, which has saved millions of lives, this approach has been associated with several 
limitations. This has resulted in antibiotic therapeutic failure and subsequent development of 
antibiotic resistance over the years37. Antibiotics were designed to treat and prevent bacterial 
infections by killing and inhibiting their growth through conventional antibiotic therapies38. 
Unfortunately, limitations associated with traditional dosage forms have been reported. These 
include a fast bio/chemical degradation and reduced circulation time in the bloodstream, non-site-
specific and non-target-oriented drug delivery, as well as inadequate drug uptake at the site of 
infection, which leads to sub-optimal therapeutic outcomes. In this case, the frequency of 
administration is increased to maintain a fixed/desirable plasma drug level, which may lead to the 
development of side effects and subsequent poor patient compliance39. These shortcomings 
became the major contributors to the development of resistance, which has reduced the antibiotic 
timeline between the antibiotic introduction and resistance development40. The decline of 
antibiotic therapy resulted in many pharmaceutical companies opting to discontinue their 
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investments towards the development of newer classes of antibiotics due to low profits, the short 
life span of the product and complicated regulatory approval procedures41. As shown in Figure 2 
below, since 1984, no new class of antibiotics has been discovered, which is being outpaced by 
the continuous spread of AMR42. Therefore, the innovative alternative approaches that can 
enhance therapeutic outcomes of the current antibiotics to combat drug resistance development are 
warranted.   
 
 
Figure 2. History of antibiotics and resistance42, 43.  
 
Over the past decades, the use of nanotechnology based-nanomedicine through integrated 
approaches in an attempt to enhance and restore the efficacy of the drugs has been widely reported 
in literature44. Nanomedicine involves the use of nanoscale structures for diagnosis, monitoring, 
control, prevention, treatment of diseases, and for better understanding the pathophysiology of 
diseases to improve the quality of life of patients45, 46. Since the discovery of nanoscale structures, 
they have become a promising tool to overcome the therapeutic failures associated with 
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conventional therapeutic treatments46-48. Figure 3 below represents the first generation of 
nanotechnology-based drug delivery systems (DDSs) that were approved by the FDA for clinical 
use and several drug nanocarriers, including antibiotic nanocarriers, are in different stages of 
development49-52. Furthermore, DDSs have been identified as a promising strategy to addresses 
several problems associated with antibiotic therapy, including antibiotic resistance53. These 
nanomaterials for antibiotic delivery offers several major advantages such as: i) targeting drug 
delivery to a specific site of infection; ii) improving the delivery of poorly soluble drugs and 
prevent serum instability issues; iii) improving transportation of the drug across tight epithelial 
and endothelial barriers; iv) preventing non-specific binding of the drug to healthy cells; v) 
releasing drugs at a sustained rate and controlled manner; vi) enabling uniform distribution in the 
target tissue and vii) improving cellular internalization. These advantages restore and improve the 
pharmacokinetic properties of the drug with reduced frequency of administration, toxicity and 
related side effects, which may improve patient compliance51, 53, 54. A range of nanodelivery 
systems including liposomes, solid lipid nanoparticles (SLNs), polymeric nanoparticles (PNPs), 
dendrimers, nanoemulsions (NEs), lipid polymer hybrid nanoparticles (LPHNs) and micellar 
systems are among the nanodelivery systems used for antibiotic delivery55. Even though there has 
been a great advancement in nanotechnology-based medicine, the application of nanoantibiotic 
formulation is still a new concept as compared to cancer and cardiovascular diseases56. Therefore, 
this suggests a need to develop more novel nanoantibiotic delivery systems to explore their 





Figure 3. Timeline of nanotechnology-based drug delivery57.  
 
Nanodrug delivery systems have shown promising results in preclinical studies (animal models) 
through passive and receptor-mediated targeting, as well as enhanced permeability and retention 
(EPR) effect. However, they suffer from non-specific bio-distribution and uncontrollable drug 
release 58, 59. To overcome these challenges, a significant progress has been made in developing 
stimuli-responsive nanocarriers that respond to the intrinsic physicochemical and pathological 
factors at the disease site to increase the specificity of drug delivery58-60. This could lower the 
dosage frequency while maintaining the required drug dose in the targeted organs/tissues for a 
much longer period at a very low toxicity range, thus improving therapeutic efficacy59. The 
common stimuli used for active targeting and drug release can be classified into physical (e.g., 
magnetic field, electric field, ultrasound, temperature, and osmotic pressure); chemical (e.g., pH, 
ionic strength and glucose); and biological (enzymes and endogenous receptors)61, 62. Among these 
stimuli-responsive nanodelivery systems reported for effective drug delivery, pH-responsive 
nanosystems have been investigated for delivery of the drug at disease sites characterized by low 




Briefly, bacterially infected tissues are associated with lower pH conditions due to anaerobic 
fermentation and subsequent inflammation; therefore, pH factor becomes the prime lead in 
developing innovative approaches and alternative strategies to treat bacterial infections58. The pH 
variation that exists across the biological system (both cellular and systemic levels in the 
pathological state) has been exploited for targeted drug delivery and triggered release in response 
to subtle environmental changes associated with pathological conditions that are different from 
physiological pH 7.463. Therefore, designing pH-responsive nanosystems requires a good 
understanding of the target site and the mechanism of release. In general, targeted drug delivery 
using stimuli-responsive nanomaterials is achieved through long-term stability in blood circulation 
as well as EPR, reduced premature drug release to the non-specific sites, as well as their ability to 
accumulate and enhance drug release once at the target site in response to a specific stimuli64. 
Additionally, there are two main mechanisms of targeted drug release in which pH-responsive 
nanosystems adapt in response to change in pH. These are i) the use of biomaterials with ionizable 
groups that undergo either or both conformational and solubility changes and ii) the use of 
biomaterials with acid-labile bond/linkers that hydrolyze under acidic conditions to facilitate drug 
release at the target site58, 65. The figure below (Figure 4) summarizes strategic ways in which a 






Figure 4. Approaches to design pH‐responsive nanosystems. A) use of charge shifting polymers, 
B) Acid-labile linkages or C) Crosslinkers that can either combine charge shifting polymers with 
non‐cleavable linkages to create swellable particles or acid-labile linkages, which lead to pH‐
responsive disassembly66. 
 
There is a range of biomaterials that have been incorporated in the formulation of nanodrug 
delivery systems such as lipids, polymers, and metals67. These biomaterials can be functionalized 
to impart stimuli-responsive properties of the nanocarrier to maximize targeted delivery. Most 
DDSs have been faced with the challenges associated with toxicity except for lipid-based drug 
delivery systems (LBDDSs), which have been considered as the safer DDS68. The significant 
benefits of LBDDSs include simplicity in modification for multiple applications, biocompatibility 
and biodegradability. They also possess membrane-like properties that facilitate its application as 
a nanocarrier for intracellular delivery69. LBDDSs have been studied and several lipid-based 
carriers, including liposomes, nanoemulsions, solid lipid nanoparticles, micelles, core-shell-type 
biomimetic vesicles, lipid-polymer hybrids, have been developed for mostly cancer therapy70-73. 
Additionally, extensive progress has been made in the development of pH-responsive LBDDSs 
for cancer therapy and have demonstrated promising results, but major progress is needed for 
antibiotic delivery. Additionally, the application of nanomedicines for bacterial infections is still 
a relatively new concept.49. Therefore, to address the challenges associated with conventional 
antibiotic dosage forms and the emergence of antibiotic-resistant bacteria, novel lipid-based 
nanoantibiotic approaches are warranted. Therefore, in this study, we explored three novel 
approaches, which employ the use of lipid materials to formulate lipid-based nanodelivery systems 
with stimuli-responsive properties: i) pH-responsive liposomes derived from novel two chain fatty 
acid-based lipids, ii) pH-responsive micelles from an oleic acid-lipid dendritic amphiphile and, iii) 
pH-responsive lipid-polymer hybrid nanoparticles (LPHNPs) from a stearic acid-based lipid 
amphiphile to efficiently deliver and enhance VCM activity against MRSA infections.  
 
Liposomes are one of the first generations of LBDDSs that were FDA approved and 
commercialized 74-76. They are phospholipid vesicles consisting of one or more lipid bilayers and 
can effectively encapsulate and deliver both hydrophilic and hydrophobic bioactive materials40. 
Since the discovery of liposomes, some changes have been made in their basic structure to facilitate 
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triggered release in response to environmental conditions and to enhance their in vivo liposome-
mediated drug delivery77. For example, liposomes containing pH-sensitive lipid components are 
designed specifically to control the release of the drug in response to acidic pH of the endosomal 
system78. More studies have been conducted to investigate the therapeutic efficacy of pH-
responsive liposomes and reports in the literature suggest that pH-responsive liposomes can target 
and accumulate the anti-cancer drugs in tumours more efficiently than the conventional 
liposomes78, 79. Even though more studies have confirmed the efficiency of pH-responsive 
liposomes as the best candidate for the delivery of drugs to the disease site characterized by acidic 
pH, very few studies have been reported on antibiotic delivery. pH-responsive liposomes for 
delivery of antibiotics reported so far include gentamycin80, streptomycin81 and VCM82, amongst 
others. Cationic, anionic and zwitterionic lipids are commonly used to formulate of pH-responsive 
liposomes, which contribute towards the overall surface charge of liposomes83. However, cationic 
and anionic lipids are still faced with challenges that limit their in vivo application. For example, 
even though negatively charged, or neutral liposomes can avoid early opsonization, their cellular 
internalization is affected because of the repulsive force between the liposome and negatively 
charged cell membrane84, 85. On the other hand, cationic liposomes can maximize cellular 
internalization through electrostatic interaction/binding with the negatively charged cell 
membrane but also suffer from non-specific binding with serum proteins before reaching the site 
of infection83. This makes zwitterionic lipids the best candidate to impart fusogenic and pH-
responsive properties, possessing positive attributes from both anionic and cationic lipids86. 
Zwitterionic lipids can be differentially ionized to promote surface charge switching in response 
to change in pH. For instance, at physiological pH, they remain neutral or negatively charged to 
avoid early opsonization and non-specific binding; and under acidic conditions they induce surface 
charge switching to positive, thus maximizing cellular internalization to enhance therapeutic 
outcome87-89. Limited studies have been conducted exploring the potential applicability of 
zwitterionic lipids in the formulation of pH-responsive liposome in the fight against disease 
infections characterized by acidic pH, such as bacterial infections. Since gram-positive bacteria, 
such MRSA, have negatively charged teichoic acids linked to thick peptidoglycan layers, using 
surface charge switching lipids such as zwitterionic lipids in the formulation of liposomes can 
facilitate electrostatic binding and enhance fusogenic properties of liposomes; which will further 
enhance cellular uptake90. Therefore, designing fusogenic liposomal systems with pH-responsive 
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properties can enhance targeting and remain to be explored for enhanced therapeutic outcomes in 
several diseases associated with acidic conditions at the disease site such as infections and cancer. 
 
The self-assemblies of dendritic amphiphiles have become an attractive strategy in developing a 
new class of delivery systems, possessing positive attributes from both polymeric and small 
molecular self-assemblies91. Dendritic amphiphiles are highly branched architectures with 
multiple functional headgroups, which self-assemble into nanosystems that are highly stable 
polymeric assemblies and display membrane properties like in small molecular assemblies92. 
However, several reports have shown their lack of active targeting and active release of the drug 
carrier in response to a specific stimulus for an improved pharmacokinetics and 
pharmacodynamics for the drug with reduced undesired side effects93. Among the endogenous 
stimuli, pH has been widely used as a control parameter for targeted drug delivery and controlled 
drug release because of the pH difference that exists between the healthy and disease sites94. Given 
the acidic conditions of the bacterially infected site, using pH-responsive dendritic amphiphiles 
can lead to the development of a more stable, membrane penetrating nanosystem with controlled 
drug release properties for efficient drug delivery. This can ensure sufficient eradication of 
bacterial infection and reduced chances of antibiotic-resistance development. pH-responsive 
dendritic polymeric micelles are the one of the well-studied hyperbranched and multifunctional 
nanosystems for the efficient delivery of anticancer drugs95. To the best of to our knowledge, no 
pH-responsive lipid-dendritic micelles for antibiotic delivery have been reported in the literature. 
Therefore, this study highlights the need for the synthesis and delivery application of a lipid-based 
dendritic amphiphile to explore their potential in targeted delivery.  
 
Since the discovery of liposomes and polymer-based nanosystems, extensive progress has been 
made in developing new and advance DDSs that address their challenges that limit their scope of 
application in the fight against different disease types96. Lipid polymer hybrid nanoparticles have 
emerged as one of the promising novel DDS, derived from both liposomes and polymeric based 
nanoparticles to overcome their shortcomings96, 97. This novel DDS has shown to enhance cell 
membrane permeability and long circulation time and display serum stability, differential targeting 
and biocompatibility. Using fatty acid-based zwitterionic pH-responsive lipids in the formulation 
of LPHNPs can facilitate their efficiency of targeted delivery at disease site characterized by acidic 
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pH, such bacterial infection. Even though LPHNPs have accumulated so much interest as the new 
generation of novel DDSs, they still remain under investigated98. To the best of our knowledge 
there is no report on fatty acid-based zwitterionic pH-responsive lipid for the development of 
LPHNPs for targeted delivery of any drug type. This highlights the importance of developing pH-
responsive LPHNPs to enhance the therapeutic efficacy of antibiotics. Our group have reported 
pH-responsive hybrid nanosystems for targeted of delivery of VCM against MRSA infections with 
promising in vivo results99, 100. Therefore, using these pH-responsive nanosystems for VCM 
delivery to treat MRSA infections can help address the therapeutic limitations associated with 
traditional dosage forms of VCM. 
 
Vancomycin is a tricyclic glycopeptide antibiotic, used to treat acute infections caused by gram-
positive bacteria, especially with the emergence of MRSA in hospitals101. Vancomycin mechanism 
of action against gram-positive bacteria is through inhibiting cell wall synthesis in susceptible 
organisms. However, the extensive use of VCM to treat MRSA infections has led to the 
development of new MRSA isolates termed vancomycin-intermediate Staphylococcus aureus 
(VISA) with reduced susceptibility to VCM102. The common occurrence of these resistant isolates 
of MRSA, MSSA, and VISA, is the reduced potential ability of VCM to treat these infections, 
which can lead to life-threatening conditions, such as sepsis103-105. In this regard, alternative 
treatment approaches are warranted. Therefore, the proposed studies were aimed at enhancing the 
antibacterial activity and performance of VCM against MRSA using nano-drug delivery systems 
such as pH-responsive liposomes consisting of fatty acid-based lipids and pH-responsive micelles 
derived from oleic acid-based dendritic lipid amphiphiles, respectively. Chapters two, three and 
four highlight the strategies used in the development of new nanosystems to efficiently deliver 
VCM against MRSA. 
1.3 Problem statement  
Among infectious diseases, the resistance of bacterial pathogens to common antimicrobial 
therapies are increasing rapidly and it has been associated with high morbidity and mortality 
globally. Several limitations such as drug exposure to healthy tissue, insufficient drug 
concentration at infection/target sites due to low bioavailability, rapidly degradation and quick 
elimination, high frequency of administration, severe adverse effects and poor patient compliance 
have been encountered using conventional dosage forms. These limitations are the leading cause 
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of poor therapeutic outcomes and subsequent development of antimicrobial resistance crisis 
globally. Nano-drug delivery systems have become an attractive solution to overcome challenges 
associated with traditional dosage forms. The identification and application of novel nano-based 
approaches to enhance antibiotic therapy through targeting infection sites, can contribute to 
enhancing patient therapy and disease treatments. The design and synthesis of unconventional lipid 
materials for developing pH-responsive nano-formulations are essential to improve the 
antibacterial effect of the currently available antibiotics. Additionally, nano-drug delivery systems 
that are specifically responsive to unique conditions at disease sites are a current trend in 
nanotechnology aimed at enhancing drug therapy. 
1.4 Aims and objectives of this study 
The broad aim of this study was to design and synthesize fatty acid-based pH-responsive lipids 
and explore their potential for the preparation of pH-responsive nano-based drug delivery systems 
to treat infectious diseases caused by S. aureus and MRSA infections. The specific aims and 
objectives of this study are highlighted below. 
Aim 1 
The aim of the study was to synthesize four novel pH-sensitive two chain fatty acid-based lipid 
derivatives (stearic, oleic, linoleic and linolenic acid derivatives) and explore their potential in the 
formulation of pH-responsive liposomes for the targeted delivery of VCM against S. aureus and 
MRSA. To achieve this aim, the objectives of the study were to: 
1. Use a six-step synthetic scheme to synthesize four novel pH-sensitive two chain fatty acid-
based lipid derivatives (stearic, oleic, linoleic and linolenic acid derivatives):  
a. Di -Stearoyl Amino Propionic acid tert-butyl Ester (DSAPE) 
b. Di - Oleoyl Amino Propionic acid tert-butyl Ester (DOAPE) 
c. Di- Linoleoyl Amino Propionic acid tert-butyl Ester (DLAPE) 
d. Di- LinoLenoyl Amino Propionic acid tert-butyl Ester (DLLAPE) 
2. Characterize the lipid derivatives using structural elucidation techniques such as FT-IR, 1H 
NMR and 13C NMR and HRMS. 




4. Formulate VCM-loaded liposomes from lipids with pH-responsive properties and evaluate 
them in terms of size, PDI, ZP, morphology, entrapment efficiency, in vitro drug release, 
bacterial cell viability using flow cytometry, in vitro and in vivo antibacterial activity. 
Aim 2  
The aim of the study was to synthesis a novel oleic acid-derived lipid dendritic amphiphile (OLA-
sodium propionate dendritic amphiphile (OLA-SPDA)) and explored its potential in the 
formulation of pH-responsive micelles for the targeted delivery of VCM against S. aureus and 
MRSA. To achieve this aim, the objectives of the study were to: 
1. Use a seven-step synthetic scheme to synthesize a novel oleic acid-derived lipid dendritic 
amphiphile (OLA-sodium propionate dendritic amphiphile (OLA-SPDA)). 
2. Characterize the lipid derivatives using structural elucidation techniques such as FT-IR, 1H 
NMR and 13C NMR and HRMS. 
3. Determine the in vitro cytotoxicity of the synthesized lipid derivatives to confirm its bio-
safety profile. 
4. Formulate VCM-loaded micelles with pH-responsive properties and evaluate them in terms 
of critical micelle concentration (CMC), size, PDI, ZP, morphology, entrapment efficiency, 
in vitro drug release, bacterial cell viability using flow cytometry, in vitro and in vivo 
antibacterial activity. 
Aim 3  
The aim of the study was to synthesize a novel fatty acid-based bi-tailed zwitterionic lipid 
conjugated to dimethylglycine head groups (DMGSAD-lipid) and explore its potential in the 
formulation of pH-responsive LPHNPs for the targeted delivery of VCM against S. aureus and 
MRSA. To achieve this aim, the objectives of the study were to: 
1. Use an eleven-step synthetic scheme to synthesize a novel fatty acid-based bi-tailed 
zwitterionic DMGSAD-lipid. 
2. Characterize the DMGSAD-lipid using structural elucidation techniques such as FT-IR, 1H 
NMR and 13C NMR and HRMS. 
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3. Determine the in vitro cytotoxicity of the synthesized lipid derivative to confirm its bio-
safety profile. 
4. Formulate VCM-loaded LPHNPs with pH-responsive properties and evaluate them in 
terms of size, PDI, ZP, morphology, entrapment efficiency, in vitro drug release, bacterial 
cell viability using flow cytometry, in vitro and in vivo antibacterial activity. 
1.5 The novelty of the study 
The novelty of the research work presented in the two experimental chapters is as follows, 
Aim 1 
The research work performed in this study is novel for the following reasons: 
• This study reports the synthesis and characterization of bi-tailed fatty acid-based pH-
responsive zwitterionic lipids, which have not been reported in the literature previously. 
• This study reports the use of bi-tailed fatty acid-based pH-responsive zwitterionic lipids to 
formulate liposomes, which have not been reported previously for intracellular delivery of 
any class of drugs. 
• This work reports for the first time the surface charge switching liposomes comprising of 
novel bi-tailed fatty acid-based pH-responsive zwitterionic lipids for targeted delivery of 
VCM against S. aureus and MRSA. 
Aim 2 
• This study reports the design and synthesis of a novel oleic acid-derived lipid dendritic 
amphiphile (OLA-sodium propionate dendritic amphiphile (OLA-SPDA)), which has not 
been reported in the literature before. 
• OLA-SPDA has not been reported in the literature for any application, including its use as 
a nano-based delivery system for any class of drugs. 
• The study is the first to investigate the antibacterial potential of OLA-SPDA as an antibiotic 
delivery vehicle against S. aureus and MRSA. 
• Whilst polymeric-based dendritic amphiphiles have been reported to deliver anti-cancer 
agents only, this is the first study that reports the encapsulation and delivery of an antibiotic 




• This study reports the synthesis and characterization of fatty acid-based bi-tailed pH-
responsive zwitterionic DMGSAD-lipid, which has not been reported in the literature 
before. 
• This study reports the use of novel fatty acid-based bi-tailed pH-responsive zwitterionic 
DMGSAD-lipid to formulate LPHNPs, which have not been reported before for 
intracellular delivery of any class of drug. 
• This work report for the first time the surface charge switching LPHNPs comprising of 
novel fatty acid-based bi-tailed pH-responsive zwitterionic DMGSAD-lipid for targeted 
delivery of VCM against S. aureus and MRSA. 
1.6 The significance of the study 
The novel approach adopted in this study using the nano-based delivery system to enhance 
antibiotic efficacy can contribute to overcoming the current challenge of antibiotic resistance and 
avoid limitations associated with their conventional dosage forms. The significance of this study 
is highlighted below: 
New pharmaceutical products: The proposed VCM-loaded pH-responsive liposomes and VCM-
loaded pH-responsive micelles are new pharmaceutical products that have not been yet reported, 
which has the potential to stimulate the local pharmaceutical industries to manufacture cost-
effective, superior medicines. 
Improved patient therapy and disease treatment: The proposed formulations can improve patient 
therapy and treatment of various diseases associated with bacterial infections by enhancing 
antibacterial performance, minimizing doses, lowering side effects and improving patient 
compliance. It can, therefore, contribute to enhancing the quality of lives of patients and saving 
lives. 
Creation of new knowledge to the scientific community: These proposed studies can lead to new 
knowledge being generated in pharmaceutical sciences. It can include the following: 
• Synthesis schemes for new materials, preparation procedures for the novel drug delivery 




• The extensive in vivo testing of these novel systems can provide knowledge for in vitro in 
vivo correlations. 
Stimulation of new research: The proposed pH-responsive VCM-loaded liposomes, micelles and 
LPHNPs systems hold great potential as nano-delivery systems in enhancing the antibacterial 
activity of VCM against MSSA and MRSA infections. It can stimulate further studies on their 
clinical evaluation, the potential for other applications and the design of new materials. 
1.7 Overview of dissertation 
The research work performed is presented in this thesis in a publication format, according to the 
guidelines of the University of Kwa-Zulu Natal, College of Health Sciences. It specifies the 
inclusion of a brief introductory chapter, published papers, and a final chapter on the conclusions. 
A PhD study requires at least three first-authored papers, two of which must be experimental. 
CHAPTER 2: EXPERIMENTAL PAPER ONE: This chapter addresses Aim 1, Objectives 1 - 
4 and is a first-authored experimental article published in an ISI International Journal: Journal of 
Drug Targeting (Impact Factor = 3.277). This article highlights the synthesis of novel two-tail fatty 
acid-based lipid derivatives and explores their potential in the formulation of pH-responsive 
liposomes. Also, the in vitro toxicity evaluation, formulation of the ultra-small vesicles (VCM-
liposome) to deliver VCM, characterization of its physical properties and in vitro and in vivo 
antibacterial properties were also highlighted. 
CHAPTER 3: EXPERIMENTAL PAPER 2: This chapter addresses Aim 2, Objectives 1 - 4 
and is a first-authored experimental article published in the ISI international journal: Journal of 
Pharmaceutical Sciences (Impact Factor 3.197). This article highlights the synthesis of a novel 
OLA-SPDA lipid dendritic amphiphile. It also highlights the in vitro toxicity evaluation, hemolytic 
study, formulation of the pH-responsive micelles (VM-OLA-SPDA-micelles) for targeted delivery 
of VCM, characterization of its physical and antibacterial properties both in vitro and in vivo 
activity. 
CHAPTER 4: EXPERIMENTAL PAPER 3: This chapter addresses Aim 3, Objectives 1–3 and 
is a first-authored experimental article in preparation for submission. This article highlights the 
synthesis of a novel fatty acid-based bi-tailed pH-responsive zwitterionic DMGSAD-lipid, the in 
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vitro toxicity evaluation, formulation development of LPHNPs, characterization of its physical 
properties, in vitro and in vivo antibacterial properties. 
CHAPTER 5. CO-AUTHORED PAPER: In addition to the first authored experimental papers 
in Chapters 2, 3 and 4 focusing on aims 1, 2 and 3, I have also been involved in other papers within 
our group as a Ph.D. student. As these papers also focused on the broad aim of this PhD project to 
improve the treatment of bacterial infections, these papers have been included in the thesis. This 
chapter, therefore, includes one published experimental paper and one communicated review 
article in an ISI International Journals: Colloids and Surfaces B: Biointerfaces (Impact Factor = 
4.389) and WIREs Nanomedicine & Nanobiotechnology (Impact Factor = 7.689). 
CHAPTER 6: CONCLUSION: This chapter includes the overall conclusions from research 
findings in the study which, provides information on the potential significance of the findings and 
makes recommendations for future research work in the field of strategic solutions to combat 





1.           World Health Organization. (2014). Antimicrobial resistance: global report on surveillance. 
World Health Organization. Retrieved from https://apps.who.int/iris/handle/10665/112642. 
2. Dan M. Infectious diseases--the progress is huge--a lot remains to be done. Harefuah. 2009; 
148 (11):775-7.. 
3. Brownlie, J.;  Peckham, C.;  Waage, J.;  Woolhouse, M.;  Catherine Lyall, C.;  Meagher, 
L.;  Tait, J.;  Baylis, M.; Nicoll, A., Infectious Diseases: Preparing for the Future: Future Threats. 
London: Office of Science and Innovation 2006. 
4. Michael, C. A.;  Dominey-Howes, D.; Labbate, M., The antimicrobial resistance crisis: 
causes, consequences, and management. Frontiers in public health. 2014, 2, 145. 
5. Bloom, D. E.; Cadarette, D., Infectious Disease Threats in the 21st Century: Strengthening 
the Global Response. Frontiers in immunology. 2019, 10, 549. 
6. Nelson, D. W.;  Moore, J. E.; Rao, J. R., Antimicrobial resistance (AMR): significance to 
food quality and safety. Food quality and safety. 2019, 3 (1), 15-22. 
7. Fenner, F.;  Henderson, D. A.;  Arita, I.;  Jezek, Z.; Ladnyi, I. D., Smallpox and its 
eradication. World Health Organization Geneva: 1989, 4(2), 343-5. 
8. Ligon BL. Penicillin: its discovery and early development. In Seminars in pediatric 
infectious diseases. 2004, 15 (1), 52-57. 
9. Zaffiri, L.;  Gardner, J.; Toledo-Pereyra, L. H., History of antibiotics. From salvarsan to 
cephalosporins. Journal of Investigative Surgery. 2012, 25 (2), 67-77. 
10. Vouga, M.; Greub, G., Emerging bacterial pathogens: the past and beyond. Clinical 
Microbiology and Infection. 2016, 22 (1), 12-21. 
11. Ventola, C. L., The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and 
therapeutics. 2015, 40 (4), 277. 
12. Gould, I. M.; Bal, A. M., New antibiotic agents in the pipeline and how they can help 
overcome microbial resistance. Virulence. 2013, 4 (2), 185-191. 
13. Bhatia, R., Universal health coverage framework to combat antimicrobial resistance. The 
Indian journal of medical research. 2018, 147 (3), 228. 
14. World Health Organization. (2018). Antimicrobial resistance and primary health care: 
brief. World Health Organization. Retrieved from https://apps.who.int/iris/handle/10665/328084. 
15. King DT, Wasney GA, Nosella M, Fong A, Strynadka NC. Structural insights into 
inhibition of Escherichia coli penicillin-binding protein 1B. Journal of Biological Chemistry. 
2017; 292 (3): 979-93. 
16. Kapoor, G.; Saigal, S.; Elongavan, A., Action and resistance mechanisms of antibiotics: A 
guide for clinicians. Journal of anaesthesiology, clinical pharmacology. 2017, 33 (3), 300. 
20 
 
17. Centers for Disease Control and Prevention. (2013). Antibiotic resistance threats in the 
United States. Retrieved from www.cdc.gov/drugresistance/threat-report-2013. 
18. Gelband, H.;  Molly Miller, P.;  Pant, S.;  Gandra, S.;  Levinson, J.;  Barter, D.;  White, A.; 
Laxminarayan, R., The state of the world's antibiotics 2015. Wound healing southern Africa. 2015, 
8 (2), 30-34. 
19. Rodvold, K. A.; McConeghy, K. W., Methicillin-resistant Staphylococcus aureus therapy: 
past, present, and future. Clinical infectious diseases. 2014, 58 (1), 20-27. 
20. Garoy, E. Y.;  Gebreab, Y. B.;  Achila, O. O.;  Tekeste, D. G.;  Kesete, R.;  Ghirmay, R.;  
Kiflay, R.; Tesfu, T., Methicillin-resistant Staphylococcus aureus (MRSA): prevalence and 
antimicrobial sensitivity pattern among patients—a multicenter study in Asmara, Eritrea. Canadian 
Journal of Infectious Diseases and Medical Microbiology. 2019, 2019. 
21. Ahmed M . Methicillin Resistant Staphylococcus Aureus (MRSA), A Challenge and an 
Opportunity! . WebmedCentral PUBLIC HEALTH 2011;2(6):WMC001996. 
22. Monecke S, Coombs G, Shore AC, Coleman DC, Akpaka P, Borg M, Chow H, Ip M, 
Jatzwauk L, Jonas D, Kadlec K. A field guide to pandemic, epidemic and sporadic clones of 
methicillin-resistant Staphylococcus aureus. PloS one. 2011; 6 (4), 17936. 
23. Hassoun, A.;  Linden, P. K.; Friedman, B., Incidence, prevalence, and management of 
MRSA bacteremia across patient populations—a review of recent developments in MRSA 
management and treatment. Critical care. 2017, 21 (1), 211. 
24. Köck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans JA, Mielke 
M, Peters G, Skov RL, Struelens MJ, Tacconelli E. Methicillin-resistant Staphylococcus aureus 
(MRSA): burden of disease and control challenges in Europe. Eurosurveillance. 2010; 15 (41): 
19688. 
25. World Health Organization. (2014). Antimicrobial resistance: global report on 
surveillance. World Health Organization. Retrieve from 
https://apps.who.int/iris/handle/10665/112642. 
26. Abdulgader, S. M.;  Shittu, A. O.;  Nicol, M. P.; Kaba, M., Molecular epidemiology of 
Methicillin-resistant Staphylococcus aureus in Africa: a systematic review. Frontiers in 
microbiology. 2015, 6, 348. 
27. World Health Organization. (2014). WHO’s first global report on antibiotic resistance 
reveals serious, worldwide threat to public health. Retrieved from https://www.who.int/news-
room/detail. 
28. Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP. MRSA in Africa: filling the 
global map of antimicrobial resistance. PloS one. 2013; 8 (7): 68024. 
29. Di Ruscio, F.;  Guzzetta, G.;  Bjørnholt, J. V.;  Leegaard, T. M.;  Moen, A. E. F.;  Merler, 
S.; De Blasio, B. F., Quantifying the transmission dynamics of MRSA in the community and 
21 
 
healthcare settings in a low-prevalence country. Proceedings of the National Academy of Sciences. 
2019, 116 (29), 14599-14605. 
30. Holmes, N. E.;  Tong, S. Y.;  Davis, J. S.; Van Hal, S. J. In Treatment of methicillin-
resistant Staphylococcus aureus: vancomycin and beyond, Seminars in respiratory and critical care 
medicine, Thieme Medical Publishers. 2015; 36 (1): 17-30. 
31. Barna, J.; Williams, D., The structure and mode of action of glycopeptide antibiotics of the 
vancomycin group. Annual review of microbiology. 1984, 38 (1), 339-357. 
32. Rasmussen, R. V.;  Fowler Jr, V. G.;  Skov, R.; Bruun, N. E., Future challenges and 
treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future microbiology. 
2011, 6 (1), 43-56. 
33. Panlilio, A. L.;  Culver, D. H.;  Gaynes, R. P.;  Banerjee, S.;  Henderson, T. S.;  Tolson, J. 
S.;  Martone, W. J.; System, N. N. I. S., Methicillin-resistant Staphylococcus aureus in US 
hospitals, 1975–1991. Infection Control & Hospital Epidemiology. 1992, 13 (10), 582-586. 
34. Drews, T. D.;  Temte, J. L.; Fox, B. C., Community-associated methicillin-resistant 
Staphylococcus aureus: review of an emerging public health concern. Wisconsin Medical Journal-
MADISON. 2006, 105 (1), 52. 
35. Choo, E. J.; Chambers, H. F., Treatment of methicillin-resistant Staphylococcus aureus 
bacteremia. Infection & chemotherapy. 2016, 48 (4), 267-273. 
36. Tang, J.;  Hu, J.;  Kang, L.;  Deng, Z.;  Wu, J.; Pan, J., The use of vancomycin in the 
treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a 
survey in a tertiary hospital in China. International journal of clinical and experimental medicine. 
2015, 8 (10), 19436. 
37. Davies, J.; Davies, D., Origins and evolution of antibiotic resistance. Microbiology and 
Molecular Biology Reviews. 2010, 74 (3), 417-433. 
38. Walsh, C., Antibiotics: actions, origins, resistance. American Society for Microbiology. 
2003, 13 (11): 3059–3060. 
39. Gao, W.;  Chen, Y.;  Zhang, Y.;  Zhang, Q.; Zhang, L., Nanoparticle-based local 
antimicrobial drug delivery. Advanced drug delivery reviews 2018, 127, 46-57. 
40. Aminov, R. I., A brief history of the antibiotic era: lessons learned and challenges for the 
future. Frontiers in microbiology 2010, 1, 134. 
41. Cheesman, M. J.;  Ilanko, A.;  Blonk, B.; Cock, I. E., Developing new antimicrobial 
therapies: are synergistic combinations of plant extracts/compounds with conventional antibiotics 
the solution? Pharmacognosy reviews 2017, 11 (22), 57. 
42. Andrei, S.;  Valeanu, L.;  Chirvasuta, R.; Stefan, M.-G., New FDA approved antibacterial 
drugs: 2015-2017. Discoveries. 2018, 6 (1), 81. 
22 
 
43. Madhav, N.;  Oppenheim, B.;  Gallivan, M.;  Mulembakani, P.;  Rubin, E.; Wolfe, N., 
Pandemics: risks, impacts, and mitigation. In Disease Control Priorities: Improving Health and 
Reducing Poverty. 3rd edition, The International Bank for Reconstruction and Development/The 
World Bank. 2017, 9, 315 – 345. 
44. Wang, R.;  Billone, P. S.; Mullett, W. M., Nanomedicine in action: an overview of cancer 
nanomedicine on the market and in clinical trials. Journal of Nanomaterials. 2013, 2013, 12. 
45. Tinkle, S.;  McNeil, S. E.;  Mühlebach, S.;  Bawa, R.;  Borchard, G.;  Barenholz, Y.;  
Tamarkin, L.; Desai, N., Nanomedicines: addressing the scientific and regulatory gap. Annals of 
the New York Academy of Sciences. 2014, 1313 (1), 35-56. 
46. Patra, J. K.;  Das, G.;  Fraceto, L. F.;  Campos, E. V. R.;  del Pilar Rodriguez-Torres, M.;  
Acosta-Torres, L. S.;  Diaz-Torres, L. A.;  Grillo, R.;  Swamy, M. K.; Sharma, S., Nano based drug 
delivery systems: recent developments and future prospects. Journal of nanobiotechnology. 2018, 
16 (1), 71. 
47. Zazo, H.;  Colino, C. I.; Lanao, J. M., Current applications of nanoparticles in infectious 
diseases. Journal of Controlled Release. 2016, 224, 86-102. 
48. Saidi, T.;  Fortuin, J.; Douglas, T. S., Nanomedicine for drug delivery in South Africa: a 
protocol for systematic review. Systematic reviews. 2018, 7 (1), 1-7. 
49. Immordino, M. L.;  Dosio, F.; Cattel, L., Stealth liposomes: review of the basic science, 
rationale, and clinical applications, existing and potential. International journal of nanomedicine. 
2006, 1 (3), 297. 
50. Wagner, V.;  Dullaart, A.;  Bock, A.-K.; Zweck, A., The emerging nanomedicine 
landscape. Nature biotechnology. 2006, 24 (10), 1211-1217. 
51. Zhang, L.;  Gu, F.;  Chan, J.;  Wang, A.;  Langer, R.; Farokhzad, O., Nanoparticles in 
medicine: therapeutic applications and developments. Clinical pharmacology & therapeutics. 
2008, 83 (5), 761-769. 
52. Davis, M. E., Zhuo (Georgia) Chen and Dong M. Shin. Nanoparticle therapeutics: an 
emerging treatment modality for cancer Nature. Nature Reviews Drug Discovery. 2008, 7 (9):771-
82. 
53. McNeil, S. E., Nanoparticle therapeutics: a personal perspective. Wiley Interdisciplinary 
Reviews: Nanomedicine and Nanobiotechnology. 2009, 1 (3), 264-271. 
54. Soares, S.;  Sousa, J.;  Pais, A.; Vitorino, C., Nanomedicine: principles, properties, and 
regulatory issues. Frontiers in chemistry, 2018, 6, 360. 
55. Kalhapure, R. S.;  Suleman, N.;  Mocktar, C.;  Seedat, N.; Govender, T., Nanoengineered 
drug delivery systems for enhancing antibiotic therapy. Journal of pharmaceutical sciences. 2015, 
104 (3), 872-905. 
23 
 
56. Huh, A. J.; Kwon, Y. J., “Nanoantibiotics”: a new paradigm for treating infectious diseases 
using nanomaterials in the antibiotics resistant era. Journal of controlled release. 2011, 156 (2), 
128-145. 
57. Shi, J.;  Votruba, A. R.;  Farokhzad, O. C.; Langer, R., Nanotechnology in drug delivery 
and tissue engineering: from discovery to applications. Nano letters. 2010, 10 (9), 3223-3230. 
58. Mura, S.;  Nicolas, J.; Couvreur, P., Stimuli-responsive nanocarriers for drug delivery. 
Nature materials. 2013, 12 (11), 991-1003. 
59. Rao, N. V.;  Ko, H.;  Lee, J.; Park, J. H., Recent progress and advances in stimuli-
responsive polymers for cancer therapy. Frontiers in bioengineering and biotechnology. 2018, 6, 
110. 
60. Mi, P., Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and 
theranostics. Theranostics. 2020, 10 (10), 4557. 
61. Zhao, Y.;  Guo, Y.; Tang, L., Engineering cancer vaccines using stimuli-responsive 
biomaterials. Nano Research. 2018, 11 (10), 5355-5371. 
62. Lopes, J. R.;  Santos, G.;  Barata, P.;  Oliveira, R.; Lopes, C. M., Physical and chemical 
stimuli-responsive drug delivery systems: targeted delivery and main routes of administration. 
Current pharmaceutical design. 2013, 19 (41), 7169-7184. 
63. Liu, J.;  Huang, Y.;  Kumar, A.;  Tan, A.;  Jin, S.;  Mozhi, A.; Liang, X.-J., pH-sensitive 
nano-systems for drug delivery in cancer therapy. Biotechnology advances. 2014, 32 (4), 693-710. 
64. Su, C.;  Liu, Y.;  Li, R.;  Wu, W.;  Fawcett, J. P.; Gu, J., Absorption, distribution, 
metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems. 
Advanced drug delivery reviews. 2019, 143, 97-114. 
65. Luo, M.;  Jia, Y.-Y.;  Jing, Z.-W.;  Li, C.;  Zhou, S.-Y.;  Mei, Q.-B.; Zhang, B.-L., 
Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and 
UCCs-2 for targeted treatment of Helicobacter pylori. Colloids and Surfaces B: Biointerfaces. 
2018, 164, 11-19. 
66. Deirram, N.;  Zhang, C.;  Kermaniyan, S. S.;  Johnston, A. P.; Such, G. K., pH‐Responsive 
Polymer Nanoparticles for Drug Delivery. Macromolecular rapid communications. 2019, 40 (10), 
1800917. 
67. Xie, J.;  Fan, Z.;  Li, Y.;  Zhang, Y.;  Yu, F.;  Su, G.;  Xie, L.; Hou, Z., Design of pH-
sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery 
and combination cancer therapy. International journal of nanomedicine. 2018, 13, 1381. 
68. Kaur, I. P.;  Kakkar, V.;  Deol, P. K.;  Yadav, M.;  Singh, M.; Sharma, I., Issues and 
concerns in nanotech product development and its commercialization. Journal of Controlled 
Release. 2014, 193, 51-62. 
24 
 
69. Čerpnjak, K.;  Zvonar, A.;  Gašperlin, M.; Vrečer, F., Lipid-based systems as promising 
approach for enhancing the bioavailability of poorly water-soluble drugs. Acta pharmaceutica. 
2013, 63 (4), 427-445. 
70. Li, R.;  He, Y.;  Zhang, S.;  Qin, J.; Wang, J., Cell membrane-based nanoparticles: a new 
biomimetic platform for tumor diagnosis and treatment. Acta Pharmaceutica Sinica B. 2018, 8 (1), 
14-22. 
71. Zhang, R. X.;  Ahmed, T.;  Li, L. Y.;  Li, J.;  Abbasi, A. Z.; Wu, X. Y., Design of 
nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and 
lipid building blocks. Nanoscale. 2017, 9 (4), 1334-1355. 
72. Stella, B.;  Peira, E.;  Dianzani, C.;  Gallarate, M.;  Battaglia, L.;  Gigliotti, C. L.;  Boggio, 
E.;  Dianzani, U.; Dosio, F., Development and characterization of solid lipid nanoparticles loaded 
with a highly active doxorubicin derivative. Nanomaterials. 2018, 8 (2), 110. 
73. Jaiswal, M.;  Dudhe, R.; Sharma, P., Nanoemulsion: an advanced mode of drug delivery 
system. 3 Biotech. 2015, 5 (2), 123-127. 
74. Sercombe, L.;  Veerati, T.;  Moheimani, F.;  Wu, S. Y.;  Sood, A. K.; Hua, S., Advances 
and challenges of liposome assisted drug delivery. Frontiers in pharmacology. 2015, 6, 286. 
75. Gabizon, A.;  Dagan, A.;  Goren, D.;  Barenholz, Y.; Fuks, Z., Liposomes as in vivo carriers 
of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer research. 
1982, 42 (11), 4734-4739. 
76. Zylberberg, C.; Matosevic, S., Pharmaceutical liposomal drug delivery: a review of new 
delivery systems and a look at the regulatory landscape. Drug Delivery. 2016, 23 (9), 3319-3329. 
77. Ferreira, D. d. S.;  Lopes, S. C. d. A.;  Franco, M. S.; Oliveira, M. C., pH-sensitive 
liposomes for drug delivery in cancer treatment. Therapeutic delivery. 2013, 4 (9), 1099-1123. 
78. Paliwal, S. R.;  Paliwal, R.; Vyas, S. P., A review of mechanistic insight and application of 
pH-sensitive liposomes in drug delivery. Drug delivery. 2015, 22 (3), 231-242. 
79. Karanth, H.; Murthy, R., pH‐Sensitive liposomes‐principle and application in cancer 
therapy. Journal of pharmacy and pharmacology. 2007, 59 (4), 469-483. 
80. Lutwyche, P.;  Cordeiro, C.;  Wiseman, D. J.;  St-Louis, M.;  Uh, M.;  Hope, M. J.;  Webb, 
M. S.; Finlay, B. B., Intracellular delivery and antibacterial activity of gentamicin encapsulated in 
pH-sensitive liposomes. Antimicrobial agents and chemotherapy. 1998, 42 (10), 2511-2520. 
81. Su, F.-Y.;  Chen, J.;  Son, H.-N.;  Kelly, A. M.;  Convertine, A. J.;  West, T. E.;  Skerrett, 
S. J.;  Ratner, D. M.; Stayton, P. S., Polymer-augmented liposomes enhancing antibiotic delivery 
against intracellular infections. Biomaterials science. 2018, 6 (7), 1976-1985. 
82. Omolo, C. A.;  Megrab, N. A.;  Kalhapure, R. S.;  Agrawal, N.;  Jadhav, M.;  Mocktar, C.;  
Rambharose, S.;  Maduray, K.;  Nkambule, B.; Govender, T., Liposomes with pH responsive ‘on 
25 
 
and off’switches for targeted and intracellular delivery of antibiotics. Journal of liposome research 
2019, 1-19. 
83. Sudimack, J. J.;  Guo, W.;  Tjarks, W.; Lee, R. J., A novel pH-sensitive liposome 
formulation containing oleyl alcohol. Biochimica et Biophysica Acta (BBA)-Biomembranes. 
2002, 1564 (1), 31-37. 
84. Bernkop-Schnürch, A., Strategies to overcome the polycation dilemma in drug delivery. 
Advanced drug delivery reviews. 2018, 136, 62-72. 
85. Foteini, P.;  Pippa, N.;  Naziris, N.; Demetzos, C., Physicochemical study of the protein–
liposome interactions: Influence of liposome composition and concentration on protein binding. 
Journal of liposome research. 2019, 29 (4), 313-321. 
86. Kim, M. W.;  Kwon, S.-H.;  Choi, J. H.; Lee, A., A promising biocompatible platform: 
lipid-based and bio-inspired smart drug delivery systems for cancer therapy. International journal 
of molecular sciences. 2018, 19 (12), 3859. 
87. Sabín, J.;  Vázquez-Vázquez, C.;  Prieto, G.;  Bordi, F.; Sarmiento, F. l., Double charge 
inversion in polyethylenimine-decorated liposomes. Langmuir. 2012, 28 (28), 10534-10542. 
88. Obata, Y.;  Tajima, S.; Takeoka, S., Evaluation of pH-responsive liposomes containing 
amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. 
Journal of Controlled Release. 2010, 142 (2), 267-276. 
89. Kim, M. W.;  Jeong, H. Y.;  Kang, S. J.;  Choi, M. J.;  You, Y. M.;  Im, C. S.;  Lee, T. S.;  
Song, I. H.;  Lee, C. G.; Rhee, K.-J., Cancer-targeted nucleic acid delivery and quantum dot 
imaging using EGF receptor aptamer-conjugated lipid nanoparticles. Scientific reports. 2017, 7 
(1), 1-11. 
90. Makhathini, S. S.;  Kalhapure, R. S.;  Jadhav, M.;  Waddad, A. Y.;  Gannimani, R.;  Omolo, 
C. A.;  Rambharose, S.;  Mocktar, C.; Govender, T., Novel two-chain fatty acid-based lipids for 
development of vancomycin pH-responsive liposomes against Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus (MRSA). Journal of drug targeting. 2019, 27 (10), 
1094-1107. 
91. Thota, B. N.;  Berlepsch, H. v.;  Böttcher, C.; Haag, R., Towards engineering of self-
assembled nanostructures using non-ionic dendritic amphiphiles. Chemical Communications. 
2015, 51 (41), 8648-8651. 
92. Thota, B. N.;  Urner, L. H.; Haag, R., Supramolecular architectures of dendritic 
amphiphiles in water. Chemical reviews. 2016, 116 (4), 2079-2102. 
93. Ramireddy, R. R.;  Raghupathi, K. R.;  Torres, D. A.; Thayumanavan, S., Stimuli sensitive 
amphiphilic dendrimers. New Journal of Chemistry. 2012, 36 (2), 340-349. 
94. Xu, S.;  Krämer, M.; Haag, R., pH-Responsive dendritic core-shell architectures as 
amphiphilic nanocarriers for polar drugs. Journal of drug targeting. 2006, 14 (6), 367-374. 
26 
 
95. Fleige, E.;  Achazi, K.;  Schaletzki, K.;  Triemer, T.; Haag, R., pH-responsive dendritic 
core–multishell nanocarriers. Journal of Controlled Release. 2014, 185, 99-108. 
96. Zhang, L.; ZHANG, L., Lipid–polymer hybrid nanoparticles: synthesis, characterization 
and applications. Nano Life. 2010, 1 (01n02), 163-173. 
97. Wakaskar, R. R., General overview of lipid–polymer hybrid nanoparticles, dendrimers, 
micelles, liposomes, spongosomes and cubosomes. Journal of drug targeting. 2018, 26 (4), 311-
318. 
98. Mukherjee, A.;  Waters, A. K.;  Kalyan, P.;  Achrol, A. S.;  Kesari, S.; Yenugonda, V. M., 
Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, 
emerging technologies, and perspectives. International journal of nanomedicine. 2019, 14, 1937. 
99. Maji, R.;  Omolo, C. A.;  Agrawal, N.;  Maduray, K.;  Hassan, D.;  Mokhtar, C.;  Mackhraj, 
I.; Govender, T., pH-Responsive Lipid–Dendrimer Hybrid Nanoparticles: An Approach To Target 
and Eliminate Intracellular Pathogens. Molecular pharmaceutics. 2019, 16 (11), 4594-4609. 
100. Hassan D, Omolo CA, Fasiku VO, Mocktar C, Govender T. Novel chitosan-based pH-
responsive lipid-polymer hybrid nanovesicles (OLA-LPHVs) for delivery of vancomycin against 
methicillin-resistant Staphylococcus aureus infections. International Journal of Biological 
Macromolecules. 2020; 147, 385-98. 
101. Bruniera, F.;  Ferreira, F.;  Saviolli, L.;  Bacci, M.;  Feder, D.;  da Luz Goncalves Pedreira, 
M.;  Sorgini Peterlini, M.;  Azzalis, L.;  Campos Junqueira, V.; Fonseca, F., The use of vancomycin 
with its therapeutic and adverse effects: a review. European review for medical and 
pharmacological sciences. 2015, 19 (4), 694-700. 
102. Vazquez-Guillamet, C.; Kollef, M. H., Treatment of gram-positive infections in critically 
ill patients. BMC infectious diseases. 2014, 14 (1), 92. 
103. Hasan, R.;  Acharjee, M.; Noor, R., Prevalence of vancomycin resistant Staphylococcus 
aureus (VRSA) in methicillin resistant S. aureus (MRSA) strains isolated from burn wound 
infections. Tzu Chi Medical Journal. 2016, 28 (2), 49-53. 
104. McGuinness, W. A.;  Malachowa, N.; DeLeo, F. R., Focus: infectious diseases: 
vancomycin resistance in Staphylococcus aureus. The Yale journal of biology and medicine. 2017, 
90 (2), 269. 
105. Kullar, R.;  Sakoulas, G.;  Deresinski, S.; van Hal, S. J., When sepsis persists: a review of 







CHAPTER 2: EXPERIMENTAL PAPER 1 
2.1 Introduction 
This chapter addresses Aim 1 and Objectives 1 – 3 and it is a first authored published experimental 
article. This chapter highlights the formulation and characterization of VCM-loaded liposomes 
(VCM-Lipo) from synthesized novel pH-responsive fatty acid-based lipids. The lipids were 
evaluated for in vitro toxicity and the formulated liposomes were evaluated for their 
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The development of bacterial resistance against antibiotics is attributed to poor localization of 
lethal antibiotic dose at the infection site. This study reports on the synthesis and use of novel two 
chain fatty acid-based lipids (FAL) containing amino acid head groups in the formulation of pH-
responsive liposomes for the targeted delivery of vancomycin (VAN). The formulated liposomes 
were characterized for their size, polydispersity index (PDI), surface charge and morphology. The 
drug loading capacity, drug release, cell viability, and in vitro and in vivo efficacy of the 
formulations were investigated. A sustained VAN release profile was observed and in vitro 
antibacterial studies against S. aureus and MRSA showed superior and prolonged activity over 72 
hours at both pH 7.4 and 6.0. Enhanced antibacterial activity at pH 6.0 was observed for the 
DOAPA-VAN-Lipo and DLAPA-VAN-Lipo formulations. Flow cytometry studies indicated a 
high killing rate of MRSA cells using DOAPA-VN-Lipo (71.98%) and DLAPA-VN-Lipo 
(73.32%). In vivo studies showed reduced MRSA recovered from mice treated with formulations 
by 4 and 2 folds lower than bare VN treated mice respectively. The targeted delivery of VAN can 
be improved by novel pH-responsive liposomes from the two-chain (FAL) designed in this study 
Keywords  
















2.5 Introduction  
Bacterial infections remain a major public health concern worldwide [1], with the emergence of 
antimicrobial resistance increasingly compromising the effectiveness of first-line antibiotics. 
Methicillin-resistant Staphylococcus aureus (MRSA) is one such example, having developed 
resistance against the drug Vancomycin (VAN), which is one of the last options for treating this 
superbug [2, 3, 4]. There are reports on the increasing numbers of MRSA infections in different 
settings such as health care and community-associated MRSA across the globe and the 
development of resistance against VAN indicate an urgent need for alternative therapeutic methods 
to mitigate MRSA infections [5]. Unless there is an intervention, recent reports have indicated that 
resistant pathogens such as MRSA could increase mortality rate up to 10 million yearly by 2050 
worldwide [6]. 
One of the strategies to fight antimicrobial resistance has been through nano-drug delivery systems 
that target infection sites. This can lead to efficient cellular uptake, improved antibiotic activity, 
reduced side effects, improved patient compliance and decreased resistance development [7, 8]. 
Liposomes are lipid-based vesicular nano-drug delivery systems with an aqueous core that can be 
employed to deliver both hydrophilic and hydrophobic drugs. Due to the versatility in formulating 
liposomes, materials responsive to specific stimuli, such as enzymes [9], temperature [10], Redox-
sensitive [11], pH and others, can be incorporated in the bilayer or on the surface. This can 
potentiate a selective delivery of their payloads to the targeted infection site [12]. 
The acidic environment associated with some pathological conditions, compared with healthy 
states, can be exploited to potentiate targeted delivery by using pH-responsive delivery systems 
[13, 14]. Bacteria can thrive under acidic conditions, where antibiotics are prone to losing their 
activity [15]. Therefore, incorporating bio-safe pH-responsive biomaterials in the liposome 
formulation facilitates targeting and triggered drug release in response to change in pH at the site 
of infection [12]. pH-responsive liposomes have been extensively studied as a potential 
intracellular delivery system for various drug classes to treat infectious diseases [13, 16], however 
there is limited literature available on pH-responsive liposomes for delivery of antibiotics [17, 18, 
19, 20, 21] Several approaches such as using dioleoylphospatidylethanolamine (DOPE) and 
ionizable acid lipids such as cholesteryl hemisuccinate lipid (CHEMS) [20, 22] have been 
employed to impact pH-sensitivity, fusogenic ability, stability in biological fluids and cellular 
internalization of the liposomes with great success [23, 24]. 
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Several reports suggest that zwitterionic lipids, which can be differentially ionized and have better 
response in various pH conditions and are particularly useful in imparting a surface charge 
switching mechanism onto the liposomal surface [25]. Furthermore, these lipids undergo 
conformational changes that lead to disturbance in the membrane bilayer of the liposome thereby 
increasing the leakage of the drug at acidic conditions [15]. The surface switching of these lipids 
contributes to the overall cationic charge of the liposomes, promoting electrostatic targeting with 
the negatively charged bacterial cellular membrane, and enhancing fusogenicity and cellular 
uptake efficiency [26]. It is also reported that fusogenic properties of liposomes can be enhanced 
by incorporating fusogenic lipids bearing a long unsaturated/saturated acyl chain [27].  
By designing lipids with above-mentioned properties and combining with a zwitterionic head 
group, both pH-responsive and fusogenic limitations can be addressed to enhance targeting. In this 
study, we devised and explored the potential of novel fatty acid based zwitterionic lipids to 
construct pH-responsive liposomes. These lipids typically contained a β-alanine amino acid head 
(ionizable head groups) that is connected to two long fatty acid tails by ester linkages. The pH-
sensitivity of the lipids is achieved through protonation and deprotonation mechanisms of 
secondary amine and free carboxylic group with a change in pH [14, 15]. The limited literature on 
pH-responsive liposomes derived from novel synthetic pH-responsive fatty acid-based lipids 
highlights the need to explore novel pH-responsive lipids for targeted delivery of antibiotics, such 
as vancomycin (VAN). A recent study on pH-responsive liposome formulated from fatty acid 
based lipids with similar architecture to the one we are proposing demonstrated that pH-responsive 
liposome can restore the VAN activity and reduce antibiotic resistance development [18]. 
In this study, four novel pH-responsive two chain fatty acid-based lipid derivatives (stearic, oleic, 
linoleic and linolenic acid derivatives) were synthesized, characterized and employed to develop 
pH-responsive liposomes for the targeted delivery of vancomycin against S. aureus and MRSA. 
We envisage these lipids to be biocompatible for formulation into stable pH-responsive liposomes 
with good drug entrapment, sustained drug release, and most importantly, improved pH sensitivity 







2.6 Materials and methods 
2.6.1 Materials 
Analytical grade 2-amino-1, 3-propanediol, Triisopropylsilane (TIPS) and tert-butyl acrylate were 
obtained from Sigma-Aldrich Co. Ltd., (UK). Stearic acid (SA), linoleic acid (LA), Oleic acid 
(OA), Linolenic acid (LLA), p-dimethylamino pyridine (DMAP), Cholesterol (Chol) and 
Vancomycin HCl (VAN) were purchased from Sigma-Aldrich Co. Ltd. (USA). 
Phosphatidylcholine from soybean (PC) was purchased from Lipoid (USA) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Trifluoroacetic acid (TFA) and N, 
N'-dicyclohexylcarbodiimide (DCC) were purchased from Merck Co. Ltd., (Germany). Nutrient 
Broth, Nutrient Agar and Mueller Hinton Agar (MHA) were obtained from Biolab Inc. (South 
Africa) whilst Mueller- Hinton broth 2 (MHB) was obtained from Sigma-Aldrich (USA). Purified 
water was obtained using Elix® system from Millipore Corp. (USA). Bacterial strains used were 
S. aureus Rosenbach (ATCC®BAA-1683TM) (MRSA) and S. aureus (ATCC 25923).  
 
2.6.2 Instrumentation 
1H NMR and 13C NMR of all the lipid derivatives were recorded using Bruker 400 and 600 
Ultrashield™ (United Kingdom) NMR spectrometer. FT-IR analysis was performed on a Bruker 
Alpha-p spectrometer with diamond ATR (Germany) whilst HRMS was performed on a Waters 
Micromass LCT Premier TOF-MS (United Kingdom) for all lipid derivatives. Purified water used 
in this study was obtained from the Milli-Q purification system (Millipore corp., USA). Optical 
density (OD) measurements were taken using a spectrophotometer (Spectrostar nano, Germany). 
Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK) was used to measure and record particle 
size, polydispersity index and zeta potential whilst Jeol, JEM-1010 (Japan) at 200 kV was used to 
take Transmission Electron Microscopy (TEM) Images. Cell viability study was performed on The 









2.7 Methods  
2.7.1 Synthesis and characterization of the lipids 
Scheme 1: Synthesis of mono-substituted two chain pH-responsive lipids (PRL) 
 
2.7.2 Synthesis of tert-butyl 3-((1,3-dihydroxypropan-2-yl) amino)propanoate (3) 
Compound 3 was synthesized by adding 2-amino-1,3-propanediol 1 (1.0 mmol) dropwise at room 
temperature to a mixture of tert-butyl acrylate 2 (1.10 mmol) in ethanol and stirred for 5 hours. 
The crude product was obtained by removing the remaining ethanol and excess tert-butyl acrylate 
under vacuum. This crude was then recrystallized using a mixture of hexane and ethyl acetate (3:1) 
yielding a final product 3 as a white solid (92%). Characterization was as follows: 1H NMR (400 
MHz, (CD3)2SO) δ(ppm): 1.22 (bs, 9H), 2.13 (t, 2H, J=6.65 Hz), 2.27-2.33 (m, 2H), 2.57 (t, 2H, 
J=6.65 Hz), 3.08-3.20 (m, 6H); 13C NMR (400 MHz, (CD3)2SO) δ(ppm): 27.7, 36.1, 42.9, 60.7, 
61.3, 63.3, 79.4, 171.4. HRMS (ES-TOF) [M + H]+ calculated for C10H21NO4+H
+: 242.1367 found 
242.1368.  
2.7.3 General procedure for esterification for compound 5a-d 
To make a series of compounds (5a- d), the fatty acid (2.02 mmol) was added to a stirring solution 
of compound 3 (1 mmol) with DCC (2.025 mmol) and DMAP (0.1 mmol) in dry DCM. The 
reaction mixture was further stirred at room temperature (rt) for 24 hours under inert conditions 
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(nitrogen atmosphere). The dicyclohexylurea formed (precipitate) was filtered off and the filtrate 
(organic solvent) was removed under reduced pressure (vacuum), and the resulting crude material 
was purified by column chromatography on silica gel using an illusion system composed of ethyl 
acetate in hexane (10-15% v/v ) to yield an ester derivative. For all the derivatives, yields of above 
85% were obtained. 
The synthesized ester derivatives were named with the following acronyms: 
Di -Stearoyl Amino Propionic acid tert-butyl Ester (DSAPE) 
Di - Oleoyl Amino Propionic acid tert-butyl Ester (DOAPE) 
Di- Linoleoyl Amino Propionic acid tert-butyl Ester (DLAPE) 
Di- LinoLenoyl Amino Propionic acid tert-butyl Ester (DLLAPE) 
2.7.3.1 Synthesis of DSAPE (5a). Stearic acid (5.2 g, 18.28 mmol) was added to a stirring solution 
of compound 3 (2.01 g, 9.12 mmol), DCC (3.763 g, 18.24 mmol) and DMAP (0.112 g, 0.92 mmol) 
in dry DCM (40 ml) under nitrogen at room temperature and the resulting mixture was stirred for 
24 hours. The resulting product was separated into a white solid using the general procedure 
section (2.2.2) with a high yield of above 87%. Characterization was as follows; 1H NMR (400 
MHz, CDCl3) δ(ppm): 0.810 (t, 6H, J=7.07 Hz), 1.18 (m, 56H),1.38 (s, 9H),1.56-1.51(m, 4H), 
2.29 (t, 4H, J =7.53 Hz), 2.50(t, 2H, J =7.40 Hz), 2.63(t, 2H, J =6.83 Hz), 3.30-3.23(m, 1H), 4.23(d, 
4H, J =4.52 Hz); 13C NMR (400 MHz, CDCl3) δ(ppm): 14.10, 22.68, 24.70, 28.0, 29.10, 29.4, 
29.6, 31.9, 34.0, 42.4, 55.57, 79.5, 171.4, 173.3. HRMS (ES-TOF) [M + H]+ calculated for 
C46H89NO6+H
+: 774.6588, found 774.6595. 
2.7.3.2 Synthesis of DOAPE (5b). Oleic acid (5.15 g, 18.24 mmol) was added to a stirring solution 
of compound 3 (2.0 g, 9.12 mmol), DCC (3.763 g, 18.24 mmol) and DMAP (0.111 g, 0.912 mmol) 
in dry DCM (40 ml) under nitrogen at room temperature and the resulting mixture was stirred for 
24 hours. The resulting product was isolated into a colourless oil using the general procedure 
section (2.2.2) with a high yield of above 92%. Characterization was as follows; 1H NMR (400 
MHz, CDCl3) δ (ppm): 0.76 (t, 6H), 1.15-1.19 (m, 40H), 1.33(s, 9H), 1.58-1.50 (m, 4H),1.87-1.90 
(m, 8H), 2.18-2.22 (m, 4H), 2.3 (t, 2H, J=7.67 Hz), 2.79 (t, 2H, J=6.34 Hz), 2.93(m, 1H), 3.9-4.0 
(s, 4H), 5.21-5.26 (m, 4H); 13C NMR (400 MHz, CDCl3) δ(ppm): 14.0, 22.6, 24.80, 27.1, 28.0, 
29.10, 31.8, 34.0, 34.0, 35.8, 42.9, 55.3, 80.4,129.6, 129.8, 171.7, 173.3. HRMS (ES-TOF) [M + 
H]+ calculated C46H85NO6+H
+: 770.6275, found 770.6281. 
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2.7.3.3 Synthesis of DLAPE (5c). Compound 5c was synthesized by adding linoleic acid (4.47 g, 
15.96 mmol) to a stirring mixture of compound 3 (3.5 g, 15.9 mmol), DCC (6.58 g, 31.92 mmol) 
and DMAP (0.194 g, 1.59 mmol) in dry DCM (40 ml) under nitrogen at room temperature and the 
resulting mixture was stirred for 24 hours. The resulting product was isolated as a pale-yellow oil 
using the general procedure section (2.2.2) with a high yield of above 89%. Characterization was 
as follows; 1H NMR (400 MHz, CDCl3) δ (ppm) : 0.80-0.84 (m, 6H), 1.19-1.27 (m, 32H), 1.39 (s, 
9H), 1.58-1.51 (m, 4H), 1.91-2.0 (m, 8H), 2.24 (t, 4H, J=7.54 Hz), 2.34 (m, 2H), 2.69 (m, 4H), 
2.83 (t, 2H, J=6.48 Hz), 2.99-2.93 (m, 1H), 4.03 (d, 4H, J=5.48 Hz), 5.34-5.21 (m, 8H); 13C NMR 
(400 MHz, CDCl3) δ (ppm): 14.07, 22.3, 24.7, 25.0, 26.8, 28.0, 28.0, 28.9, 28.9, 29.5, 29.6, 29.8, 
31.2, 32.5, 35.14, 37.0, 42.7, 55.3, 60.14, 80.0, 127.8, 129.7, 172.1, 173.3. HRMS (ES-TOF) [M 
+ H]+ calculated for C46H81NO6+H
+: 766.5962, found 766.5976. 
2.7.3.4 Synthesis of DLLAPE (5d). Linolenic acid (7.62 g, 26.36 mmol) was added to a stirring 
mixture of compound 3 (3 g, 13.68 mmol), DCC (5.65 g, 27.36 mmol) and DMAP (0.167 g, 1.37 
mmol) in dry DCM (40 ml) under nitrogen at room temperature and the resulting mixture was 
stirred for 24 hours. The resulting product was isolated as a pale brown oil using the general 
procedure section (2.2.2) with a high yield of above 85.6%. Characterization was as follows; 1H 
NMR (400 MHz, CDCl3) δ(ppm): 0.804 (t, 6H, J=7.35 Hz), 1.15-0.97 (m, 24H), 1.28 (s, 9H), 1.30-
1.27 (m, 4H), 2.0-1.75 (m, 8H), 2.11 (t, 4H, J=7.25 Hz), 2.34 (t, 2H, J=6.46 Hz), 2.68-2.40 (m, 
8H), 3.60-3.54 (m, 1H), 4.0 (d,4H, J=5.73 Hz), 5.30-5.22 (m, 12H); 13C NMR (400 MHz, CDCl3) 
δ(ppm): 13.9, 19.9, 24.1,25.0, 26.5, 28.4, 28.6, 28.9, 30.3, 30.8, 39.4, 41.3, 54.5, 59.7, 126.8, 
127.6, 129.7, 131.3, 171.5, 172.2. HRMS (ES-TOF) [M + H]+ calculated for C46H77NO6+H
+: 
762.5649, found 762.5663. 
2.7.4 General procedure for hydrolysis  
To a solution of tert-butyl ester derivative (4a-d) in dry dichloromethane (DCM), a solution of 
DCM, trifluoroacetic acid (TFA) and triisopropylsilane (TIPS) (5:4:1 v/v/v) were added slowly, 
and this was further stirred at rt for 6 hours. The solvent and excess TFA were vacua evaporated 
and the resulting residue was triturated several times with chloroform for complete removal of 
remaining traces of TFA. The product was isolated by column chromatography on silica gel using 
an elution system composed of methanol in chloroform (10% v/v). The purified product was dried 
under vacuum for 48 hours and was then characterized by FT-IR, NMR (1H and 13C) and mass 





The synthesized final lipids were named with the following acronyms: 
Di-Stearoyl Amino Propionic Acid (DSAPA) 
Di-Oleoyl Amino Propionic Acid (DOAPA)  
Di-Linoleoyl Amino Propionic Acid (DLAPA) 
Di-LinoLenoyl Amino Propionic Acid (DLLAPA). 
2.7.4.1 Synthesis of DSAPA (6a). TFA (5 ml) and TIPS (2 ml) were added to a 10 ml mixture of 
compound 5a (2 g) in DCM, and the desired product was purified following the procedure 
described in section 2.2.3 as a white solid with a high yield above 85 %. Characterization was as 
follows; FTIR: 3465.46, 2914.88, 2848.83, 1729.88, 1678.02, 1196.56, 1161.23 cm-1; 1H NMR 
(400 MHz, (CD3)2SO)δ (ppm): 0.833 (t, 6H, J=6.69 Hz), 1.27 (m, 56H), 1.59-1.54 (m, 4H), 2.35 
(t, 4H, J=7.56 Hz), 2.50 (t, 2H, J=7.41 Hz), 2.68 (t, 2H, J=6.81 Hz), 3.74-3.70 (m, 1H), 4.23 (d, 
4H, J=4.62 Hz); 13C NMR (400 MHz, (CD3)2SO) δ(ppm): 14.25, 22.4, 24.69, 29.42,31.36, 31.70, 
33.78, 42.23, 55.38, 60.64, 172.7, 172.79; HRMS (ES-TOF) [M + H]+ calculated for 
C42H81NO6+H
+: 696.6142; found 696.6147. 
2.7.4.2 Synthesis of DOAPA (6b). TFA (7.5 ml) and TIPS (3 ml) were added to a 15 ml mixture of 
compound 5b (2.9 g) in DCM, and the desired product was purified following the procedure 
described in section 2.2.3 as a viscous pale-yellow oil with a high yield above 76%. 
Characterization was as follows; FTIR: 3462.99, 2923.28, 1730.73, 1671.76, 1190.76, 1134.66 cm-
1; 1H NMR (400 MHz, (CD3)2SO)δ (ppm): 0.78-0.80 (m, 6H), 1.20 (m, 40H), 1.49 (m, 4H), 1.91-
1.93 (m, 6H), 2.24-2.28 (m, 3H), 2.60-2.62 (m, 2H), 3.13-3.16 (m, 2H), 3.53-3.55 (m, 1H), 4.1-
4.2 (m, 4H), 5.2 (m, 3H), 7.58 (m, 1H); 13C NMR (400 MHz, (CD3)2SO) δ(ppm): 13.60, 22.0, 
24.1, 26.57, 28.6, 29.10, 31.30, 33.14, 41.4, 54.4, 60.25, 129.27, 131.0, 166, 172; HRMS (ES-
TOF) [M + H]+ calculated for C42H77NO6+H
+: 692.5829; found 692.5833  
2.7.4.3 Synthesis of DLAPA (6c). TFA (5 ml) and TIPS (2 ml) were added to a 10 ml mixture of 
compound 5c (2 g) in DCM, and the desired product was purified following the procedure 
described in section 2.2.3 as a viscous pale-brown oil with a high yield above 84.6%. 
Characterization was as follows; FTIR: 3467.60, 3007.76, 2923.46, 2864.76, 1739.38, 1666.55, 
1142.42 cm-1 ; 1H NMR (400 MHz, CDCl3) δ(ppm): 0.87 (m, 7H,), 1.16-1.3(m, 32H), 1.37 (m, 
5H),1.9-2.0 (m, 7H), 2.33-2.36 (m, 4H), 2.74-2.77 (m, 2H), 2.8 (m, 2H), 3.4 (m, 2H), 3.6-3.7 (m, 
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1H) 4.4 (m, 4H), 5.28-5.36(m, 5H); 13C NMR (400 MHz, CDCl3): δ 14.0, 22.5, 24.85, 25.6, 27.2, 
29.0, 29.3, 29.7, 31.5, 31.8, 33.6, 42.4, 56.5,59.7, 127.8, 129.9, 173.2, 174.3; HRMS (ES-TOF) 
[M + H]+ calculated for C42H73NO6+H
+: 688.5516; found 688.5524. 
2.7.4.4 Synthesis of DLLAPA (6d). TFA (10 ml) and TIPS (4 ml) were added to a 20 ml mixture 
of compound 5d (3.55 g) in DCM, and the desired product was purified following the procedure 
from section 2.2.3 as a thick brown oil with a high yield above 88.4 %. Characterization was as 
follows; FTIR: 3431.45, 3009.92, 2926.97, 2857.17, 1728.66, 1666.85, 1159.69 cm-1; 1H NMR 
(400 MHz, (CD3)2SO) δ(ppm): 0.91 (m, 4H,), 1.2507 (m, 24H), 1.50-1.52 (m, 6H), 1.98-2.05 (m, 
8H), 2.32 (t,4H, J=7.33 Hz), 2.68-2.77 (m, 8H), 3.27(m,1H), 3.76 (m, 1H), 4.29-4.30(m, 4H), 5.24-
5.36(m, 12H); 13C NMR (400 MHz, (CD3)2SO) δ(ppm): 13.9, 19.9, 24.1,25.0, 26.5, 28.4, 28.9, 
30.3, 30.8, 39.4, 41.3, 54.5, 59.7, 126.8, 127.6, 129.7, 131.3, 171.5, 172.2; HRMS (ES-TOF): [M 
+ H]+ calculated for C42H69NO6+H
+: 684.5203; found 684.5213. 
2.8 In vitro cytotoxicity 
The cytotoxicity evaluation of the newly synthesized lipid derivatives (DSAPA, DOAPA, 
DLAPA, and DLLAPA) was performed using the MTT assay as previously reported in literature 
[28]. The cell lines used in this study were: human alveolar basal epithelial cells (A549), human 
breast adenocarcinoma (MCF7), and human liver hepatocellular carcinoma (HepG2). Negative 
controls (culture medium with cells only) and positive controls (culture medium without cells) 
were conducted for validation of our results. 2.5 × 10 3 cells/mL were seeded into 96-well plates 
and treated with lipid solutions of different concentrations (20, 40, 60, 80 and 100 µg/ml) that were 
prepared from 1% w/v stock solution after incubating for 24 hours. Plates were then incubated for 
48 hours at 37 ºC in 5% CO2 humidified incubator. Thereafter spent media was replaced with fresh 
culture medium and MTT solution (100 μl) and incubated for 4 hours at 37 ºC. Spent media was 
removed and dimethyl sulfoxide was added to the well to dissolve MTT formazan crystals. 
Absorbance measurements were recorded for each well using a microplate spectrophotometer 
(Spectrostar nano, Germany) at 540 nm. All the experiments were run in triplicate. The percentage 
of viable cells was quantified using the equation below: 
% Cell viability = (A540nm treated cells/A540nm untreated cells) x 100% 
2.9 Preparation of VAN encapsulated pH-responsive liposomes 
pH-responsive liposomes were prepared using thin film hydration method [29]. This method 
involves dissolving a 100 mg (5 ml of chloroform) mixture of Chol, PC and pH-responsive lipid 
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derivative (PRL) at a ratio of 1:3:1 w/w by mass respectively in a round bottom flask (RBF). The 
solvent was evaporated using rotavapor under reduced pressure (vacuum) at 40 ºС to form a thin 
film on the inner side of the round bottom flask. The resulting film was purged with nitrogen and 
stored in a vacuum desiccator overnight to remove the remaining trace amounts of the solvent. The 
film was then hydrated with 10 ml of the VAN solution of 1 mg/ml concentration in distilled water 
over 2 hours at room temperature for complete conversion into liposomes. The formed liposomes 
were vortexed for 3 minutes and the probe sonicated for 15 minutes at 30% amplitude using an 
Omni sonic rupture 400 Ultrasonic Homogenizer (Kennesaw, GA 30144, USA). 
2.10 Particle size (PS), polydispersity index (PDI), zeta potential (ZP) and morphology 
The formulated liposomes were characterized for their PS, PDI, and ZP using dynamic light 
scattering technique. This was done by diluting the formulation to a suitable concentration with 
suitable phosphate buffer solutions. Measurements were recorded using a Zetasizer instrument 
fitted with a 633 nm laser at 173° detection optics at room temperature (25 ºC) in triplicate to 
ensure reliability. The liposomes were further characterized for their morphological features using 
TEM analysis. The samples were appropriately diluted, stained with 1% uranyl acetate solution 
for 30 seconds, dried on a copper grid and images were acquired using JEOL Microscopy (JEM 
1010, Japan) at 100 kV. 
2.11 Entrapment efficiency (EE)  
Ultrafiltration method using Amicon® Ultra-4 centrifugal filter tubes (10 kDa molecular weight 
cut-off) was used to determine encapsulated VAN amount in the liposomes. To separate the free 
drug from the vesicles, samples were centrifuged at 2000 rpm, 25 °C for 45 minutes using a 
centrifugal filter tube. The amount of drug in the supernatant was analyzed by a UV-Visible 
spectrophotometer (Shimadzu UV-1650 PC) at 280 nm. The entrapment efficiency (EE) was 





WTD is the total drug in the liposome formulation and WFD is the total free drug in the supernatant 
obtained by centrifugation.  
2.12 In vitro drug release study 
The diffusion technique using a dialysis bag was used to investigate the in vitro drug release 
behaviour and the amount of drug release from both the pH-responsive VAN-liposomes and the 
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bare VAN solution. The dialysis bag (MWCO 14,000 Da) was used to load VAN encapsulated 
formulation (2 ml) and their corresponding blanks, sealed and immersed in 40 ml phosphate buffer 
solutions (pH 7.4, and pH 6.0). Samples were incubated at 37 °C in a shaking incubator (100 rpm). 
The amount of VAN released was measured by withdrawing 3 ml of sample from the receiver to 
be analyzed using a spectrophotometric method (UV-1650PC, Shimadzu, Japan) at 280 nm in 
triplicate. In order to maintain the sink condition, the volume of the release medium was kept 
constant by replacing it with an equal amount of fresh PBS after each sampling. The drug release 
kinetics of the liposomes were computed using various mathematical models (Zero order, First 
order, Higuchi, Weibull, Hixson-Crowell and Korsmeyer–Peppas) to understand the VAN release 
profile with respect to a change in the pH and models were analyzed using DDSolver software. 
The best fit model, the correlation coefficient (R2) and root mean square error (RMSE) were 
calculated, with all experiments being performed in triplicate. Moreover, the Korsmeyer–Peppas 
model release exponent (n) and the Weibull model β value were calculated to determine the release 
mechanism [31]. 
2.13 Antibacterial studies 
2.13.1 In vitro antibacterial activity  
The in vitro antibacterial studies of liposomes formulated from synthesized pH-responsive fatty 
acid-based lipid were performed against MRSA and S. aureus. The minimum inhibitory 
concentration (MIC) of bare VAN, VAN-loaded formulations (DSAPA-VAN-Lipo, DOAPA-
VAN-Lipo, DLAPA-VAN-Lipo and DLLAPA-VAN-Lipo), each containing 1 mg/ml of VAN and 
VAN free formulations (DSAPA- Lipo, DOAPA-Lipo, DLAPA -Lipo and DLLAPA- Lipo), were 
evaluated using the broth dilution method [32]. The MICs for all lipid derivatives (DSAPA, 
DOAPA, DLAPA, and DLLAPA) were also determined using the same procedure. Nutrient Broth 
was used to culture S. aureus and MRSA for 18 hours in a shaking incubator at 37 °C (Labcon, 
USA) set at 100 rpm. The bacterial cultures were diluted with sterile distilled water using a DEN-
1B McFarland densitometer (Latvia) to make 0.5 McFarland’s Standard (i.e. 1.5 x 108 colony 
forming units (CFU)/ml). A concentration of 1.5 x 108 colony forming units (CFU)/ml was further 
diluted 1:150 with sterile distilled water to a concentration of 5 × 105 CFU/ml. The VAN, drug-
free (blank) liposomes and vancomycin loaded liposomes were serially diluted in MHB at both pH 
6.0 and 7.4. The prepared bacterial cultures were added, and this was incubated at 37 °C for 18 
hours in a shaking incubator set at 100 rpm. The MIC was determined by inoculating each diluted 
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sample onto Mueller-Hinton Agar (MHA) plates. After incubation, 10 μl of each dilution was 
spotted on MHA and again incubated at 37 °C for 18 hours. The MIC was determined as the lowest 
concentration where there was no bacterial growth after 24 hours, this procedure was repeated at 
48 and 72 hours. All experiments including VAN free liposomes (negative control), VAN-loaded 
liposomes and bare VAN (positive controls) were performed in triplicate (n = 3). 
2.13.2 Bacterial cell viability assay 
Bacterial cell viability studies were conducted using the flow cytometry assay method [33, 34, 35]. 
The MRSA suspension was prepared as previously described to achieve a final concentration of 5 
× 105 CFU/ml. Bare VAN (7.8 μg/ml), DOAPA-VAN-Lipo (1.56 μg/ml) and DLAPA-VAN-Lipo 
(1.56 μg/ml) were prepared equivalent to their respective MICs. Bare VAN was also prepared at 
the concentration (1.56 μg/ml) equivalent to the MIC of the liposome formulation. The MRSA (15 
μl) was added to a solution in a 96-well plate and incubated at 37 °C for 6 hours in a shaking 
incubator (100 rpm). Untreated MRSA cells were used as a negative control, with percentage cell 
viability determined after incubation [33]. The volume of 50 μl of bare VAN (at both 
concentration), DOAPA-VAN-Lipo and DLAPA-VAN-Lipo were mixed with 350 μl of the sheath 
fluid in a separate flow cytometry tubes for each sample, and vortexed for 5 minutes [36]. The 
mixture was incubated at 37 °C for 30 minutes with 5 μl of the non-cell wall permeant Propidium 
iodide (PI) dye. PI fluorescence was excited by a 455-nm laser and collected through a 636 nm 
bandpass filter [37, 38]. Flow cytometry study was conducted using the BD FACSCANTO II 
(Becton Dickinson, CA, USA) instrument with the flow rate settings set up to 16 ml/min and 0.1 
ml/min for the sheath fluid and the sample respectively. Data with the fixed cells were collected 
using flow cytometer software (BD FACSDIVA V8.0.1 software [USA]). The voltage settings 
used for the fluorescence-activated cell sorting (FACS) analysis were: 731 for the forward scatter 
[FSC], 538 for the side scatter [SSC] and 444 for PI. The forward scatter was used for the initial 
gating of the bacteria, after which the appropriate size of the cells was gated and for each sample 
with at least 10,000 cells being collected in triplicate. The positions of the ‘live’ and ‘dead’ cells 
that were gated were therefore determined. The detection threshold was set to 1,000 in SSC 
analyses to reduce the background signal from particles smaller than the bacteria [35]. The 
captured data was further analyzed using the Kaluza-1.5.20 (Beckman Coulter USA) flow 





2.13.3 In vivo antibacterial activity and Histological evaluation 
All the animal experiments were performed in accordance with the protocol approved by the 
Animal Research Ethics Committee of the University of KwaZulu-Natal (Approval number 
AREC/104/015PD). The in vivo efficacy of the bare VAN, DOAPA-VAN-Lipo, and DLAPA-
VAN-Lipo were investigated against MRSA [39], which was grown as previously described and 
diluted with a sterile saline solution to an appropriate concentration of 1.5 x 108 CFU/ml. 
Biomedical Research Unit (UKZN) provided male BALB/c mice (18 - 20 g) which were divided 
into three groups: negative control, positive control and treated group. A small section at the back 
of the mice was shaved and disinfected with 70% ethanol to eliminate skin contamination prior to 
treatment. A bacterial suspension of (50 µl) was injected intradermally into the three stated groups 
of mice (n = 4 per group). After 30 minutes of infection, saline, bare VAN and VAN-liposome 
formulations were injected at the infection sites, of the mice which represent the negative control, 
positive control and treatment groups respectively. After 48 hours, the infected skin from the 
euthanized mice was harvested and homogenized in 5 ml of phosphate buffer solution pH 7.4 
(PBS). This was followed by serial dilutions of tissue homogenates using PBS. Thereafter, 20 µl 
of each dilution was plated on to Nutrient Agar plates and incubated at 37 °C for 18 hours. The 
number of CFU/ml was analyzed after incubation. The histological evaluation of the treated and 
untreated skin samples was done as per a previously reported procedure[40]. This procedure 
involved harvesting of the skin tissue from both controls and skin samples treated with 
formulations and stored in formalin for 7 days at room temperature. On day seven, ethanol was 
used to dehydrate the sample followed by fixation with paraffin wax. The infected skin sections 
were collected on slides, dried, and stained with hematoxylin and eosin (H&E). Sections were 
viewed via light microscopy using the Nikon 80i light microscope (Japan), and NIS Elements D 
software and Nikon U2 camera (Japan) was used to digitally capture the images.  
2.14 Physical Stability 
VAN-liposomes formulations were kept at different temperatures (4 °C and rt) for 90 days to 
determine their short-term physical stability. The physical stability of the formulations was 
assessed at different time intervals (30, 60 and 90 days) by measuring the particle size, PDI, ZP 





2.15 Statistical analysis 
The experiments were performed in triplicate, and the collected data are expressed as the mean 
±standard deviation. GraphPad Prism® software (Graph Pad Software Inc., Version 6, San Diego, 
CA) was used for statistical analysis. One-way analysis of variance (ANOVA), followed by 
Bonferroni's multiple comparison tests was used to determine statistical significance, with P values 
of less than 0.05 being considered statistically significant. 
 
2.16 Results and discussion 
2.16.1 Synthesis and characterization of pH-responsive lipids 
Novel pH-responsive lipids consisting of a β-alanine amino acid head group that is connected to 
two long fatty acid tails (different C-18 fatty acids) by ester linkages (DSAPA, DOAPA, DLAPA, 
and DLLAPA) were synthesized in three steps. The first step involved the formation of a carbon-
nitrogen bond via mono Aza-Michael addition reaction between tertiary butyl acrylate and serinol 
to form compound 3 (Scheme 1). A broad singlet peak at chemical shift δ 1.39 ppm integrating to 
9 protons in 1H NMR, and the appearance of peaks at δ 27.7, 36, 48, 79.4 and 171 ppm in 13C 
NMR corresponding to C(CH3)3-COO-, -CH2C=O-, -CH2-NH-and C=O functional groups, 
confirmed the formation of compound 3. The compounds belonging to the series 5a-d were 
obtained by esterification of different fatty acids (Stearic, Oleic, Linoleic, and Linolenic acid), 
with compound 3 using DCC/DMAP coupling chemistry. The appearance of peaks at chemical 
shift δ 0.806 (triplet), δ 1.18 (multiplet), δ 1.54 (multiplet) and δ 2.27 ppm (triplet) in 1H NMR 
confirmed the formation of the products. The tertiary butyl ester groups of compounds 5a-d were 
hydrolyzed using TFA and TIPS (scavenger) combination to obtain the desired pH-responsive 
lipids 6a-d, as shown in scheme 1. The disappearance of the t-boc peak at 1.38 ppm in 1H NMR 
and at 28 ppm in 13C NMR confirmed the formation of the final product. Furthermore, the HRMS 
analysis confirmed the molecular mass of newly synthesized compounds, indicating their 
successful synthesis.  
2.16.2 In vitro cytotoxicity 
A cytotoxicity study of newly synthesized materials (lipid derivatives) is of importance in 
evaluating its biosafety [41, 42, 43]. Cell viability was quantified using the MTT (tetrazolium) 
cytotoxicity assay by exposing the tested material to mammalian cells that have the capacity to 
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metabolically reduce tetrazolium to insoluble formazan crystals. The reduction of tetrazolium can 
be related to cell metabolic activity, thus, the amount of formazan crystals formed is equivalent to 
the number of viable cells. Human cell lines (A549, MCF 7 and Hep G2) were used to assess the 
biosafety of all four lipids (DSAPA, DOAPA, DLAPA, and DLLAPA) samples. The MTT results 
revealed that all synthesized novel lipids displayed a high percentage cell viability (> 75%) after 
48-hour exposure across all concentration range studied. The percentage cell viability of lipids 
from the different cell lines ranged from 79 - 86% for the A549 cells, 84 - 86% for the MCF 7 
cells, and 80 - 84% for the Hep G2 cells for all concentrations studied, as shown in figure 1. The 
cell viability of all lipids was greater than 75%, with no dose-dependent trends observed. The low 
toxicity level of these lipids can be attributed to the non-toxic nature of the parent fatty acids, these 
findings confirming that the derivatization maintains the non-toxic nature of these biomaterials, 
and hence are safe for biomedical applications [44].  
 
Figure 1. Cell viability study against A549, MCF 7 and Hep G2 cells exposed at various 







2.16.3 Preparation and Characterization of VAN-loaded liposomes 
2.16.3.1 Size, Surface charge, Entrapment efficiency, and Morphology  
Having confirmed the biosafety of the two chain fatty acid based-lipids, the thin film hydration 
method was used in the subsequent preparation of the pH-responsive liposomes, with VAN as a 
model antibiotic drug [29]. The pH-responsive liposomes, composed of PC/Cholesterol/ pH-
responsive lipid (PRL’s) in a ratio of 1:3:1 w/w, were prepared in a stepwise process by thin film 
hydration, sonication and filtration [29, 45]. Stable pH-responsive liposomes were formed by 
varying the quantity of PRL’s and Chol concentration. pH-responsive liposomes (VAN free and 
loaded) prepared using optimized formula were characterized for their size, PDI, surface charge 
switching (zeta potential), VAN entrapment efficiency and morphology.  
The entrapment efficiency of VAN-Lipo, DSAPA-VAN-Lipo, DOAPA-VAN-Lipo, DLAPA-
VAN-Lipo and DLLAPA-VAN-Lipo formulations was 37.83 ± 2.5%, 36.43 ± 0.64%, 44.27 ± 
9.2%, 38.68 ± 4.7% and 29.86 ± 4.5% respectively (table 1), demonstrating similar results to 
previous reports of VAN-loaded liposomes prepared using this method [25]. The results, as shown 
in table S1a and S1b, indicate that all formulations presented a uniform liposome size ranging 
from 86.28 ± 11.76 to 282 ± 31.58 nm, with their respective PDI’s ranging from 0.151 ± 0.016 to 
0.204 ± 0.014 at different pHs. The TEM images revealed spherical shape with sizes that were in 
agreement with those obtained from DLS studies. The size range is in-line with the results obtained 
from our previously reported VAN loaded pH-responsive liposomes [18].  
The effect of pH on the size and surface charge of all formulations was evaluated using DLS by 
exposing the liposome to different pH environments (pH 7.4, 6.0 and 5.5) (table S1a and S1b). 
At pH 7.4, the liposome surface charge was found to be -11.8 ± 2.99 mV. However, as the pH 
decreased from the physiological pH to acidic pH, the surface charge switched to a positive value 
of 3.10 ± 0.583 mV at pH 5.5. This change in ZP was associated with an increase in the size of the 
liposomes (table S1a and S1b). The change in physical properties of the liposomes can be 
attributed to their swelling and aggregation due to the protonation of the PRL within the bilayer 
membrane of liposomes. As the PRL gets protonated at acidic conditions, it induces a positive 
overall surface charge of the liposomes [46, 47]. The surface charge of the system switching is 
important for antibacterial activity, as it indicates possible binding of the positively charged 
liposomes to the negatively charged bacterial cell wall for enhancing the targeting and killing of 
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the bacteria.[15]. The two-chain fatty acid-based lipids designed in this study were therefore 
capable of successfully generating pH-responsive liposomes.  
 
Table 1: Effect of the two-tailed fatty acid-based lipids on the entrapment efficiency of pH-
responsive liposomes 
Formulations Entrapment efficiency (% EE) 
VAN-Lipo 37.83 ± 2.5% 
DSAPA-VAN-Lipo 36.43 ± 0.64% 
DOAPA-VAN-Lipo 44.27 ± 9.2% 
DLAPA-VAN-Lipo 38.68 ± 4.7% 
DLLAPA-VAN-Lipo 29.86 ± 4.5% 
 
 
[Figure 2. TEM images of VAN loaded liposomes (A) DSAPA-VAN-Lipo, (B) DOAPA-VAN-







2.16.4 In vitro drug release and release kinetics 
 In vitro drug release studies were performed to determine the release profiles of the VAN from 
both the liposomes and the bare drug solution at pH 7.4 and 6.0. Figure: 3A-B represents the in 
vitro release profiles of the VAN loaded liposomes at both pH 7.4 and 6.0. During the first 3 hours, 
the cumulative VAN release from all the formulations was less than 30%, demonstrating a slow 
and sustained release profile, whilst the bare VAN solution released approximately 40% of VAN 
after 3 hours. Thus, the liposomal formulations displayed slower release across all pHs when 
compared to the bare VAN after the first 3 hours. The amounts of VAN released at both pH 7.4 
and 6.0 were compared to determine whether there was a pH-dependent release of the VAN from 
the liposomal formulations.  
The effect of a change in pH on the amount of VAN released between pH 7.4 and 6.0 was 
insignificant for all formulations at all-time intervals. It was observed that although the surface 
charge of the system switched from negative to positive, it did not induce a faster release at acidic 
pH as expected. However, after 5 hours, the DLLAPA-VAN-Lipo showed a higher release, with 
percentage cumulative VAN release of 31.75 ± 3.49 at pH 7.4 and 45.74 ± 0.77 at pH 6.0, whereas 
at the end of 24 hours, the VAN release was 39.33 ± 3.68% at pH 7.4 and 82.84 ± 3.86% at pH 
6.0. More than one factor (acidic pH and degree of saturation) may have contributed towards the 
increase in the VAN release from the DLLAPA-VAN-Lipo after the fifth hour. The effect of acidic 
pH, structural conformation and the pecking order of the fatty acid chain within the bilayer can 
contribute towards the drug release mechanism of the liposomes formulated [48]. The effect of the 
acidic pH can lead to conformational changes of the PRL lipids within the bilayer, inducing 
swelling of the liposome vesicles, thus enhancing the VAN release via diffusion. The degree of 
unsaturation of the C18 fatty acid chain affects the pecking order of the lipids from forming bilayer 
into forming non-bilayer structures. It has been reported that the increase in the cis double bonds 
creates kink and bends at the position of the double bond, making it difficult to pack into a bilayer 
structure, which can contribute towards drug permeability, resulting in a high percentage 
cumulative release of the drug [48]. 
The release mechanism of the formulations was then analyzed with various mathematical models. 
The release kinetic analysis for all formulations at both pHs using mathematical models (Zero 
order, First order, Higuchi, Korsmeyer-Peppas, Hixon-Crowell, and Weibull) was performed to 
further understand the release behaviour of the VAN from the formulated liposomes. Among all 
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models tested for drug release behaviour from all the formulations at both pHs, the Weibull model 
was found to be the best fit, as it had the highest correlation coefficient (R2) that was closer to 1 
and the lowest root mean square error (RMSE) (table S2a and 2b). This model is mostly 
applicable when comparing the release profiles of the matrix type drug delivery by fitting 
parameters and is also useful in describing the release of pharmaceutical doses in terms of the 
fraction of drug accumulated in solution at a given time [49, 50]. In this manner, the model allows 
for direct assessment and quantification of proportionality and can predict the trajectory of the 
dissolution curve over time.  
To further understand the VAN release mechanism for all formulations, the β value which 
describes the shape of the dissolution curve progression was calculated and found to fall within 
the range of 0.75 < β < 1 (table S3) at both pHs, indicating that more than one release mechanism 
was involved. The diffusion controlled release in the normal Euclidean substrate and pH controlled 
release contributed to the release mechanism (combined release mechanism) and the shape of the 
dissolution profile of the formulation [50]. This suggested that the incorporation of pH-responsive 
lipids initiate release of the drug in response to change in pH. The release mechanism was also 
evaluated using the Korsmeyer-Peppas model exponent value (n), where n was found to be within 
the range of 0.43 < n < 0.85 (table S3), confirming that the release mechanism from all 
formulations was non-Fickian at both pHs. The exponent values from the Korsmeyer-Peppas 
model and the beta value from the Weibull model gave an indication of the involvement of more 
than one drug release mechanism, a diffusion and pH-controlled release. Therefore, a high degree 
of unsaturation and reduced pH may contribute towards a high and fast VAN release which can 
enhance the antibacterial activity by improving the drug localization and bioavailability at the 




Figure 3: In vitro VAN release profile from (B) are VAN, DSAPA-VAN-Lipo, DOAPA-VAN-
Lipo, DLAPA-VAN-Lipo and DLLAPA-VAN-Lipo formulations at both (A) pH 7.4 and (B) 6.0. 
 
 
2.16.5 Antibacterial Efficacy 
2.16.5.1 In vitro antibacterial activity 
MRSA accounts for more than 64% of healthcare-associated Staphylococcus aureus infections and 
MRSA infections incidents, medical cost and mortality due to therapeutic failure were reported to 
be higher than those of methicillin-sensitive Staphylococcus aureus(MSSA) infections [51]. 
Infectious Diseases Society of America guidelines still suggest VAN as the drug of choice against 
pathogens belonging to gram-positive bacteria such as S. aureus and its resistant strain (MRSA) 
and have reported that vancomycin trough concentrations should be maintained at 15–20 mg/L for 
serious infections to avoid MRSA resistance to vancomycin [51, 52]. Reports suggest that unless 
alternative therapeutic methods are adopted, the extensive use of vancomycin reduces its 
effectiveness against MRSA infections [53]. Therefore, in this study VAN was used as a drug of 
choice for SA and MRSA, the latter was selected as a positive strain for the study and S. aureus 
was used as a control as it is a less lethal strain of the bacteria. 
The MIC values of the parent lipid derivatives (DSAPA, DOAPA, DLAPA, and DLLAPA), bare 
VAN, VAN-liposomes (DSAPA-VAN-Lipo, DOAPA-VAN-Lipo, DLAPA-VAN-Lipo, and 
DLLAPA-VAN-Lipo) and their respective VAN free liposome formulations, are shown in tables 
2a and 2b. The parent lipid derivatives and VAN free liposome formulations showed no activity 
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at both pHs. Although the results from our previous study reported that the fatty acids used in the 
synthesis of these lipids have activity at higher concentration (> 625 µg/ml) [54], the lack of 
antibacterial activity could be attributed to the derivatization of the fatty acids into lipids and the 
low concentration of lipids used (< 100 µg/ml). Bare VAN at both pH 7.4 and 6.0 against S. aureus 
showed a loss of activity by 2-fold with a decrease in pH, which correlates with previously reported 
data (table 2a and 2b) [15, 55]. A concentration of 7.8 µg/ml of bare VAN was required against 
MRSA at both pHs to induce the antibacterial effect. VAN loaded liposomes from all lipid 
derivatives against both S. aureus and MRSA demonstrated a superior antibacterial activity when 
compared to the bare VAN at both pHs, confirming that the nano-formulations improved the 
activity of VAN.  
The superiority of the formulation can be attributed to the encapsulation of VAN with surface 
charge switching liposomes which enhances the targeted delivery and provides protection against 
acidic conditions, which could extend the half-life and restore effectiveness at the site of infection, 
where bare VAN is known to lose its activity [56]. Surface charge switching liposomes can 
increase its association with the negatively charged bacterial membrane through increased 
electrostatic binding affinity under acid conditions creating a passage for the drug to the bacterial 
cells at a lethal dose. Therefore, enhanced cellular uptake of the drug using pH-responsive 
liposomes can significantly improve the therapeutic effect of antibiotics while minimizing the 
development of resistance. Additionally, MRSA membrane thickness and vancomycin affinity 
trapping prevent the diffusion of large molecules like vancomycin from reaching the cytoplasmic 
membrane where cell wall synthesis begins. This can be closely linked to vancomycin-resistance 
development requiring high levels of the drug to achieve membrane before reaching the site of 
action, thus the need for increased MIC in MRSA than SA [57]. However, through targeting via 
surface switching liposomes more drug can be delivered to the bacteria as the drug will only be 
released at the site of infection (bacterial vicinity). Also, the pH-responsive lipids are made of fatty 
acids which have been reported to transport the drug in the bacteria thus the reduction in MIC 
compared to the bare drug [58]. 
VAN loaded liposomes formulations were also compared at different pHs to assess their 
responsiveness in terms of antibacterial activity. The DSAPA-VAN-Lipo after 24 hours at both 
pHs against S. aureus had the MIC of 1.56 µg/ml, whereas against MRSA the activity was 
improved by 2.5-fold at pH 6.0 when compared to pH 7.4. DOAPA-VAN-Lipo, DLAPA-VAN-
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Lipo and DLLAPA-VAN-Lipo enhanced the VAN activity by 2-fold at pH 6.0 against both S. 
aureus and MRSA strain as compared to pH 7.4. All the formulations had activity over a period 
of 72 hours at pH 6.0, however, DOAPA-VAN-Lipo and DLAPA-VAN-Lipo had the lowest MIC 
against both S. aureus and MRSA strain over a period of 72 hours at pH 6.0 when compared to pH 
7.4.  
These findings suggest that among all formulations, the DOAPA-VAN-Lipo and DLAPA-VAN-
Lipo against both S. aureus and MRSA showed better activity at pH 6.0 when compared to pH 
7.4, with the MIC values being 1.56 µg/ml for both formulations over a period of 72 hours. 
Particularly at pH 6.0, enhanced activity of the formulations can be associated with the protonation 
of the PRLs in the liposomes, contributing towards an overall positive surface charge of the 
liposomes. This can facilitate a fusion process by increasing the electrostatic binding affinity with 
the negatively charged bacterial membrane, which can improve targeting and enhance the exposure 
of the drug to the bacterial cells at a lethal dose [21]. The above-mentioned formulations also had 
sustained and extended activity, which can be correlated to their sustained drug release profile.  
It is also widely reported from studies focusing on the structural relationship of long-chain 
unsaturated/saturated fatty acids, fatty acids derivatives and their antibacterial properties, that 
long-chain unsaturated fatty acids such as oleic acid and other unsaturated fatty acid are 
bactericidal against important pathogens including Methicillin-resistant Staphylococcus aureus, 
whereas stearic acid and other saturated long-chain fatty acids were found to be less active  [59]. 
Therefore, zwitterion lipids derived from these fatty acids, possess antimicrobial activity which 
can help enhance the activity of the formulation [60]. These results suggest that pH-responsive 
lipids with a long unsaturated fatty-acid chain used in the formulation of liposomes can be a 
promising alternative for the targeted and enhanced delivery of antibiotics against S. aureus and 
MRSA at acidic infection sites. These results could be vital in lowering the dose required to treat 
infections with VAN without affecting the therapeutic outcomes and could go a long way towards 
improving patient compliance and lowering the dose-dependent toxicity of vancomycin, such as 






Table 2a. In vitro antibacterial activity of bare VAN and VAN loaded pH-responsive liposomes 
at pH 7.4. 
MIC/ µg/ml 24 hours  48 hours   72 hours  
 S. aureus MRSA  S. aureus MRSA  S. aureus MRSA 
Bare VAN 1.95 7.8  NA NA  NA NA 
DSAPA-VAN-Lipo 1.95 3.9  3.9 3.9  NA NA 
DOAPA-VAN-Lipo 0.78 1.56  3.1 1.56  3.1 6.25 
DLAPA-VAN-Lipo 0.78 1.56  1.56 1.56  3.1 1.56 
DLLAPA-VAN-
Lipo 
0.98 3.9  3.9 7.8  3.9 7.8 
NA = No Activity 
Table 2b. In vitro antibacterial activity of bare VAN and VAN loaded pH-responsive liposomes 
at pH 6.0. 
MIC/ µg/ml 24 hours   48 hours   72 hours  
 S. aureus MRSA  S. aureus MRSA  S. aureus MRSA 
Bare VAN 3.9 7.8  NA NA  NA NA 
DSAPA-VAN-Lipo 1.95 1.95  3.9 3.9  3.9 3.9 
DOAPA-VAN-Lipo 0.78 1.56  0.78 1.56  1.56 1.56 
DLAPA-VAN-Lipo 0.78 1.56  1.56 1.56  1.56 1.56 
DLLAPA-VAN-
Lipo 
1.95 1.95  1.95 3.9  3.9 3.9 
NA = No Activity 
 
2.16.5.2 Bacterial cell viability assay 
Cell (MRSA) viability was performed using a rapid flow cytometry method [61]. This study was 
performed on the DOAPA-VAN-Lipo and DLAPA-VAN-Lipo formulations, which were 
identified from the in vitro antibacterial activity study as the most promising formulations when 
compared to bare VAN and other formulations. Using a specialized dye (PI fluorescent), dead 
MRSA cell were detected after 6 hours incubation with bare VAN, DOAPA-VAN-Lipo and 
DLAPA-VAN-Lipo mediums separately by observing the morphological changes of the bacterial 
cell. PI fluorescent dye is a non-cell wall permeant that allows for the classification of cells into 
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dead cells in the population [62]. Histogram plots of the PI fluorescence versus cell count (PI 
uptake) of the incubated samples (figure 4) were generated using Kaluza-1.5.20 (Beckman Coulter 
USA) flow cytometer software. Figure 4A represents live cells (negative events) with no PI uptake.  
Vancomycin has a well-known mode of action in inhibiting bacterial cell wall synthesis, thus upon 
treatment of the bacteria with VAN, the uptake of PI, which is a non-cell wall permeant dye it is 
expected. This results in a shift in fluorescence upon intercalation with the DNA of the bacteria, 
which can be quantified. The gates were created beyond the fluorescence of the viable cells for 
detecting the dead cells in the population. After treating the MRSA cells with bare VAN, DOAPA-
VAN-Lipo, and DLAPA-VAN-Lipo, a PI fluorescence shift was observed (figure 4B, C, and D). 
VAN (figure 4E), DOAPA-VAN-Lipo (figure 4C), DLAPA-VAN-Lipo (figure 4D) at their 
respective MICs (7.8 µg/ml, 1.56 µg/ml and 1.56 µg/ml) displayed 63.40 ± 1.51%, 71.98 ± 1.3% 
and 73.32 ± 1.21% of MRSA dead cells in the population respectively. This indicates that at a 
lower concentration, the formulations showed higher killing percentages.  
Incubating the MRSA cells with bare VAN at the same concentration as the MIC of the 
formulations (1.56 µg/ml), which is 5-folds lower than the MIC of bare VAN, displayed a killing 
percentage of only about 32.98 ± 1.49% dead cells. These results are in support with those from 
the previous section (in vitro antibacterial activity), thereby showing the superiority of 
encapsulating the VAN into the liposome, in terms of improving the antibacterial activity of VAN 
compared to conventional methods. This suggests that encapsulating the VAN in the pH-
responsive liposomes enhances their efficacy and reduces the daily dose required to treat the 




Figure 4: (A) untreated MRSA (live cells), B, C, D and E representing the percentage of dead cells 
after incubation with VAN, DOAPA-VAN-Lipo and DLAPA-VAN-Lipo at 1.59 mg/mL MIC and 
VAN at its MIC (7.8 mg/mL) respectively at pH 7.4. 
2.16.5.3 In vivo antibacterial activity and Histological evaluation 
DOAPA-VAN-Lipo and DLAPA-VAN-Lipo formulations when compared to the bare VAN and 
other formulation, demonstrated superior results from both the in vitro antibacterial activity and 
the bacterial cell viability studies. These formulations were further evaluated to confirm their in 
vivo efficacies in a biological system. This was performed using a BALB/c mice skin infection 
model, and the number of CFUs were being quantified for untreated, bare VAN, DOAPA-VAN-
Lipo, and DLAPA-VAN-Lipo treated groups and represented as log10 CFU/ml. The one-way 
ANOVA tests demonstrated a significant reduction (P < 0.0002) in the bacterial load recovered 
from the treatment groups treated with the bare VAN, DOAPA-VAN-Lipo and, DLAPA-VAN-Lipo 
when compared to the untreated group.  
The MRSA count was 7.7-fold significantly higher (P = 0.0043) for the untreated group when 
compared to the VAN treated mice skin. In all conditions, the DOAPA-VAN-Lipo and DLAPA-
VAN-Lipo were the most effective in efficiently reducing the MRSA count of the treated skin. The 
MRSA count in the untreated mice, when compared to the DOAPA-VAN-Lipo and DLAPA-VAN-
Lipo, was 32.4- fold (P < 0.0002) and 16- fold (P < 0.0003) folds. The DOAPA-VAN-Lipo and 
DLAPA-VAN-Lipo formulation reduced the MRSA count by 4.2-fold (P = 0.023) and 2.1-fold (P 
= 0.035) respectively when compared to the bare VAN. There was no significant difference in the 
CFU/mL reduction when comparing the groups treated with the DOAPA-VAN-Lipo and DLAPA-
VAN-Lipo formulations (P > 0.9). These in vivo antibacterial activity results, together with the in 
vitro antibacterial activity and cell viability results of the formulations, show the effectiveness of 
the fatty acid-based lipid derivatives in formulations of pH-responsive liposomes as a practical 




Figure 5: MRSA count post 48 h of treatment. Data represent the mean ± SD (n = 3). *denotes 
statistical significance for DOAPA-VAN-Lipo and DLAPA-VAN-Lipo versus the bare VM. 
**denotes significant difference between untreated versus bare VAN, and ***denotes the 





Figure 6: Schematic illustration of VAN-Lipo formulation and their in vivo efficacy 
The morphological analysis was performed on all removed skin samples (untreated, bare VAN, 
DOAPA-VAN-Lipo and DLAPA-VAN-Lipo treated groups) to evaluate the histological changes 
and skin integrity at 48 hours after the MRSA infection. Using H&E stained slides, untreated skin 
samples showed signs of tissue inflammation and abscess formation (figure 6A). There was also 
signs of swelling and abscess formation on the bare VAN treated group, although the degree of 
inflammation was much less than that of the untreated group (figure 6B). A smaller region of 
abscess formation with a decreased inflammation, as represented by the decreased swelling, was 
observed from the DOAPA-VAN-Lipo treated group (figure 6C). This group (figure 6D) 
displayed no signs of abscess formation, with minimal signs of tissue inflammation being 
observed. The presence of white blood cells (WBCs) at the infection site is also an indication of 
the degree of inflammation. The untreated and bare VAN treated groups presented large quantities 
of WBCs, whereas the DLAPA-VAN-Lipo treated group presented a lower quantity of WBCs, 
which were minimal in the DLAPA-VAN-Lipo treated group.  
There was a direct correlation between the histomorphological observations and the recovered 
bacterial loads from each study. A high count of bacteria loads at the infection site of the untreated 
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and VAN treated skin samples represented by high levels of inflammation, abscess formation and 
the presence of white blood cells as a result of the increased immune response. Whereas, infected 
skin samples treated with DOAPA-VAN-Lipo and DLAPA-VAN-Lipo showed a reduced immune 
response indicating the lowest count of isolated bacteria with minimal signs of inflammation and 
abscess formation. These findings of the histomorphological studies confirmed the antimicrobial 
advantage and superiority of the DOAPA-VAN-Lipo and DLAPA-VAN-Lipo compared to bare 
VAN.  
Figure 7: Light Microscopy (LM) micrographs of the control and the treated skin samples 
stained with H&E; (X40) (A) Untreated (MRSA and Saline), (B) Bare VM, (C) 
DOAPA-VAN-Lipo and (D) DLAPA-VAN-Lipo. 
2.16.6 Physical stability studies 
All formulations were investigated for short-term physical stability under different storage 
conditions (room temperature and at 4 ºС) for 3 months. The physical appearance, particle size, 
PDI and zeta potential were observed at 0, 30, 60 and 90 days. All formulations showed stability, 
with no significant differences (P > 0.05) in size, PDI and zeta values over a period of 90 days at 
4 ºС. At room temperature, the DOAPA-VAN-Lipo and DLAPA-VAN-Lipo proved to be more 
stable than the DSAPA-VAN-Lipo and DLLAPA-VAN-Lipo formulations, which showed 
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instability in terms of physical appearance, indicating some precipitate after the second month, and 
a significant increase in particle size and PDI (P < 0.05) when compared to DOAPA-VAN-Lipo 
and DLAPA-VAN-Lipo 
2.17 Conclusion 
Bacterial resistance against one of the last-line antibiotics (e.g. VAN) has become a major concern 
to public health worldwide. Alternative therapeutic strategies, such as targeted delivery to address 
this problem, have been introduced. In this study, pH-responsive, VAN loaded liposomes were 
developed from novel pH-responsive two tail fatty acid-based lipid derivatives for targeted and 
sustained delivery of VAN at the site of infection. There were changes in size, PDI and zeta 
potential of the formulated liposome with respect to a change in pH from 7.4 to 6.0. The DOAPA-
VAN-Lipo and DLAPA-VAN-Lipo were the most effective formulated liposomes, demonstrating 
enhanced in vitro antibacterial activity at acidic conditions. The in vivo studies also confirmed the 
superiority of these formulations over bare VAN against MRSA. The percentage killing of 71.98 
± 1.3% and 73.32 ± 1.21% for DOAPA-VAN-Lipo and DLAPA-VAN-Lipo, respectively 
suggested that these formulations are better than bare VAN at very low concentrations. This can 
help reduce effective doses required thereby preventing possible drug resistance. The biosafety of 
the lipids, together with their enhanced antibacterial activity, demonstrate the possible diverse use 
of these materials to develop pH-responsive delivery systems to deliver a range of drugs to treat 
various diseases that are characterized by acidic conditions. 
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Table S1a: Effect of pH on Particle size, PDI and ZP value for different pH-sensitive VCM loaded liposomes. 
liposome DSAPA-VCM-Lipo  DOAPA-VCM-Lipo 
pH Size(nm) PDI ZP (mV)  Size (nm) PDI ZP (mV) 
7.4 89.37±0.549 0.184±0.007 -10.4±2.38  96.92±8.732 0.204±0.014 -8.85±3.19 
6.0 114.0±2.972 0.629±0.107 -1.20±0.176  162.8±0.012 0.176±0.012 1.54±0.101 
5.5 118.8±1.680 0.370±0.016 2.05±0.659  114.5±12.54 0.208±0.023 0.667±0.654 
 
Table S1b: Effect of pH on Particle size, PDI and ZP value for different pH-sensitive VCM loaded liposomes. 
Liposome  DLAPA-VCM-Lipo  DLLAPA-VCM-Lipo 
pH Size (nm) PDI ZP(mV)  Size (nm) PDI ZP (mV) 
7.4 86.26±11.76 0.203±0.010 -11.3±2.22  88.52±5.078 0.151±0.016 -11.8±2.99 
6.0 158±1.908 0.129+0.019 1.02±0.1012  301.2±24.41 0.644±0.230 -1.26±0.427 
5.5 97.37±8.928 0.350±0.235 3.10±0.583  282±31.58 0.532±0.170 -0.318±0.746 
 
Table S2a: In vitro VCM release data from the different Liposome formulations at pH 7.4 
 
No Name of 
release model 
DSAPA-VCM-Lipo DOAPA-VCM-Lipo DLAPA-VCM-Lipo DLLAPA-VCM-Lipo 
R2 RSME AIC R2 RSME AIC R2 RSME AIC R2 RSME AIC 
1 Zero order 0.4277 17.72 90.54 0.5626 16.05 87.61 0.4188 17.63 90.40 0.6067 17.45 90.07 
2 First Order 0.9457 24.29 64.18 0.9609 4.292 57.89 0.9367 5.494 64.16 0.1185 12.88 83.49 
3 Higuchi 0.9358 5.919 66.44 0.9634 4.770 61.08 0.9365 5.692 65.43 0.6945 7.610 71.70 
4 Korsmeyer-
Peppas 
1 2 38 0.9836 2.372 38.92 0.9886 1.924 36.06 0.9878 2.231 32.55 
5 Weibull 0.9960 1.124 25.57 0.9752 2.926 43.86 0.9882 2.044 38.95 0.9951 0.9455 24.30 
6 Hixson-
Crowell 
0.8921 7.606 71.86 0.9347 5.203 61.66 0.8818 7.593 71.48 0.1052 14.45 85.98 
 
Table S2b: In vitro VCM release data from the different Liposome formulations at pH 6.0 
No Name of release 
model 
DSAPA-VCM-Lipo DOAPA-VCM-Lipo DLAPA-VCM-Lipo DLLAPA-VCM-Lipo 
R2 RSME AIC R2 RSME AIC R2 RSME AIC R2 RSME AIC 
1 Zero order 0.0033 21.14 94.39 0.0783 22.15 95.33 0.2067 21.71 95.03 0.3804 19.37 92.49 
2 First Order 0.8325 8.631 74.74 0.9067 7.041 70.25 0.9322 6.096 66.43 0.9699 4.056 57.22 
3 Higuchi 0.8841 7.186 70.60 0.8990 7.280 70.45 0.9160 6.932 69.70 0.9566 5.027 62.53 
4 Korsmeyer-
Peppas 
0.9947 1.407 31.59 0.9969 1.162 27.65 0.9767 3.237 48.07 0.9941 1.568 33.75 
5 Weibull 0.9957 1.252 29.70 0.9963 1.226 28.93 0.9818 2.877 46.47 0.9958 1.326 31.07 






Table S3. In vitro release best fit values for different formulation at pH 7.4 and 6.0  
pH  7.4 6.0 
Formulation Model Equation Release Exponent Release Exponent 
DSAPA-VCM-Lipo KP Q = k.tn n = 0.777 n=0.625 
 WB Q = 1 exp [-(t)a/b n = 0.856 β= 0.792 
DOAPA-VCM-Lipo KP Q = k.tn n = 0.629 β= 0.646 
 WB Q = 1 exp [-(t)a/b n = 0.840 β= 0.842 
DLAPA-VCM-Lipo KP Q = k.tn n = 0.777 β= 0.658 
 WB Q = 1 exp [-(t)a/b n = 0.830 β= 0.825 
DLLAPA-VCM-Lipo KP Q = k.tn n =0.536 n= 0.679 
 WB Q = 1 exp [-(t)a/b n = 0.540 β= 0.667 
KP= Korsmeyer-Peppas, WB= Weibull 
Table S4a: Effect of storage on physicochemical characteristics of vancomycin loaded liposomes (DSAPA-VCM-Lipo) 
Storage condition Particle size PDI ZP 
Time (days) RT 4 ºC RT 4 ºC RT 4 ºC 
0 94.44±0.8581 96.94±0.8865 0.225±0.008 0.232±0.007 -11.3±2.65 -7.93±24 
30 231.6±71.74 107.4±8.824 0.686±0.264 0.381±0.052 -17.7±8.89 -9.10±3.15 
60 681.6±71.74 97.84±6.859 0.686±0.264 0.250±0.046 -22.4±10.5 -15.1±6.94 
90 1073±8.741 104.4±9.384 0.534±0.256 0.318±0.077 -25±8.5 -12.2±2.98 
 
Table S4b: Effect of storage on physicochemical characteristics of vancomycin loaded liposomes (DOAPA-VCM-Lipo) 
Storage condition 
Time (days) 
Particle size PDI ZP 
RT 4 ºC RT 4 ºC RT 4 ºC 
0 79.83±1.505 84.17±5.957 0.192±0.009 0.169±0.024 -12.8±3.79 -13.0±3.45 
30 84.13±12.59 86.46±1.368 0.248±0.068 0.198±0.025 -15.8±5.45 -12.4±3.82 
60 93.30±12.44 80.33±1.566 0.293±0.054 0.191±0.021 -20.2±8.82 -14.4±0.183 









Table S4c: Effect of storage on physicochemical characteristics of vancomycin loaded liposomes (DLAPA-VCM-Lipo) 
Storage condition Particle size PDI ZP 
Time (days) RT 4 ºC RT 4 ºC RT 4 ºC 
0 82.92±2.615 76.98±0.8767 0.161±0.010 0.170±0.016 -11.8±3.39 -11.2±2.90 
30 128.6±5.178 87.13±8.114 0.078±0.010 0.204±0.043 -16.3±3.91 -13.1±5.70 
60 157.7±1.754 74.40±1.467 0.207±0.016 0.194±0.020 -18.6±4.4 -14.6±3.51 
90 177.6±3.284 81.86±1.249 0.223±0.020 0.182±0.011 -33.2±7.81 -13.2±3.24 
 
Table S4d: Effect of storage on physicochemical characteristics of vancomycin loaded liposomes (DLLAPA-VCM-Lipo) 
Storage condition Particle size PDI ZP 
Time (days) RT 4 ºC RT 4 ºC RT 4 ºC 
0 91.20±16.42 83.90±6.13 0.217±0.080 0.149±0.017 -10.1±3.06 -11.0±3.27 
30 177±7.86 80.51±2.332 0.450±0.376 0.168±0.00 -19.4±13.0 -12.4±3.20 
60 257.5±55.86 92.05±4.297 0.296±0.151 0.232±0.052 -11.0±14.5 -13.7±3.94 






















CHAPTER 3: EXPERIMENTAL PAPER 2 
3.1 Introduction 
This chapter addresses Aim 2 and Objectives 1 – 4 and it is a first authored published experimental 
paper. This chapter highlights the formulation and characterization of pH-responsive micelles from 
a fatty acid-based lipid Dendritic Amphiphile. The dendritic amphiphile was evaluated for in vitro 
toxicity and used in the formulation of micelles which was also characterized for their 
physicochemical properties, morphology, bacteria-killing percentage, in vitro and in vivo 
antibacterial properties. 
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3.4 Abstract 12 
The aim of this study was to synthesize a novel biocompatible pH-responsive oleic acid-based dendritic 13 
lipid amphiphile (OLA-SPDA) which self-assembled into stable micelles (OLA-SPDA -micelles) with a 14 
relatively low critical micelle concentration (CMC) of 5.6x10-6M. The formulated micelles had particle 15 
size, polydispersity index (PDI) and zeta potential (ZP) of 84.16±0.184 nm, 0.199±0.011 and -42.6±1.98 16 
mV, respectively, at pH 7.4. The vancomycin (VCM) encapsulation efficiency was 78.80±3.26%. The 17 
micelles demonstrated pH-responsiveness with an increase in particle size to 141.1±0.0707 nm and a much 18 
faster release profile at pH 6.0, as compared to pH 7.4. The minimum inhibitory concentration (MIC) of 19 
VCM-OLA-SPDA-micelle against methicillin-resistant staphylococcus aureus (MRSA) was 8-fold lower 20 
compared to bare VCM, and the formulation had a 4-fold lower MIC at pH 6.0 when compared to the 21 
formulation’s MIC at pH 7.4. MRSA viability assay showed the micelles had a percentage killing of 93.39% 22 
when compared bare-VCM (58.21%) at the same MIC (0.98 µg/ml). In vivo mice (BALB/c) skin infection 23 
models showed an 8-fold reduction in MRSA burden after treatment with VCM-OLA-SPDA-micelles when 24 
compared with bare VCM. The above results suggest that pH-responsive VCM-OLA-SPDA-micelles has 25 
the potential to be an effective carrier to enhance therapeutic outcomes against infections characterized by 26 
low pH. 27 
Keywords: dendritic amphiphile, pH-responsive micelles, antibacterial, vancomycin, methicillin resistance 28 




3.5 Introduction 31 
Resistant gram-positive bacteria, such as methicillin-resistant staphylococcus aureus (MRSA), have 32 
become one of the greatest threats to the global healthcare system 1-3. The treatment of MRSA infections 33 
has been limited within the lipopeptides class of antibiotics, such as vancomycin (VCM); and in recent 34 
decades, VCM has remained the last resort in the treatment of serious MRSA infections 3. However, the 35 
emergence of non-susceptible MRSA strains has been associated with the failure of VCM treatment against 36 
MRSA, suggesting the need for more effective therapies and therapeutic approaches 1.    37 
 38 
Traditional pharmaceutical formulations or dosage forms of antibiotics have been associated with the 39 
difficulty in maintaining an effective antibiotic concentration at the site of infection, thus contributing to 40 
compromised antibiotic therapeutic outcomes 4, 5. High antibiotic doses are frequently administered to 41 
maintain an effective concentration, which adversely increases the risk of toxic side-effects in the normal 42 
cells 6. These suboptimal concentrations at target sites prevent a complete eradication of infection, resulting 43 
in the development of resistant strains 6. Novel nano-sized, and smart biocompatible, drug carriers have 44 
demonstrated the potential to overcome the limitations of conventional dosage forms, showing improved 45 
drug pharmacokinetics, safety and drug efficacy through targeting 6, 7. Most importantly, they can reduce 46 
drug-resistance development through high drug dose localisation and high cellular uptake with minimal 47 
toxic side-effects 8.  48 
 49 
Nanosystems responsive to a specific stimulus (pH, temperature, enzymes, etc.) were introduced to achieve 50 
the optimum therapeutic effect through targeted and triggered drug release in response to a specific 51 
stimulant, thus facilitating drug accumulation at the desired location 9.  pH-responsive drug delivery systems 52 
such as micelles have emerged as one of the alternative therapies for diseases characterized by low pH at 53 
the disease site, such as inflammation, cancer and bacterial infections 10, 11. Acidic pH has been found in a 54 
wide range of bacterially infected sites, such as soft tissue infections, respiratory tract, urinary tract, skin 55 
and intra-abdominal 12, 13. The pH-responsive micelles can accelerate drug release at the target site, allowing 56 
for high drug concentrations for efficient eradication of the bacterial infection 14. Therefore, developing a 57 
pH-responsive delivery system can increase the accumulation of the drug at the infected site and restore the 58 
effectiveness of antibiotics such as VCM 15. 59 
 60 
Micelles are self-assembled nanostructures of classical amphiphilic molecules characterized by a 61 
hydrophobic-hydrophilic segment and offer a wide range of applications in nanomedicine as suitable 62 
carriers for poorly soluble drugs 16, 17.  Although pH-responsive micelles are among the most attractive 63 
smart drug delivery systems, they still suffer from thermodynamic and kinetic instability after intravenous 64 
90 
 
injection, which causes the micelles to disintegrate 18. This results in premature drug release (dose dumping) 65 
of the encapsulated drug at unexpected locations when diluted in body fluids 19. Also, low drug 66 
encapsulation efficiency and difficulty in transportation through cell membranes are some of the limitations 67 
that hinder the advancement of micelles from bench to clinical trials 20.  68 
 69 
Dendritic amphiphiles provide an alternative to the classical amphiphiles in the formulation of structurally 70 
stable micelles 21. These micelles are stable as polymeric assemblies and displays membrane properties like 71 
those of the low molecular weight assemblies for better transportation across the cell membrane 21. They 72 
also possess enhanced permeability and retention (EPR) effect. However, most of the reports have 73 
demonstrated a lack of active release and targeting of the encapsulated drug in response to a specific 74 
stimulus for efficient drug delivery and enhanced therapeutic outcome at the target site 22. Therefore, 75 
designing a stable pH-responsive micelle from pH-responsive dendritic amphiphiles can make micelles a 76 
more efficient drug delivery system that can lead to drug accumulation at a lethal dose at disease sites 77 
through triggered release. This can ensure sufficient bacterial infection eradication, thus reducing the 78 
chances of antibiotic-resistance development 23  79 
 80 
pH-responsive dendritic polymeric micelles are the most commonly studied hyperbranched and 81 
multifunctional nanosyatem for efficient delivery of anticancer and antitumor agents 18. According to our 82 
knowledge, no pH-responsive lipid-dendritic micelles for antibiotic delivery have been reported in the 83 
literature. The bicephalous dianionic amphiphile is one of the recently reported branched lipid amphiphiles 84 
with a similar structural arrangement to dendritic amphiphiles, forming a stable micellar structure with 85 
relatively low CMC when compared to convention amphiphiles 21, 24. The advantage of  multivalence of the 86 
hydrophilic portion of the branched amphiphiles provides room for surface functionalization for site-87 
specific drug release in response to specific stimuli 25. The optimum therapeutic outcome of pH-responsive 88 
micelles can be achieved through acid-triggered drug release which quickly releases the drug at the target 89 
site through a protonation/deprotonation mechanism of the amphiphile. This process induces disassembly 90 
of the micelle structure which leads to the drug being released in response to reduced pH, such as the site 91 
of infection. Additionally, lipid-based branching amphiphiles can offer high stability, high drug loading 92 
capacity for both hydrophilic and lipophilic drugs, longer circulation, and ability to mimic biological 93 
membrane components when compared to conventional classical amphiphiles in the formulation of micelles 94 
26, 27. Thus, these positive attributes of the branched lipid amphiphiles advocate for more research in this 95 





The acidic bacterial environment can be exploited using pH-responsive micelles to achieve an optimum 99 
antibiotic therapeutic index. Previously, our group has reported on pH-responsive lipid nanosystems, such 100 
as liposomes28, solid lipid nanoparticles29 and nanostructured lipid carriers 30. These systems significantly 101 
enhanced the activity of VCM through drug localisation, high interaction of the lipid system with the cell 102 
membrane, and pH-triggered drug releases.  Therefore, in continuation of our search for optimal pH-103 
responsive lipid systems for the efficient delivery of VCM, we herein introduce a pH-responsive lipid-104 
dendritic based nanosystems, formulated from an oleic acid-based dendritic lipid amphiphile that has not 105 
been reported before for any class of drug. 106 
 107 
In this study, we designed and synthesized a novel oleic acid-derived lipid dendritic amphiphile (OLA-108 
sodium propionate dendritic amphiphile (OLA-SPDA)) to self-assemble into stable micelles containing 109 
VCM for targeted delivery at acidic bacterial infection sites for the enhanced eradication of MRSA 110 
infection. We envisaged this lipid amphiphile to be biosafe for the formation of stable micelles with 111 
properties such as high stability and encapsulation efficiency, pH-responsiveness, and fusion ability with 112 
the bacterial cell membrane, for the improvement of antibiotic activity against bacterial infection as a 113 
strategy for addressing the current global antimicrobial drug resistance crisis. Furthermore, this pH-114 
responsive lipid-dendritic micellar system can be used for the delivery of other drugs to disease sites 115 
characterized by low pH. 116 
 117 
3.6 Materials and Methods  118 
3.6.1 Materials 119 
1,3-Diamino-2-propanol was purchased from Sigma-Aldrich (UK). N, N’-dicyclohexyl carbodiimide 120 
(DCC) and trifluoroacetic acid (TFA) were procured from Merck (Germany) while tertiary butyl acrylate 121 
(TBA) and triisopropylsilane (TIPS) were both purchased from Sigma-Aldrich (Germany). Mueller Hinton 122 
agar (MHA) and Nutrient broth were purchased from Biolab Inc. (South Africa). The following reagents; 123 
oleic acid (OA), Mueller Hinton broth 2 (MHB), Vancomycin hydrochloride, 4-(dimethylamino) pyridine 124 
(DMAP), dialysis tubing cellulose membrane and all other materials were purchased from Sigma-Aldrich 125 
(USA).  The vancomycin free base (VCM) was obtained from converting vancomycin hydrochloride as 126 
described from a previously reported method [21]. An Elix® water purification system Millipore Corp. 127 
(USA) was used to obtain milli-Q purified water. Bacterial strains Staphylococcus aureus (ATCC 25922) ( 128 
S.aureus) and Staphylococcus aureus (Rosenbach) (ATCC®BAA-1683) (MRSA) were used for this project. 129 
A Bruker Alpha-p spectrometer with a diamond ATR (Germany) was used to obtain FT-IR spectra for all 130 
the compounds synthesized. 1H and 13C NMR spectra were obtained by using a Bruker 400 and 600 Ultra 131 
shield™ (United Kingdom) NMR. 132 
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3.6.2 Methods  133 
3.6.2.1 Synthesis and characterization of the lipid amphiphile (OLA-SPDA) 134 
 135 
Scheme 1: Synthesis of the oleic acid-sodium propionate dendritic amphiphile (OLA-SPDA) as per the 136 
above scheme 137 
3.6.2.2 Tetra-tert-butyl3,3',3'',3'''- ((2-hydroxypropane-1,3-diyl)bis(azanetriyl)) tetrapropionate (3). 138 
In a round-bottom flask kept under inert conditions (purged with nitrogen), 1,3-diamino-2-propanol (2 g, 139 
22.19 mmol) was diluted in methanol (30 ml) and then tert-butyl acrylate (28 g, 221.92 mmol) was added 140 
and stirred for 24 h at room temperature while maintaining dark conditions. After reaction completion, the 141 
solvent and excess of tert-butyl acrylate were removed under reduced pressure (vacuum) in a rotavapor to 142 
give a colourless, oily product with a quantitative yield above 91%. Characterization was as follows: 1H 143 
NMR (400 MHz, CDCl3) δ(ppm): 1.33 (s, 36H), 2.28-2.24 (m, 12H), 2.74-2.60 (m, 8H), 3.67-3.64 (m, 1H); 144 
13C NMR (400 MHz, CDCl3) δ(ppm): 28.0, 33.5, 49.8, 58.5, 65.9, 80.2, 171.7. 145 
3.6.2.3 Tetra-tert-butyl 3,3',3'',3'''- ((2-(oleoyloxy)propane-1,3-diyl)bis(azanetriyl)) tetrapropionate 146 
(5). To synthesize compound 5,  oleic acid (2.81g, 9.95 mmol) was added to a stirring mixture of compound 147 
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3 (5 g, 8.30), DCC (2.58 g, 13.46 mmol) and DMAP (0.101 g, 0.829 mmol) in dry DCM and further stirred 148 
for 24 h under a nitrogen atmosphere at room temperature. Dicyclohexylurea formed was filtered off and 149 
the crude product was obtained by removing the solvent (filtrate) under reduced pressure (vacuum). The 150 
crude product was then purified by column chromatography on silica gel using ethyl acetate in hexane (10-151 
15% v/v) to give a yield of 95%. Characterization was as follows: 1H NMR (400 MHz, CDCl3) δ(ppm): 152 
0.88 (m, 3H), 1.28-1.25 (m, 20H), 1.42 (s, 36H), 1.61-1.56 (m, 2H), 2.0-1.97 (m, 4H), 2.28-2.24 (m, 2H), 153 
2.39-2.31 (m, 8H), 2.59-2.48 (m, 4H), 2.82-2.73 (m, 8H), 4.98-4.94 (m, 1H), 5.34-5.31 (m,2H); 13C NMR 154 
(400 MHz, CDCl3) δ(ppm):14.0, 22.6, 24.8, 27.2, 28.1, 29.0, 29.1, 29.2, 29.3, 29.5, 29.7, 31.8, 33.3, 33.7, 155 
34.5, 49.8, 50.0, 55.4, 58.5, 70.9, 80.5, 171.8, 173.2 156 
3.6.2.4 3,3',3'',3'''-((2-(oleoyloxy)propane-1,3-diyl)bis(azanetriyl)) tetrapropionic acid (6). 157 
Compound 5 (4 g, 4.6 mmol) was treated with 25% trifluoroacetic acid (TFA) in DCM and stirred for 2 h 158 
at room temperature. The reaction was monitored by TLC to verify completion. The TFA was removed 159 
under reduced pressure to give a viscous oil product. The product was re-dissolved in methanol (10 ml) and 160 
evaporated under reduced pressure at least 3 times for a complete TFA removal.  The vacuum dried product 161 
gave a yield above 89 % and characterization was as follows: 1H NMR (400 MHz, CDCl3) δ(ppm): 0.90 162 
(m, 3H), 1.33-1.29 (m, 20H), 1.62-1.57 (m, 2H), 2.07-2.04, (m, 4H), 2.19-2.16 (m, 1H), 2.60-2.39 (m, 10H), 163 
2.78-2.74 (m, 3), 2.97-2.91 (m, 2H), 3.15-3.04 (m, 5H), 3.29-3.22 (m, 3H), 5.37-5.30 (m, 3H); 13C NMR 164 
(400 MHz, CDCl3) δ(ppm): 13.8, 22.5, 25.5, 27.07, 27.2, 27.8, 29.3, 31.4, 31.9, 50.6, 56.3, 62.5, 127.6, 165 
129.5, 160.3, 179.2 166 
3.6.2.5 Sodium 3,3',3'',3'''- ((2-(oleoyloxy)propane-1,3-diyl)bis(azanetriyl)) tetrapropionate (7).  167 
Compound 7 (1.56 g, 2.43 mmol) was added to an aqueous solution of Na2CO3 (0.514 g, 4.85 mmol) under 168 
vigorous stirring, in small portions, until the starting material was completely dissolved. This was stirred 169 
for 2 h in an open beaker and the resulting solution was freeze-dried for 48 h to give a white hydroscopic 170 
product with a yield of 97 %. Characterization was as follows: 1H NMR (400 MHz, CDCl3) δ(ppm): 0.90 171 
(m, 3H), 1.33-1.29 (m, 20H), 1.62-1.57 (m, 2H), 2.07-2.04, (m, 4H), 2.19-2.16 (m, 1H), 2.60-2.39 (m, 10H), 172 
2.78-2.74 (m, 3), 2.97-2.91 (m, 2H), 3.15-3.04 (m, 5H), 3.29-3.22 (m, 3H), 5.37-5.30 (m, 3H); 13C NMR 173 
(400 MHz, CDCl3) δ(ppm): 13.8, 22.5, 25.5, 27.07, 27.2, 27.8, 29.3, 31.4, 31.9, 50.6, 56.3, 62.5, 127.6, 174 
129.5, 160.3, 179.2 175 
3.6.3 In vitro cytotoxicity (MTT assay) and In vitro hemolysis analysis 176 
The MTT assay is a commonly used cell-based study for newly synthesized compounds to assess their 177 
cytotoxic effect leading to cell death 31, 32. After successful synthesis, the biosafety of the OLA-sodium 178 
propionate dendric amphiphile (OLA-SPDA) was assessed via MTT assay using three cell lines: human 179 
liver hepatocellular carcinoma (HEP G2), human breast adenocarcinoma (MCF7) and adenocarcinoma 180 
human alveolar basal epithelial (A549), as described in a previously reported study 33. Briefly, the cell lines 181 
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were grown under humidified conditions (5% CO2) and 96-well plates were used to seed cells at a density 182 
of 2.5 × 103 and incubated for 24 h at 37 ℃. After the incubation, the cells were treated with 20, 40, 60, 80, 183 
100 and 120 μg/ml concentrations of the test compound and further incubated for 24 h. After the incubation 184 
period, the culture medium was discarded and replaced with the fresh medium, followed by addition of 100 185 
μl of MTT solution (5 mg/ml) in phosphate buffer solutions (PBS) to each well. This was incubated for a 186 
further 4 h at 37 ℃ and the reaction was quenched by lysing the cells with dimethyl sulfoxide (100 μl) in 187 
each well. The absorbance for each well was recorded using a microplate spectrophotometer (Mindray MR-188 
96A) set at 540 nm.  The culture medium with cells and without cells was used as the positive and negative 189 
control respectively. All the experiments were replicated six times. The percentage cell viability of every 190 
treated sample was calculated using the following equation: 191 
                   % Cell viability = (
A 540 nm treated cells
A 540 nm untreated cells 
) ×  100         (1) 192 
The hemolysis analysis is a part of the biosafety study within the blood system and was performed on 193 
different concentrations of OLA-SPDA against red blood cells (RBCs) according to a previously described 194 
method 34. Briefly, RBCs were harvested from fresh sheep blood by centrifugation at 2800 rpm for 5 min, 195 
followed by washing with PBS solution several times and centrifuging to ensure no haemoglobin release. 196 
Different concentrations of OLA-SPDA (1.8 ml) ranging from 0.250 to 0.0075 mg/ml were incubated with 197 
RBCs suspension (0.2 ml) at 37 ◦C for 60 min. RBCs incubated with PBS and with distilled water were 198 
treated as negative and positive controls, respectively. After this, the samples were then centrifuged at 3000 199 
rpm for 10 min. The hemolytic effect from samples can be qualitatively determined through observation of 200 
the sample mixtures, indicated by a colour change from clear to red showing release of haemoglobin for 201 
samples that are hemolytic. Quantitatively, the percentage of hemolysis can be measured in terms of the 202 
amount of haemoglobin released using UV Spectrophotometric (Shimadzu UV- 1650 PC) at 570 nm of the 203 
supernatant from each sample at different concentrations. The degree of hemolysis was calculated by the 204 
following equation: 205 
% hemolysis = (
A(test)−A(negtive control)
A(positive control)−A(negetive control) 
) ×  100         (2) 206 
 207 
3.6.4 Determining Critical Micelle Concentration (CMC) 208 
A Malvern Zetasizer, NANO ZS90 (Malvern Instruments Limited, U.K.), fitted with a 4 mW He–Ne laser 209 
set at a wavelength of 633 nm was used to determine the CMC of the OLA-tetracephelous tetra ionic 210 
amphiphile. The detection angle of the scattered light was fixed at an angle of 90° to produce optimal 211 
detection of scattered light with a high-quality signal. An aqueous stock solution (0.5 M) of OLA-SPDA 212 
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was used in preparing solutions of concentration ranging from 1×10−2 to 1×10−6 M. A polystyrene cell was 213 
used to measure the scattering intensity at 25 °C (n=3) and the output data was processed using a computer 214 
attached to the instrument. The CMC value was determined by plotting the changes in intensity (kcps) 215 
against the concentration of the corresponding samples 35. 216 
3.7 Preparation and Characterization of VCM-OLA-SPDA-micelles  217 
3.7.1 Preparation  218 
The blank micelles were prepared via a self-assembly approach using the solvent evaporation method 219 
reported in the literature 33. Typically, the OLA-SPDA lipid was completely dissolved in 3 ml THF which 220 
was then added dropwise into 10 ml of distilled water under vigorous stirring. The organic solvent was 221 
allowed to evaporate by keeping the solution open to air under stirring for 24 h. The solution obtained had 222 
a blue tint colour, which was an indication of the successful formation of micelles. The preparation of the 223 
drug-loaded formulation followed the same procedure, except that the amphiphilic lipid was added 224 
dropwise into 10 ml solution of 0.5 mg/ml VCM in distilled water. 225 
3.7.2 Size, Polydispersity Index (PDI), Zeta Potential (ZP) and Morphology  226 
The physicochemical properties of micelles (size, PDI and ZP) were evaluated using a dynamic light 227 
scattering technique. Appropriate dilutions of the formula were made using PBS (pH 7.4 and 6.0) prepared 228 
using milli-Q water. Measurements were recorded at room temperature (25º C) using a Zetasizer Nano 229 
ZS90 (Malvern Instruments, UK) fitted with a 633 nm laser at 173° detection optics. All parameters were 230 
analysed in triplicate from different batches prepared separately to ensure reproducibility of the results. The 231 
morphological features of the nanoparticles were characterized by TEM analysis. The prepared samples 232 
were negatively stained with 1% uranyl acetate and fixed on a copper grid for drying and images were 233 
acquired at 100 kV using JEOL Microscopy (JEM 2010, Japan). 234 
3.7.3 Entrapment Efficiency (EE) and Drug Loading (DL) 235 
The encapsulated VCM amount in micelles was determined using an ultrafiltration method by separating 236 
the free drug from the encapsulated drug using centrifugal filter tubes (Amicon® Ultra-4) of 10 KDa 237 
molecular weight cut-offs. The drug-loaded formulations (2 ml) were placed in the centrifugal filter tube 238 
and centrifuged at 3000 rpm for 30 minutes at 25 °C. To determine the VCM concentration in the filtrate 239 
(the unencapsulated VCM), high-performance liquid chromatography (HPLC), Shimadzu Prominence 240 
DGU-20A3 at 280 nm was used. The optimized conditions for HPLC were as follows: C18 reversed-phase 241 
column (Nucleosil 120-5 C18; 4 × 150 mm, 5μm); acetonitrile: 0.1% TFA in water (15:85 v/v) as a mobile 242 
phase; and column temperature, injection volume and flow rate were set at 25 °C, 100μL and 1 mL/min, 243 
respectively. The unknown amount of VCM was calculated using the following linear regression equation 244 
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y = 24598x−3125.7 with linearity (R2) of 0.999. The following equations were used to calculate %EE and 245 
%DL. 246 
                          EE (%) = (
 Weight of VCM in micelles
Weight of VCM added
) ×  100           (3) 247 
                         DL (%) = (
Weight of VCM in micelles
Total weight of micelles
) ×  100            (4) 248 
Where the weight of VCM in micelles,  represents the amount of drug entrapped in micelles after separation 249 
using centrifugation;  weight of VCM added refers to the initial amount of VCM used in the formulation 250 
and the total weight of micelles refers to the weighed amount of all the excipients used to formulate micelles 251 
in their dry powder form. 252 
3.7.4 Thermal Profiles  253 
Differential scanning calorimetry (Shimadzu DSC-60, Japan) is a widely used thermoanalytical technique 254 
to measure the thermal profiles of samples 36. The thermal profiles of the lipid, freeze-dried drug-loaded 255 
formulation, the physical mixture of all the components, and the drug (VCM), were determined by weighing 256 
2 mg of the samples, placing them in aluminium pans and sealing them using a crimper. These (both loaded 257 
and empty) pans were heated up to 300 ℃ at a constant rate of 10 ℃/min under a constant nitrogen flow of 258 
20 ml/min. 259 
3.7.5 In vitro drug release  260 
The in vitro VCM release behavior from VCM-loaded pH-responsive micelles was investigated using 261 
diffusion technique using  dialysis tubing of cellulose membrane, average flat width 10 mm (MWCO 262 
10,000- 14,000 Da, Sigma-Aldrich, USA) 37. Briefly, 2 ml of the formulations (blank and drug-loaded) 263 
were loaded into dialysis tubes of specified pore size, sealed and dialysed against 40 ml PBS (7.4 and 6.0) 264 
at 37 °C in an incubator maintained at 100 rpm. The amount of VCM released was determined with HPLC 265 
through following a  previously reported procedure, conditions specified in section 2.3.3 38. A fresh PBS of 266 
the equal amount was added after each sampling to keep sink conditions constant and all experiments were 267 
performed in triplicate. 268 
3.8 Antibacterial Studies 269 
3.8.1 In vitro antibacterial activity   270 
The minimum inhibitory concentration (MIC) of vancomycin-loaded micelles and bare VCM against S. 271 
aureus and MRSA at pH 7.4 and pH 6.0 was determined using a broth dilution method 38. Bacterial cultures 272 
of S. aureus and MRSA in nutrient broth were grown for 24 h at 37 °C in a Labcon 3081u shaking incubator 273 
(USA). The 0.5 McFarland standard (1.5x108 CFU)/ml) was achieved by diluting the cell culture with sterile 274 
distilled water and measured using a DEN-1B suspension McFarland densitometer (Latvia). This was 275 
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further diluted to 1:150 with sterile distilled water giving a concentration of 5 × 105 colony forming units 276 
(CFU)/ml necessary for this study. The serially diluted samples (bare VCM, blank micelles, and VCM-277 
OLA-SPDA-micelles) prepared in MHB (pH 7.4 and pH 6) in a 96-well plate, were treated bacterial cell 278 
culture (5 × 105 (CFU)/ml). The plates were incubated at in a shaking incubator set at 37 °C, 100 rpm for 279 
24 h. The MIC values were determined by spotting 5 μl of the sample mixture on Mueller-Hinton (MHA) 280 
plates at different time intervals (24h, 48h and 72h). The vancomycin-loaded micelles and bare VCM 281 
solution were used as positive controls whereas the blank formulation was used as a negative control. All 282 
experiments for this study were performed in triplicate. 283 
3.8.2 Bacterial cell viability  284 
Flow cytometry is a commonly used technique to quantify viable MRSA cells 39. A bacterial cell culture, 285 
prepared as described in Section 2.4.1, was treated with VCM solution (positive control) and VCM-OLA-286 
SPDA-micelles at the concentration equivalent to their respective MICs and were incubated at 37 °C for 6 287 
h. Untreated MRSA cells were utilised as a negative control. In separate flow cytometry tubes containing 288 
350 μl of sheath liquid, 50 μl of the VCM and VCM-OLA-SPDA-micelles solutions were added and 289 
vortexed for 5 min. Thereafter, propidium iodide (PI) dye (5 μl) was used to stain the mixture which was 290 
incubated for 30 min. As described from a previously reported protocol for assessing the viability of treated 291 
cell samples, a BD FACSCANTO II flow cytometer (Becton Dickinson, USA) was used in this study, with 292 
a minimum of 10,000 cells being gathered 40. 293 
3.8.3  In vivo antibacterial activity  294 
The protocol approved by the Animal Research Ethics Committee of the University of KwaZulu-Natal 295 
(approval number: AREC/104/015PD) was followed when conducting this experiment. As per reported 296 
procedure, mice skin infection models were used to further evaluate the in vivo efficacy of the VCM-OLA-297 
SPDA-micelle formulation in comparison with bare VCM against MRSA 41. Male BALB/c mice (18-20 g) 298 
models were used for this experiment, provided by the Biomedical Research Unit at the University of 299 
KwaZulu-Natal. The mice were shaved, disinfected with 70 % ethanol and separated into three groups of 300 
four (negative control, positive control and treatment group) before the day of the experiment. The final 301 
MRSA concentration of 1.5 × 108 CFU/ml was achieved by diluting 50 µl MRSA with a saline solution 302 
which was intradermally administered. After 30 minutes of infection, a positive control group was treated 303 
with bare VCM.  The treatment group was treated with the formulation whilst the negative control group 304 
was treated with saline. After observing for 48 h and keeping the animals under normal conditions, the 305 
infected skin from the sacrificed mice was harvested and homogenised in 5 ml of PBS (pH 7.4). The tissue 306 
homogenates were serially diluted with PBS and spotted (20 µl) onto on nutrient agar plates. The CFU 307 
counts were determined after the incubating for 24 h at 37 °C.  308 
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3.9 Physical Stability  309 
The short-term physical stability of OLA-SPDA-micelles formulation kept under different storage 310 
conditions (4 °C and room temperature) was evaluated for 90 days. The formulations physical stability was 311 
reported at predetermined time intervals (30, 60 and 90 days) by measuring the particle size, PDI, ZP, and 312 
assessing their physical appearance. All experiment for this study were performed in triplicate. 313 
3.10 Statistical Analysis 314 
The collected results were analyzed by one-way analysis of variance (ANOVA), followed by Bonferroni’s 315 
multiple comparison tests using GraphPad Prism® 6 (GraphPad Software Inc., USA), were used for 316 
statistically significant difference analysis. The results were expressed as a mean ± standard deviation (SD) 317 
and a data point difference between the two groups tested being considered statistically significant when p-318 
value < 0.05. 319 
3.11 Results and Discussion 320 
3.11.1 Synthesis of  OLA-Sodium Propionate Dendritic Amphiphile (OLA-SPDA) 321 
The synthesis of the oleic acid-derived dendritic amphiphile was done in four steps as shown in Scheme 1 322 
(above). The first step involved the addition of tertiary butyl acrylate (2) to 1,3-diaminopropano-2-ol (1) to 323 
form compound 3 with four branches, via bis-aza-Michael addition, which was confirmed by both 1H NMR 324 
and 13C NMR.  A strong singlet peak at chemical shift δ 1.33 ppm, which integrates to 36 protons from the 325 
tert-butyl group in 1H NMR, and the presence of carbon peaks at chemical shifts δ 28, 33.5, 49.8, 58.5, 80.2 326 
and 171.7 ppm in 13C NMR, corresponding to C (CH3)3-COO-, CH2C=O-, CH2-N- and C=O functional 327 
groups, confirmed the formation of compound 3. Using the alcoholic functionality from compound 3, the 328 
second step involved esterification of oleic acid using DCC/DMAP coupling chemistry to form compound 329 
5. The chemical shifts in 1H NMR spectra confirmed the formation of the product through the identification 330 
of peaks at δ 0.86 (multiplet), δ 1.26 (multiplet), δ 1.61 (multiplet), δ 2.0 (multiplet), δ 2.28 (multiplet) and 331 
δ 5.35 ppm (multiplet), corresponding to the aliphatic chain of oleic acid coupled to compound 3. The 332 
hydrolysis of tertiary butyl ester groups from compound 5 to form compound 6, with four branches of free 333 
carboxyl group using TFA and TIPS (scavengers), was the third step of the synthesis. After the purification 334 
procedure, the product structure was elucidated using 1H NMR, which showed the disappearance of 335 
isobutane peaks at δ 1.33 ppm and at δ 28 ppm in 13C NMR, confirming a successful hydrolysis reaction. 336 
The last step was to convert compound 6 into sodium salt to enhance its solubility in water. This procedure 337 
involved the dissolution of compound 6 into an aqueous solution of Na2CO3. 338 
3.11.2 In Vitro Cytotoxicity and In Vitro Hemolysis Study 339 
The cytotoxicity effect of OLA-sodium propionate dendritic amphiphile (OLA-SPDA) was evaluated using 340 
an MTT assay over a range of different sample concentrations (20 – 120 µg/ml). This method is based on 341 
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the activity of mitochondrion of a living cell, able to convert MTT into formazan crystals. The total activity 342 
of the mitochondria is relatable to the number of viable cells in the cell population treated with a potential 343 
toxicant. Using human cell lines (A549, Hep G2 and HEK-293), the MTT results demonstrated a high 344 
percentage (> 75%) of cell viability after 48 h co-incubation at different sample concentrations studied (Fig. 345 
1A).  The cell viability of the dendritic lipid amphiphile against different human cell lines A549, Hep G2 346 
and HEK was 98%, 80% and 80%, respectively, with no dose-dependent trend noticed for all concentrations 347 
used. Since the cell viability was above 75%, these results suggest that OLA-SPDA has excellent 348 
biocompatibility and level of safety and it can be considered as safe for biomedical use 42.  349 
 350 
Fig. 1: In vitro cytotoxicity and hemolytic activity of OLA-SPDA. A) Percentage cell viability of human 351 
cells (A549, HEP G2 and HEK-293) after treatment; B) percentage hemolysis; C) visual assessment of the 352 
tubes containing diluted blood after exposure to OLA-SPDA. 353 
We are proposing an intravenous route of administration for our system, and most biomaterials end up in 354 
the bloodstream and come into contact with red blood cells (RBCs) 43. As an additional biosafety measure, 355 
the hemolytic effect of OLA-SPDA was evaluated using sheep’s blood. As shown in Figures 1B and 1C, 356 
above, the sample was slightly hemolytic at high concentrations, with low amounts haemoglobin released, 357 
as compared to samples treated with water which showed high percentages of hemolysis. The highest and 358 
lowest OLA-SPDA concentrations had a hemolytic effect of ⁓ 5% and ⁓ 0.01%, respectively, which showed 359 
a much lower hemolytic effect than that of water (control). This percentage hemolysis is similar and 360 
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significantly lower than the hemolytic effect of other previously reported biomaterials used in formulations 361 
44. Therefore, after conducting hemolytic analysis and a cell-based study (MTT assay), we conclude that 362 
our system may be considered safe for use in the formulation of nanosystems for in vivo delivery.  363 
3.11.3 Critical Micelle Concentration (CMC) Determination 364 
The stability of micelles, measured as the lowest concentration of the amphiphile in which they remain 365 
assembled, is of importance for in vivo application. For this study, the DLS technique was used by recording 366 
intensity values and which were plotted against each sample concentration of OLA-SPDA-micelle, as 367 
illustrated in Figure 2. The point of intersection of the two straight lines drawn corresponds to the lowest 368 
concentration in which OLA-SPDA will remain assembled (5.6×10−6M). This was significantly lower than 369 
the CMC values of other low-molecular-weight surfactants (1.6×10−4M) reported with the similar structural 370 
arrangement, and also falling within the CMC range of polymeric micelles (10-6 to 10-7 M) 24, 33. This could 371 
be attributed to a balance between the hydrophilic branched head and hydrophobic chain lengths from oleic 372 
acid, resulting in the formation of stable micelles. The double-headed sodium salt version of oleic acid-373 
derived amphiphiles, with a single tail, with 2:1 head-to-tail ratio, has been reported to improve the CMC 374 
value of the self-assembled micelles when compared to single-headed oleic acid-derived amphiphiles with 375 
a 1:1 head-to-tail ratio. In this study, OLA-SPDA with four-head groups and single tail (4:1) demonstrated 376 
a remarkably low CMC which can be correlated to the increased hydrophilicity of OLA-SPDA, creating a 377 
hydrophobic-hydrophilic balance when compared to single and double-headed amphiphile; steric 378 
stabilisation promoting a unique pecking order that allows for the assembly of a stable system; and 379 
nanosystems with zeta potential greater than ±25 mV, which have a higher degree of stability. These can 380 
significantly contribute towards low the CMC of OLA-SPDA-micelles.  381 
 382 




Fig. 3: Particle size distribution of OLA-SPDA-micelles below CMC value: (A) 3 × 10−6 mol/L and (B) 1 385 
× 10−6 mol/L. PDI; 0.606 and 0.807, respectively. Particle size distribution above CMC value: (C) 1 × 10−5 386 
mol/L and (D) 7× 10−6 mol/L. PDI; 0.254 and 0.301, respectively. (n = 3) 387 
The histogram representation of OLA-SPDA-micelles particle size distribution (PDI) in Figures 3C and D 388 
confirmed the stability of micelles, at and above the CMC, with a uniform PDI. Below the CMC there was 389 
uneven PDI which confirms the disassembly of micelles (Figs. 3A and B).  390 
3.11.4 Preparation and Characterization of VCM-Loaded OLA-SPDA-Micelles 391 
3.11.4.1 Size, Surface charge, Entrapment efficiency, and Morphology  392 
The optimum conditions for the preparation of pH-responsive OLA-SPDA-micelles were achieved through 393 
the screening of water-miscible solvents and an amount of OLA-SPDA to obtain an average particle size 394 
ranging from 10 to 200 nm. This is the preferred size distribution necessary to evade phagocytosis and 395 
create longer circulation, which can enhance the accumulation of the micelles at the site of infection 45. 396 
Also, the pH-responsiveness of the micelles was assessed by dispersing the formulation in different buffer 397 
solutions (pH 7.4, 6.0 and 4.5), and the physicochemical properties (particle size, polydispersity index (PDI) 398 
and zeta potential) were measured. In this study, 100 mg of OLA-SPDA in 3 ml of THF was used to 399 
formulate both blank and VCM-loaded OLA-SPDA-micelles using a solvent evaporation method. Then the 400 
physicochemical properties were measured at different pH values (7.4, 6.0 and 4.5) to evaluate its pH-401 
responsiveness. The optimised micelle formulation was then loaded with VCM to evaluate its encapsulation 402 
efficiency.  As shown in Table 1, the particle size at pH 7.4, 6.0 and 4.5 was 84.16±0.184, 144.3±11.42 403 
and 142.7±3.938 nm, respectively, showing stable micelles at physiological pH (7.4) with a PDI of 404 
0.121±0.063. pH responsiveness was confirmed with the increase in particle size and PDI at different pHs. 405 
The average particle size increased from 84.16±0.184 to 144.3±11.42 nm with the change in pH from 7.4 406 
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to 6.0, and this change in size can be beneficial for fast drug release at target sites since pH 6 represents an 407 
acidic condition at the bacterially-infected site.  The increase in size could result from the rearrangement of 408 
the amphiphiles in response to changes in pH, causing swelling of micelles. This rearrangement and change 409 
in the size of micelles can potentiate a quick release of VCM at the target site at a dose lethal for the efficient 410 
eradication of bacterial infection. The change in the physical appearance of samples suspended in different 411 
buffer solutions can be correlated with a change in size, with respect to change in pH, as shown in Figure 412 
4D. The sample at pH 7.4 is clear, demonstrating no sign of change in particle size or shape; whereas, at 413 
pH 6.0 and pH 4.5, the sample becomes more turbid, indicating a disruption of the system, resulting in 414 
precipitation or disassembly of micelles in response to reduced pH. The lack of surface charge switch to 415 
positive zeta potential at pH 6.0 can be explained using the structural functionalities of OLA-SPDA, 416 
consisting of two tertiary amines and four carboxylate ions in a ratio of 2:4. Based on the calculated 417 
isoelectric point of OLA-SPDA, it indicates that the overall surface charge will remain negative in pH 418 
systems above 3.2, thus giving an overall negative surface charge for our system at pH 6.0.  Morphological 419 
properties were also analysed using HRTEM as the supporting information for the results obtained using 420 
DLS. HRTEM images of OLA-SPDA-micelles, as shown in Figures 4B and C, which showed a smooth 421 
spherical shape with a particle size similar to the one obtained using DLS (Fig. 4A). Micelles had a 422 
relatively high VCM encapsulation efficiency of about 78.79±3.26 %. The high entrapment could be a 423 
result of two mechanisms of entrapment involved. Firstly, surface groups form electrostatic interactions 424 
with the drug through ion pairing, entrapping the drug on the surface of micelles. Secondly, the drug is 425 
entrapped within the hydrophobic core matrix of micelles.  The high entrapment can help maintain required 426 
the concentration whilst reducing the frequency of administration, thus reducing the risk of toxic side-427 
effects. The high entrapment was comparable with other previously reported self-assembly nanosystems 428 
showing high entrapment of VCM 35, 38, 46 429 
Table 1: Size, PDI, ZP, EE % and DL % characterization of VCM-OLA-SPDA-micelles at pH 7.4 and 6.0. 430 
pH Size  PDI Zeta %EE %DL 
7.4 84.16±0.184 0.199±0.011 -42.6±1.98 78.80±3.26 0.392±0.015 
6.0 141.1±0.0707 0.278±0.116 -50.4±0.990  





Fig. 4: A: Histogram showing size distribution by intensity; B and C: TEM images displaying morphology 433 
of OLA-SPDA-Micelles; and D: Visual assessment of pH-responsiveness in different PBS. 434 
3.11.5 Thermal analysis of VCM-OLA-SPDA-micelles  435 
The DSC is a thermoanalytical technique which can be used to predict drug encapsulation and also the 436 
possible interaction between nanocarrier excipients and the drug and it is measured as a function of 437 
temperature 47. If thermal changes are observed, especially for the physical mixture, this would indicate that 438 
there is chemical interaction between the drug and the other excipient of the formulation. The thermal 439 
behavior of VCM, OLA-SPDA, lyophilized VCM-OLA-SPDA-micelle and the physical mixture of VCM 440 
and OLA-SPDA was investigated and compared (Fig. 5A-D). As shown in Figure 5, below, the thermal 441 
peak for VCM was observed at 125.39 ºC, whilst for OLA-SPDA a peak at 113.09 ºC was observed. The 442 
physical mixture (OLA-SPDA and VCM) showed almost similar thermal behavior to that observed from 443 
their individual thermal profiles, with a slight shift observed at 110.44 and 123.35 ºC, respectively. The 444 
minimal change in the thermal behavior of both the drug and the excipients is an indication of no chemical 445 
interaction between the drug and the amphiphile, and an indication of no chemical or structural changes in 446 
either the drug or the amphiphile. The lyophilised VCM-OLA-SPDA-micelles showed a single peak at 447 
100.83  ºC belonging to OLA-SPDA, and the disappearance the VCM peak can be associated with phase 448 
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transition of the drug amphiphile system which can also indicate the encapsulation of VCM within the 449 
OLA-SPDA matrix 48. 450 
 451 
Fig. 5: DSC thermogram of A) Bare VCM; B) OLA-SPDA; C) Lyophilised VCM-OLA-SPDA-micelles; 452 
and D) Physical mixture of bare VCM and OLA-SPDA 453 
3.11.6 In vitro release of optimal VCM-OLA-SPDA-micelles and bare VCM  454 
The in vitro VCM release profiles for bare VCM solution and VCM-loaded OLA-micelles were evaluated 455 
at physiological conditions (pH 7.4) and at the acidic environment (pH 6.0 bacterial infection site) over a 456 
period of 24 h. Also, the VCM release behavior of micelles was compared across both pH conditions to 457 
evaluate its pH-responsiveness over 24 h. As shown in Figure 6A, below, the percentage cumulative VCM 458 
release at pH 7.4 for bare VCM solution was almost 100% at 8 h; whilst the VCM release from VCM-OLA-459 
SPDA-micelles was slow and prolonged, with a cumulative release of about 48% after the same time 460 
interval as Bare VCM release profile, demonstrating a sustained release profile. Even though a rapid release 461 
from the micelles was observed within the first 8 h, micelles showed a sustained release profile after this 462 
time with a cumulative release of about 60% after 48 h when compared to the drug release profile of  Bare 463 
VCM at pH 7.4. The initial fast release can be explained via the mechanisms of release involved. The VCM 464 
which is weakly bound (adsorbed) onto micelles’ surface could contribute towards the initial rapid release 465 
via dissociation, followed by much slower release of VCM encapsulated within micelle core which is 466 
governed by diffusion and other releases mechanism49. Additionally, systems made from biomaterials with 467 
a high number of surface groups have been reported to have a high entrapment efficiency that is due to the 468 
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combined  effects of two entrapment mechanisms. The first entrapment mechanism involves surface groups 469 
that forms electrostatic interactions with the drug through ion pairing, entrapping the drug on the surface of 470 
micelles. The second mechanism involves the drug being entrapped within the hydrophobic core matrix via 471 
self-assembly method. Surface group electrostatic entrapment easily dissociates which results in an early 472 
quick release and this leads to the first phase of the release profile50, 51. Entrapment of the drug within the 473 
hydrophobic core matrix is diffusion dependent that needs the drug to partition out of the lipid core matrix, 474 
among many other proposed mechanisms which leads to the slower release53, 54. The latter encapsulation 475 
mechanism forms the second phase of the release profile52. There are reports of these kinds of systems with 476 
biphasic release profiles that show  fast initial release and  then a slower release of the loaded drug in the 477 
second phase from hours to several days55-58. Moreover, the slower release pattern observed at physiological 478 
pH suggests that micelles maintain their shape tightly and compactly to reduce the premature release of 479 
VCM at an unexpected location, thus reducing the development of toxic side-effects and promoting a 480 
possible accumulation of a sufficient amount of the drug at the required site. The slower and prolonged 481 
release profile can be helpful for prolonged and sustained antibacterial therapeutic effect. Therefore, our 482 
formulation showed superiority over bare VCM solution with a sustained release profile.  483 
 484 
Fig. 6:  In vitro drug profiles: A) between bare VCM and VCM-OLA-SPDA-micelles; and B) VCM-OLA-485 
SPDA-micelles at both pH 7.4 and 6.0 486 
Even though the VCM release profile for OLA-SPDA-micelle formulation at both pH 7.4 and 6.0 was 487 
slightly similar up to the 5th hour, (Fig. 6B), it was observed that the VCM released was pH- and time-488 
dependent with a faster release at pH 6 than at pH 7.4 up to 48 h. As mentioned above, the reduced pH 489 
slightly accelerated the release, with more than 88% VCM released at pH 6.0 and only 60% at pH 7.4 after 490 
48 h. The faster release can be attributed to protonation of the tertiary amine of the OLA-SPDA contributing 491 
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to both rearranging and swelling, or dissembling, of the micelles, thereby increasing the amount of VCM 492 
leaking out of the micellar system due to the large pores created. A similar trend was observed in our 493 
previously published work, where we formulated pH-responsive liposome for the targeted delivery of VCM 494 
59. This suggested that the pH-triggered release can protect and avoid loss of the drug at physiologic pH, 495 
whilst improving targeted release, and enhancing drug localisation and bioavailability at the acidic site of 496 
infection, which can improve its antibacterial activity.  497 
3.12 In vitro antibacterial studies  498 
3.12.1 In vitro antibacterial activity 499 
The experiments were conducted to evaluate the efficacy of VCM encapsulated into micelle, in comparison 500 
with bare VCM solution; and also, to compare the effectiveness of VCM-OLA-SPDA-micelles against 501 
S.aureus and MRSA under different pH conditions. Using the broth dilution method, the minimum 502 
inhibitory concentration (MIC) for bare VCM, VCM-loaded micelles and the blank-micelles against S. 503 
aureus and MRSA at pH 7.4 and 6.0 were investigated. As shown in Table 2, the MIC values for bare 504 
VCM were 3.9 µg/ml and 7.8 µg/ml against S. aureus and MRSA under both pH conditions, respectively; 505 
whereas VCM-loaded micelles had MIC values of 1.95 µg/ml against S. aureus at both pH conditions and 506 
3.9 µg/ml and 0.98 µg/ml against MRSA at pH 7.4 and pH 6.0, respectively. The enhanced activity that 507 
was observed over a prolonged time (72 h) for VCM-loaded micelles, whilst the bare drug lost activity after 508 
24 h, could be attributed to the encapsulation of VCM into pH-responsive micelles, providing protection 509 
against any form of degradation and reducing the loss of VCM before reaching the site of infection through 510 
targeted delivery, thus extending its half-life and restoring its effectiveness against bacterial infection. The 511 
nano-sized formulation and lipidic nature of the OLA-SPDA can facilitate long circulation, and enhance 512 
cell penetration and cellular uptake by the bacterial cell, thus increasing the bioavailability and interaction 513 
of the drug with the bacterial cell for effective bacterial eradication 514 
The antibacterial effect of bare VCM against S. aureus and MRSA at both pH conditions was reduced to 515 
no activity after the first 24 h, whilst the VCM-loaded micelles demonstrated superior and prolonged 516 
activity over a period of 72 h. VCM-loaded micelles enhanced the activity of VCM by 2-fold, against S. 517 
aureus at both pHs, and against MRSA by a magnitude of 2 and 8-folds when compared to bare VCM at 518 
pHs 7.4 and 6.0, respectively. The enhanced and prolonged activity demonstrated by the formulation over 519 
bare VCM can be closely correlated to the sustained and prolonged release profile of the formulation over 520 
bare VCM. A sustained and prolonged release profile can help to maintain the VCM concentration at a 521 
lethal dose at the target site, whilst the bare drug is prone to loss of activity through chemical or enzymatic 522 
degradation or through affinity trapping, preventing VCM from crossing the cytoplasmic membrane of 523 
MRSA. Also, the loss of VCM activity against MRSA can be correlated to cell-wall thickening from a high 524 
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amount of murein monomer produced with a high affinity to VCM, preventing it from penetrating through 525 
the bacterial cell.  These limitations associated with the bare drug can be addressed by using VCM-loaded 526 
micelles with targeting properties. The lipids in formulations are known to facilitate the fusion of 527 
formulations with the bacterial cell, thus enhancing the amount of the drug at the target site for a prolonged 528 
time, and thus reducing time-dose dependent therapies whilst maintaining the therapeutic effect.  529 
The MIC values for VCM-OLA-SPDA-micelles were compared under different pH conditions to evaluate 530 
it pH-responsiveness. The MIC values against S. aureus remained at 1.95 µg/ml for both pH conditions, 531 
whilst against MRSA, the MICs were 4-folds better at pH 6.0 than at pH 7.4. The enhanced activity at 6.0 532 
can be associated with the fast and prolonged release profile, ensuring that a sufficient amount of the drug 533 
is released at the target site in response to reduced pH. This suggests that encapsulation does not only restore 534 
the effectiveness of the antibiotic, but the use of the stimuli-responsive delivery system can also elevate its 535 
antibiotic effect through triggered release at the required zone. Therefore, this confirms the superior 536 
antibacterial activity of VCM-OLA-SPDA-micelles over bare VCM at acidic pH. 537 
Table 2: In vitro antibacterial activity of the formulations at pH 7.4 and pH 6. 538 
In vitro antibacterial activity at pH 7.4 
Time (h) 24 48 72 24 48 72 
SA (MIC μg/ml) MRSA (MIC μg/ml) 
Bare VCM 3.9 NA NA 7.8 NA NA 
VCM-OLA-SPDA -Micelle 1.95 1.95 7.81 3.9 3.9 7.81 
Blank- OLA-SPDA-Micelle NA NA NA NA NA NA 
In vitro antibacterial activity at pH 6 
Time (h) 24 48 72 24 48 72 
SA (MIC μg/ml)   MRSA (MIC μg/ml) 
Bare VCM 3.9 NA NA 7.8 NA NA 
VCM-OLA-SPDA -Micelle 1.95 1.95 3.9 0.98 0.98 1.95 
Blank-OLA-SPDA-Micelle NA NA NA NA NA NA 






3.12.2 Bacterial cell viability 543 
The quantitative cell viability analysis was done using the flow cytometry method. Specialised fluorescence 544 
dyes, propidium iodide (PI) and SYTO9, were used to differentiate dead cells from live cells after treatment.  545 
As shown in Figure 7, red and green represent live and dead cells after treatment, respectively. PI can 546 
passively transverse into a dead cell and bind to the DNA due to loss of plasma membrane integrity, 547 
irrespective of the mechanism of death; whilst SYTO9 can penetrate both alive and dead cell populations 548 
60. The PI uptake corresponds to the number of dead cells, as represented in a histogram plot of cell count 549 
(y-axis) vs PI fluorescence (x-axis) (Fig. 7A-D). The VCM inhibition mechanism against MRSA involves 550 
disruption of the bacterial cell synthesis, therefore PI uptake is expected after treating bacteria with VCM 551 
and the fluorescence intensity/count corresponds to the number of dead cells. The MRSA cells were treated 552 
with bare VCM and with VCM-OLA-SPDA-micelles. A fluorescence shift was observed, and gates were 553 
set to differentiate the viable cells from non-viable cells in the MRSA population.  As shown in Figure 7, 554 
the fluorescence shift of PI after treating bacterial cells with bare VCM and VCM-OLA-SPDA-micelles at 555 
their respective MICs (7.8 μg/ml and 0.98 μg/ml, respectively) was observed. As shown in Figure 7, A 556 
represents MRSA cells without treatment; B shows VCM-treated MRSA with a 91.01% killing; C shows 557 
VCM-OLA-SPDA-micelles treated MRSA with a 93.39% killing at their respective MICs. For comparison 558 
purposes, VCM treatment was done at the formulation MIC (0.98 μg/ml), which gave a killing percentage 559 
of only 54.21% (7D). A similar cell-viability pattern was observed from the dot plot of PI vs SYTO9 (Fig. 560 
7F to G). These results indicate that the formulation has a higher killing percentage at low concentrations 561 
when compared to bare VCM, which shows a similar killing percentage at a higher concentration (7.8 562 
μg/ml). This suggests that encapsulation maintains the same therapeutic effect exhibited by bare VCM, but 563 
at a low concentration. This holds potential for becoming an alternative mode of a treatment since it may 564 
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reduce issues related to toxic side-effects due to high doses administered to achieve therapeutic effects.565 
 566 
Fig. 7: Histogram plot from the flow cytometry analysis: A) untreated MRSA cells; B) MRSA cells treated 567 
with bare VCM at 7.81 µg/ml;  C) and D) MRSA cells treated with VCM-OLA-SPDA-micelles and bare 568 
VCM at 0.98 µg/ml; scatter plot of E), untreated MRSA cells; F) MRSA cells treated with bare VCM at 569 
7.81 µg/ml; and G) VCM-OLA-SPDA-micelles at 0.98 µg/ml showing a shift in SYTO9 and PI 570 
fluorescence after treatment. 571 
3.12.3 In vivo antibacterial activity 572 
Staphylococcus aureus and its resistant strain (MRSA) account for the majority of skin infections. A mice 573 
skin infection model study is a widely used preclinical model mimicking the infections observed in humans 574 
to assess the efficacy of any form of antimicrobial therapies against such pathogens 61. The BALB/c mice 575 
skin infection models were used for this study to further assess the efficacy of VCM-OLA-SPDA-micelles 576 
against MRSA in comparison with bare VCM. A short-term localisation of bacteria (MRSA) was performed 577 
via intradermal injection and the CFU counts were quantified for treated and untreated groups. There was 578 
a significant reduction in the bacterial count of the skin samples treated with both VCM-OLA-SPDA-579 
micelles and VCM when compared to the untreated group. 580 
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Application of the one-way ANOVA test showed a statistically significant (p < 0.0001) reduction in the 581 
bacterial (MRSA) load recovered from the group treated with bare VCM and VCM-OLA-SPDA-micelles 582 
when compared to the untreated group. The mean bacterial counts (log10 CFU) recovered from the mice 583 
skin treated with VCM and VCM-OLA-SPDA-micelles were 3.40 ± 0.053(2533 CFU/ml) and 2.50 ± 584 
0.17(300 CFU/ml), which were 133 (p = 0.0002) and 1126 (p < 0.0001) times better than the untreated 585 
group, respectively. Furthermore, the bacterial count from the sample treated with VCM-micelles showed 586 
a significant 8-fold reduction (p < 0.0001) when compared to skin samples treated with bare VCM (Fig. 8). 587 
VCM-OLA-SPDA-micelles demonstrated a high bacterial load reduction from the skin samples when 588 
compared to other groups. These results are in line with results discussed in previous sections (2.5.1 and 589 
2.5.2) demonstrating the superiority of VCM-micelles in enhancing the efficacy of VCM. The enhanced 590 
activity can be associated with the nano-size range of the formulation which allows for better penetration 591 
and enhanced cellular uptake and longer circulation within the system when compared to big molecules 592 
such as VCM. The targeting, pH triggered, and sustained release profile helps in maintaining high VCM 593 
doses at the site of infection over a prolonged time. Therefore, pH-responsive VCM-micelles could 594 

















































Fig. 8: MRSA count after 48 h of treatment. Data represent the mean ± SD (n = 3). *denotes statistical 598 
significance for VCM-OLA-SPDA-micelles versus the bare VCM. **denotes significant difference 599 
between untreated versus VCM-OLA-SPDA-micelles. ***denotes the significant difference between the 600 
untreated and bare VCM. 601 
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3.12.4 Stability During Storage 602 
A short-term physical stability study of OLA-SPDA-micelle samples stored under different conditions 603 
(room temperature and at 4oC) for three months was evaluated using DLS. The physical appearance, particle 604 
size, PDI and zeta potential were measured at predetermined times (0, 30, 60 and 90 days). The results 605 
showed that samples stored at 4oC were more stable over a period of three months (Table 3). There was 606 
insignificant change (p > 0.05) in particle size for the sample stored at 4 oC between day 0 (75.54±0.566 607 
nm) and day 90 (81.6±0.95); whereas for samples stored at room temperature, size changed significantly 608 
(p < 0.05) from 75.54±0.566 nm to 143.9±0.35 between day 0 and day 90.  Additionally, the samples stored 609 
at both temperatures showed no sign of deterioration, with no colour change observed or precipitation 610 
occurring.  This suggests that the OLA-SPDA-micelle, in aqueous solution and stored 4 oC, was stable over 611 
a period of three months, whereas samples kept at room temperature showed a moderate change in size 612 
after the first month. This suggests that 4 oC is preferable for storage for our system.  613 
 614 
Table 3. Stability studies of OLA-SPDA-micelle formulation 615 
Storage 
condition 
RT 4 °C 
Days Size (nm) PDI ZP (mV) Size (nm) PDI ZP (mV) 
0 75.54±0.566 0.239±0.003 -53.5±2.19 75.54±0.566 0.239±0.003 -53.5±2.19 
30 119.3±0.964 0.271±0.002 -80.3±0.424 75.6±0.848 0.312±0.010 -80.3±0.141 
60 121.3±2.317 0.264±0.009 -82.2±1.82 80.9±2.33 0.340±0.057 -80.8±0.53 
90 143.9±0.35 0.207±0.007 -71.1±0.07 81.6±0.95 0.296±0.007 -64.0±1.15 
 616 
3.13 Conclusion 617 
The challenges associated with conventional antibiotic dosage forms that lead to the development of 618 
bacterial resistance requires an alternative delivery system and biocompatible materials to improve the 619 
efficacy of existing antibiotics. To address these problems, in this study, pH-responsive VCM-OLA-SPDA-620 
micelles was successfully formulated from OLA-SPDA which self-assembles into stable micelles for 621 
targeted delivery of VCM against MRSA infections. The pH-responsiveness of micelles was demonstrated 622 
by the change in size and PDI with respect to change in pH from 7.4 to 6.0. The formulation displayed an 623 
encapsulation efficiency above 70% for VCM. The system also showed a sustained and prolonged VCM 624 
release profile which correlated to its prolonged in vitro antibacterial effect when compared to bare VCM. 625 
The cell viability and in vivo studies also confirmed the superiority of the formulation, showing a significant 626 
bacterial cell (MRSA) count reduction after treatment, when compared to bare VCM. The prolonged and 627 
enhanced antimicrobial activity can help reduce the frequency of administration of the antibiotic and can 628 
thus prevent the possible development of drug resistance. Therefore, this material demonstrates a possible 629 
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alternative for the delivery of other antibiotics to improve their effectiveness against bacterial infections 630 
characterized by low pH. 631 
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4.1 Introduction 865 
This chapter addresses Aim 3, Objectives 1–3 and is a first-authored experimental article in 866 
preparation for submission. This article highlights the synthesis of a novel fatty acid-based bi-867 
tailed pH-responsive zwitterionic DMGSAD-lipid, the in vitro toxicity evaluation, formulation 868 
development of VCM loaded LPHNPs, characterization of its physical properties, in vitro and in 869 
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4.3 Abstract 899 
The rampant antimicrobial resistance crisis calls for efficient and targeted drug delivery of antibiotics at the 900 
infectious site. Hence, in this study, we aimed to synthesize a zwitterionic pH-responsive dimethylglycine 901 
surface-modified branched lipid (DMGSAD-lipid). The synthesized lipid was in conjunction with 902 
polymeric surfactants (HS15 or RH40), which was explored for their potential to formulate pH-responsive 903 
lipid-polymer hybrid nanoparticles (LPHNPs) to deliver vancomycin (VCM) against MRSA infections. 904 
The structure of the synthesized lipid was confirmed using 1H NMR and 13C NMR. The biocompatibility 905 
of the DMGSAD-lipid was evaluated on HEK 293, A549 and MCF-7 cell lines using the in vitro 906 
cytotoxicity assay. The LPHNPs were formulated using the solvent evaporation method and were 907 
characterized for their physicochemical properties, morphology, in vitro drug release and in vitro 908 
antibacterial efficacy. The resulting two LPHNPs (VCM_HS15_LPHNPs and VCM_RH40_LPHNPs) 909 
were optimized after the screening, yielding a formulation with the desired size, polydispersity index (PDI) 910 
and zeta potential (ZP). Both formulations demonstrated pH-responsiveness through a change in size, PDI 911 
and ZP with respect to change in pH from 7.4 to 6.0. The ZP of RH40_VCM_LPHNPs changed from 912 
0.55±0.14 to 9.44±0.33 mV, whereas for SH15_VCM_LPHNPs, ZP changed from -1.55±0.184 Vm to 913 
9.83±0.52 Vm at pH 7.4 and 6.0, respectively. Both formulations exhibited a surface charge switch from 914 
negative to positive at reduced pH. The efficiency of encapsulation of VCM_HS15_LPHNPs and 915 
VCM_RH40_LPHNPs was 47.78±0.68 % and 43.31±1.85 %, respectively. The VCM release profile, 916 
together with release kinetic study on LPHNPs, demonstrated the influence of pH on the high rate of VCM 917 
release at pH 6.0 as compared to pH 7.4. LPHNPs had better antibacterial activity against Staphylococcus 918 
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aureus (S. aureus) and methicillin-resistance S. aureus (MRSA) at both pH conditions when compared to 919 
bare VCM. Furthermore, the antibacterial activity of LPHNPs against MRSA showed 8-fold better MICs 920 
at pH 6.0 than at 7.4. bare VCM-treated specimens. Thus, this study confirms that pH-responsive LPHNPs 921 
have the potential for enhancing the treatment of bacterial infections and other diseases characterized by 922 
acidic conditions at the target site. 923 
Keywords: Lipid-polymer hybrid nanoparticle, pH-responsive zwitterionic lipid, antibacterial, 924 
vancomycin, MRSA targeted drug delivery. 925 
 926 
 927 
4.4 Introduction 928 
Staphylococcus aureus (S. aureus) is one of the bacteria that form the normal flora of our bodies. However, 929 
it is a common source of respiratory, skin, and bone infections. During the 1950s, penicillin G was one of 930 
the β-lactam antibiotics used to treat S. aureus infections. Unfortunately, the use of different antibiotics to 931 
treat S. aureus infections over the years led to the emergence of the invasive form of S. aureus, multi-932 
resistant Methicillin-resistant S. aureus strain (MRSA). Among gram-positive bacteria, MRSA infections 933 
have been the leading cause of high morbidity and mortality rates globally. Limited therapeutic options 934 
have made it difficult to treat MRSA infections, thus posing a serious threat to public healthcare worldwide. 935 
Increasing antimicrobial resistance is narrowing the available armamentarium to treat infections from 936 
superbugs; thus, vancomycin has remained as one of the last resorts against MRSA infections. However, 937 
there is an ever-growing concern over the prevalence of vancomycin-resistant strains. Current reports have 938 
demonstrated that, if poorly treated, MRSA infections can escalate to a potentially life-threatening condition 939 
known as sepsis1, 2. Unfortunately, the lack of new antibiotics to treat MRSA infections represents a serious 940 
public health problem causing a major setback and undermining the efforts in containing the spread and 941 
severity of the MRSA infections3, 4. Therefore, according to the World Health Organization, there is an 942 
urgent need for a new effective approach to combat antibiotic resistance that arises from treating MRSA 943 
infection using conventional therapeutic ways5.  944 
The discovery and introduction of new antibiotic agents to the commercial market is a big challenge6. 945 
Moreover, the science is not straight forward; the research and development process is time-consuming 946 
(10-15 years) and discovered candidates often fail clinical trials7. Furthermore, bacteria have always 947 
become resistant once the newly introduced antibiotics enter the market8. Therefore, to mitigate resistance 948 
and to protect the existing and new antibiotics, novel drug delivery approaches are being employed as one 949 
of the approaches to combat resistance. The nano-drug delivery approach has shown to be a potential 950 
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alternative to improve the therapeutic benefits of the existing antibiotics in treating an array of microbial 951 
infections9-11. This therapeutic approach restores the efficiency of antibiotics by protecting the drug against 952 
bio/chemical degradation, minimize drug exposure to healthy tissues while maximizing concentration at 953 
infection site9, 12. Additionally, it improves the solubility of antibiotics, prolongs their systemic-circulation 954 
time, enhances targeted delivery, and provides sustained antibiotic release which will allow lower drug 955 
doses to administered and subsequently reduces systemic side effects and development of antibiotics 956 
resistance9, 12. Several nanocarriers have reached different stages of clinical trials in the fight against 957 
infectious diseases13, 14. 958 
Lipid-polymer hybrid nanoparticles (LPHNPs) are one of the nano-drug delivery systems that are 959 
promising for efficient drug delivery to overcome the shortcomings of conventional dosage forms15. The 960 
integration of their respective unique properties has proven to yield nanosystems with a sustained release 961 
profile, enhanced cell membrane permeability, long circulation time, improved serum stability, differential 962 
targeting and excellent biocompatibility15, 16. The LPHNPs are nanostructures with a lipid core surrounded 963 
by a polymer shell and stabilized by surfactants. Polymers have been employed in formulating hybrid 964 
systems with lipids because polymers have demonstrated better drug release properties17, 18. In contrast, the 965 
lipid increases drug loading efficiency and membrane permeability19, 20. The reported LPHNPs in the 966 
literature contain lipid, polymer and stabilizing surfactants. However, replacing the polymer with 967 
amphiphilic polymers could result in better systems with less excipients as there will be no need for the 968 
surfactants. Polymeric surfactants that are amphiphilic in nature are attractive biomaterials because they 969 
often offer long circulation, better stability, high loading capacity, enhanced solubilization of drugs, 970 
biodegradability and could allow surface modification via covalent bonds or complexation21. Moreover, the 971 
surface of the lipid layer of the LPHNPs can be functionalized to suit the desired application. The surface 972 
functionalization includes the use of biomaterials that have a unique response to different stimuli conditions 973 
at the disease site22. Several surface-functionalized “smart” nanocarriers that respond to endogenous stimuli 974 
such a pH, enzyme redox, temperature, etc., have been developed12, 23. These “smart” nanocarriers 975 
contribute to high drug localization through targeting and stimuli-triggered drug release at the site of 976 
infection and have been reported to enhance the efficacy of the drug and could potentially reduce the risk 977 
of drug resistance24. There has been extensive progressive research in developing “smart” biomaterials to 978 
formulate nanocarriers to tackle antibiotic resistance effectively, indicating the success in this strategy in 979 
fighting antibacterial resistance25, 26  980 
In order to formulate nano-drug delivery systems that have desirable properties, such as disease targeting 981 
and long circulation, there is a need for the design and synthesis of advanced materials to prepare superior 982 
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novel nano-drug delivery systems with enhanced antibacterial activity12. With the advancements in 983 
synthetic and analytical chemistry ,scientists can tailor biomaterials by altering chemical and physical 984 
parameters during the synthetic process27. In recent years, there has been a significant demand for the 985 
development of stimuli-responsive materials for targeted delivery of bioactive molecules12. Thus, 986 
continuous efforts to develop such biomaterials ought to be undertaken in this field. 987 
One of the stimuli-responsive biomaterials are those that are responsive to pH. Due to differences in pH 988 
conditions of healthy and disease tissue sites, pH is among the endogenous stimuli that have been widely 989 
exploited for tumor, bacteria and cancer-targeted drug delivery28. Nanoantibiotics delivery has been widely 990 
explored using different pH-responsive lipid and polymer-based nanoparticles. However, the scope of 991 
application of LPHNPs to treat bacterial infections is not known. Hence, there is limited data in the literature 992 
reported on pH-responsive LPHNPs for delivery of antibiotics26, 29, 30. Developing a novel pH-responsive 993 
biomaterial for the formulation of LPHNPs for antibiotic delivery could potentially address both limitations 994 
of conventional as well as the limitation of the above mentioned clinically approved nanoantibiotic 995 
medicine. Herein, we report a detailed synthesis of a pH-responsive lipid composed of fatty acid-based bi-996 
tailed zwitterionic lipid. 997 
The smart lipid and polymeric surfactants in the market were then employed to formulate novel LPHNPs 998 
for delivery of antibiotics. pH-responsive and surface charge switching zwitterionic lipids are known to 999 
greatly enhance drug release from the delivery system in response to change in pH while minimizing 1000 
toxicity encountered when using cationic and anionic lipids. We envisage that ionization of headgroups 1001 
(amine groups) of the fatty acid-based bi-tailed zwitterionic lipid will be responsible for the pH-responsive 1002 
behavior. Under acidic conditions, the lipid surface monolayer gets protonated, creating a repulsive force 1003 
within the lipid layer. The repulsion may lead to the rearrangement or destabilization or swelling of the 1004 
lipid layer, which may contribute to the leakage or burst release of the drug at the site of infection. Also, 1005 
the protonation mechanism will induce surface charge switching to positive, which is beneficial for surface 1006 
electrostatic binding with the negatively charged bacterial cell wall, thus enhancing cellular uptake and 1007 
drug localization. The formulation of most reported have incorporated a lipid system, a polymer and a 1008 
surfactant or several surfactants31, 32. We, therefore, also report a novel hybrid polymer lipid system that 1009 
will use the FDA approved polymeric surfactants in the market and the synthesized novel smart lipid. This 1010 
approach will reduce the number of excipients in the formulation, thus enhancing the safety profile of the 1011 
smart system. Our system is composed of a newly synthesized fatty acid-based bi-tailed zwitterionic lipid 1012 
and lipid-PEG (Cremophor® RH 40/ Solutol® HS 15) used as a surfactant. The amphiphilic zwitterionic 1013 
lipid was synthesized by conjugating fatty acid chains with dimethylglycine. The lipid tail from both 1014 
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zwitterionic lipid and lipid-PEG form a hydrophobic core to encapsulate the drug through hydrophobic 1015 
interactions. At the same time, the dimethylglycine head groups and PEG form the outer surface of the 1016 
system. The dimethylglycine head groups will be responsible for surface charge switching in response to 1017 
reduced pH to potentiate drug release, whereas PEG mainly contributed to stability and long circulation. 1018 
Thus, this system could potentially enhance the binding affinity of the positively charged LPHNPs with the 1019 
negatively charged bacterial surface for high drug localization, while minimizing exposure to healthy host 1020 
cells. 1021 
4.5 Materials and Methods  1022 
4.5.1 Materials 1023 
2-aminopropane-1,3-diol was purchased from Sigma-Aldrich (UK). 1-Ethyl-3- (3-dimethylaminopropyl) 1024 
carbodiimide hydrochloride and trifluoroacetic acid (TFA) were procured from Merck (Germany) while 1025 
Di-tert-butyl decarbonate was purchased from Sigma-Aldrich (Germany). MTT (3-(4, 5-dimethylthiazol-1026 
2-yl)-2, 5-diphenyltetrazolium bromide) was purchased from Alfa Aesar (UK), Mueller Hinton Agar 1027 
(MHA), Nutrient Agar and Nutrient Broth were obtained from Biolab (South Africa). The following 1028 
reagents: 4-(dimethylamino) pyridine (DMAP), Stearic Acid (SA), Mueller Hinton broth 2 (MHB), 1029 
Vancomycin hydrochloride, dialysis tubing cellulose membrane (MWCO 14,000 Da) and all other 1030 
materials were purchased from Sigma-Aldrich (USA).  The vancomycin free base (VCM) was obtained 1031 
from converting vancomycin hydrochloride as described from a previously reported method [21]. An Elix® 1032 
water purification system Millipore Corp. (USA) was used to obtain milli-Q purified water. Bacterial strains 1033 
S. aureus (ATCC 25922) and S. aureus (Rosenbach) (ATCC®BAA-1683) (MRSA) were used for this 1034 
project. A Bruker Alpha-P spectrometer with a diamond ATR (Germany) was used to obtain FT-IR spectra 1035 
for all the compounds synthesized. 1H and 13C NMR spectra were obtained by using a Bruker 400 and 600 1036 
Ultra shield™ (United Kingdom) NMR. 1037 
 1038 
  1039 
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4.5.2 Methods  1040 











































































Scheme1: Synthesis of 2,2-(3-((dimethylglycyl)oxy) methyl)-2-methylpropanamido) propane-1,3-1043 
diyldistearate (zwitterionic DMGSAD-lipid) as per the above scheme. 1044 
4.5.2.2 tert-butyl (1,3-dihydroxypropan-2-yl) carbamate (2). tert-butyl dicarbonate (7.90 g, 36.2 mmol) 1045 
was added to a solution of serinol (1) (3 g, 32.9 mmol) in MeOH (300 ml). The reaction mixture was then 1046 
stirred at room temperature for 14 h. After this time, the solvent was evaporated to complete dryness to give 1047 
a white crude product which was purified by flash chromatography (5 % MeOH/CH2Cl2) to yield a crystal 1048 
white solid (5.76 g, 92%): Characterization was as follows: 1H NMR (400 MHz, CDCl3) δ(ppm): 1.38 (s, 1049 
9H), 3.75 (m, 4H), 3.76 (m, 1H); 13C NMR (400 MHz, CDCl3) δ(ppm): 28.5, 54.0, 60.1, 79.4, 156.2 1050 
4.5.2.3 2-((tert-butoxycarbonyl) amino) propane-1,3-diyl distearate (3). Compound 3 was synthesized 1051 
by the addition of stearic acid (5.96 g, 20.9 mmol) to a stirring reaction mixture of compound 2 (2 g, 10.5 1052 
mmol), EDC.HCl (3.25 g, 20.9 mmol) and DMAP (0.64 g, 5.23 mmol) in dry DCM. The reaction mixture 1053 
was stirred under inert conditions (N2(g)) at room temperature for 24 h. The dicyclohexylurea was filtered 1054 
off and the solvent was removed under reduced pressure (vacuum) to obtain a crude product which was 1055 
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further purified by column chromatography on silica gel using ethyl acetate in hexane (10-15 % v/v) to give 1056 
a yield of 95%. Characterization was as follows: 1H NMR (400 MHz, CDCl3) δ(ppm): 0.88 (m, 6H), 1.30-1057 
1.26 (m, 56H), 1.42 (s, 9H), 1.64-1.51 (m, 4H), 2.32-2.0 (m, 4H), 4.30-4.27 (m, 4H), 4.78 – 4.67 (m, 1H); 1058 
13C NMR (400 MHz, CDCl3) δ(ppm): 14.1, 22.7, 25.0, 28.4, 29.0, 29.3, 29.6, 31.8, 33.9, 47.9, 63.9, 79.5, 1059 
155.6, 173.1. 1060 
4.5.2.4 2-aminopropane-1,3-diyl distearate (4). To synthesized compound 4, To a solution of Compound 1061 
3 (4.79 g, 5.5 mmol) in DCM was 25 % TFA was added dropwise and stirred for 2 h at room temperature. 1062 
After this time, TFA was removed under reduced pressure to give a viscous oil product. The traces amount 1063 
of TFA remaining was removed by re-dissolving the crude product in ethyl acetate and washed with a 1064 
saturated solution of Na2CO3 and followed by washing with brine solution separately. The organic layer 1065 
was dried over anhydrous MgSO4 to remove traces amount of water and filtered off. The solvent was 1066 
vacuum dried to give the final product at yield above 95 % and characterization was as follows: 1H NMR 1067 
(400 MHz, CDCl3) δ(ppm): 0.88 (t, 6H, J=7.0 Hz), 1.2 - 1.18 (m, 56H),1.38 (s, 9H),1.64-1.61(m, 4H), 2.23 1068 
(t, 4H, J =7.33 Hz), 3.8-3.3(m, 1H), 4.33 (d, 4H, J =4.52 Hz); 13C NMR (400 MHz, CDCl3) δ(ppm): 14.1, 1069 
22.7, 25.0, 28.4, 29.0, 29.3, 29.6, 31.8, 33.9, 47.9, 63.9, 79.5, 155.6, 173.1. 1070 
4.5.2.5 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid (7). A mixture of bis-MPA (5) (10 g, 74.55 mmol), 1071 
p-toluenesulfonic acid monohydrate (0.71 g, 3.73 mmol) and 2,2-dimethoxypropane (6) (13.8 ml, 111.83 1072 
mmol) in 50 ml acetone. The reaction mixture was stirred at room temperature for 2 h. The catalyst was 1073 
neutralized with 1 ml of NH3/MeOH solution and the solvent was vacuum evaporated at room temperature. 1074 
The crude product was re-dissolved in 200 ml CH2Cl2 and extracted three times with 20 ml water. The 1075 
organic layer was dried over MgSO4 and vacuum dried to give a white crystal product (7) at a yield above 1076 
97 %. The product was used in the following reaction step without any further structural elucidation. 1077 
4.5.2.6 2-(2,2,5-trimethyl-1,3-dioxane-5-carboxamido) propane-1,3-diyl distearate (8). To a solution 1078 
of Compound 4 (2 g, 3.2 mmol) in dry DCM, compound 7 (0.67 g, 3.8 mmol) was added followed by 1079 
addition of EDC.HCl (1.2 g, 6.4 mmol) and DMAP (0.195 g, 1.6 mmol). The reaction mixture was stirred 1080 
overnight under inert conditions (N2(g)) at room temperature. The EDC urea formed was removed by 1081 
extracting with two portions of water followed by DMAP neutralization using 1N HCl. The solution was 1082 
dried over anhydrous MgSO4 and filtered off. The organic solvent (filtrate) was evaporated under vacuum 1083 
and the crude product was purified by column chromatography on silica gel using ethyl acetate in hexane 1084 
(10-15 % v/v) to give a yield above 86%. Characterization was as follows: 1H NMR (400 MHz, CDCl3) 1085 
δ(ppm) : 0.83 (m, 6H), 1.31-1.26 (m, 56H), 1.32 – 1.31 (m, 6H), 1.39  1.36, (m, 3H), 1.62-1.59 (m, 4H), 1086 
2.60-2.32 (m, 4H), 3.88 – 3.56 (m, 2H), 4.13 (d, 2H), 4.27 (d, 4H), 4.76 – 4.73  (m, 1H); 13C NMR (400 1087 




4.5.2.7 2-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanamido) propane-1,3-diyl distearate (9). 1090 
Compound (8), 2.00 g (2.56 mmol), was dissolved in 30 ml of methanol and a scoop of a Dowex, H+ resin 1091 
was added, and the reaction mixture was stirred for 3 h at room temperature. After this time, the Dowex, 1092 
H+ resin was filtered off and carefully washed with methanol. The methanol was evaporated to give 1093 
compound 9 as white crystals at yield above 3.35 g, (97 %) and characterization was as follows: 1H NMR 1094 
(400 MHz, CDCl3) δ(ppm): 0.88 (m, 6H), 1.31 – 1.24 (m, 56H), 1.35(s, 3H), 1.66 – 1.52(m, 4H), 2.33 – 1095 
2.0(m, 4H), 3.70(s, 4H), 4.27( d, 4H), 4.80(m, 1H); 13C NMR (400 MHz, CDCl3) δ(ppm): 14.1, 15.9, 22.7, 1096 
24.9, 29.0, 29.4, 29.8, 32.2, 34.0, 47.1, 48.5, 65.1, 66.3, 174.3, 1778.5 1097 
4.5.2.8 2-(3-((dimethylglycyl)oxy)-2-(((dimethylglycyl)oxy)methyl)-2-methylpropanamido)propane-1098 
1,3-diyl distearate (11). To a solution of Compound 9 (1.6 g, 2.26 mmol), EDC.HCl (1.3 g, 6.8 mmol) and 1099 
DMAP (0.14 g, 1.1 mmol) in dry DCM, compound 10 (0.466 g, 4.5 mmol) was added. The reaction mixture 1100 
was stirred overnight under inert conditions (N2(g)) at room temperature. The EDC urea formed was 1101 
removed by extracting with two portions of water followed by DMAP neutralization using 1N HCl. The 1102 
solution was dried over anhydrous MgSO4 and filtered off. The organic solvent (filtrate) was evaporated 1103 
under vacuum and the crude product was purified by column chromatography on silica gel using ethyl 1104 
acetate in hexane (10-15 % v/v) to give a yield above 80%. Characterization was as follows: 1H NMR (400 1105 
MHz, CDCl3) δ(ppm); 0.88 (m, 6H), 1.31 - .24(m, 56H), 1.38(s, 3H), 1.65 – 1.53(m, 4H), 2.30 – 2.15(m, 1106 
4H), 2.65 (s, 4H), 2.77(s, 12H), 3.52(s, 4H), 4.30 – 4.25(m, 4H), 4.75 – 4.70(m, 1H). 13C NMR (400 MHz, 1107 
CDCl3) δ(ppm): 14.1, 22.6, 22.7, 25.0, 29.0, 29.3, 29.8, 30.1, 32.0, 33.9, 46.2, 48.0, 49.2, 64.0, 66.6, 174.3, 1108 
177.6, 204.0. 1109 
 1110 
4.5.3 In vitro cytotoxicity (MTT assay)  1111 
The evaluation of the non-toxic nature of any novel material to be used in pharmaceutical and biomedical 1112 
applications is of paramount importance33. The relative cytotoxicity associated with zwitterionic 1113 
DMGSAD-lipid was evaluated using the MTT assay. Briefly, three cell lines, human embryonic kidney 1114 
cells (HEK 293), human cervix adenocarcinoma (HeLa) cells and human breast adenocarcinoma cells 1115 
(MCF-7) were used to assess the biosafety of the lipid as described in a previously reported study34. Grown 1116 
cell lines were seeded in 96-well plate at a density of 2.5 × 103 and incubated for 24 h at 37 ℃. After this 1117 
time, seeded cells were treated with 20, 40, 60, 80, 100 μg/ml concentrations of the tested compound and 1118 
further incubated for 24 h. Culture medium and the tested material were replaced with 100 μl fresh medium 1119 
and 100 μl of MTT solution (5 mg/ml) in phosphate buffer solutions (PBS) per well and further incubated 1120 
for 4 h at 37 ℃. After that, dimethyl sulfoxide (100 μl) was added in each well to solubilize the MTT 1121 
formazan crystal. Using 96-well microplate reader (Mindray MR-96A), the amount of formazan was 1122 
measured by reading the absorbance set at 540 nm wavelength. The culture medium with cells and without 1123 
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cells was used as the positive and negative control, respectively. All the experiments were done in a replica 1124 
of six times. The percentage cell viability of every treated sample was calculated using the following 1125 
equation: 1126 
                   % Cell viability = (
A 540 nm treated cells
A 540 nm untreated cells 
) ×  100         (1) 1127 
 1128 
4.5.4 Preparation and Characterization of VCM-LPHNPs  1129 
4.5.4.1 Preparation  1130 
LPHNPs were formulated using a slightly modified solvent evaporation method as previously reported in 1131 
the literature35. The preliminary studies were performed to obtain an optimal formulation with desired 1132 
physicochemical properties. The optimal blank formulation consisted of pH-responsive zwitterionic lipid 1133 
and surfactant in specified ratios. Whereas for VCM-loaded LPHNPs, 1 mg/ml of VCM was added. Briefly, 1134 
DMGSAD-lipid was dissolved in 3 ml THF and added dropwise into 10 ml of distilled water containing 1135 
200 mg of the surfactant under vigorous sonication at 30 % amplitude. After complete addition, the solution 1136 
was sonicated for further 10 min and the organic solvent was allowed to evaporate under stirring 24 h in 1137 
the open air. The solution obtained had a blue tint colour, which was an indication of the successful 1138 
formation of LPHNPs. The drug-loaded formulations were prepared using the same procedure, except that 1139 
the drug is dissolved in the same solution as the surfactant. 1140 
4.5.4.2 Size, Polydispersity Index (PDI), Zeta Potential (ZP) and Morphology  1141 
The formulated LPHNPs were characterized for their size, PDI and ZP using dynamic light scattering 1142 
technique. Measurements were recorded using Zetasizer Nano ZS90 (Malvern Instruments, UK) fitted with 1143 
a 633 nm laser at 173° detection optics at room temperature (25º C). The formulated LPHNPs were 1144 
appropriately diluted using PBS (pH 7.4 and 6.0) and measured in triplicate from separate prepared batches 1145 
to ensure reproducibility. The morphological features of the nanoparticles were characterized by TEM 1146 
analysis. The prepared samples were negatively stained with 1 % uranyl acetate and fixed on a copper grid 1147 
for drying and images were acquired at 100 kV using JEOL Microscopy (JEM 2010, Japan). 1148 
4.5.4.3 Entrapment Efficiency (EE) and Drug Loading (DL) 1149 
The efficiency of entrapment (%EE) of VCM encapsulated into LPHNPs was determined using an 1150 
ultrafiltration method. This method works by separating the free drug from the encapsulated drug using 1151 
centrifugal filter tubes (Amicon® Ultra-4) of 10 Da molecular weight cut-off. Briefly, 2 ml of the drug-1152 
loaded formulation was placed in the centrifugal filter tube and centrifuged at 3000 rpm for 30 min at 25 1153 
°C. The filtrate was used to measure the amount of free (the unencapsulated VCM) using high-performance 1154 
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liquid chromatography (HPLC), Shimadzu Prominence DGU-20A3 set at 280 nm wavelength. The 1155 
optimized conditions for HPLC were as follows: C18 reversed-phase column (Nucleosil 120-5 C18; 4 × 1156 
150 mm, 5μm); acetonitrile: 0.1 % TFA in water (15:85 v/v) as a mobile phase; and column temperature, 1157 
injection volume and the flow rate was set at 25 °C, 100 μl and 1 ml/min, respectively. Using the following 1158 
linear regression equation y = 24598x−3125.7 with linearity (R2) of 0.999, the unknown amount of VCM 1159 
entrapped was calculated. The following equations were used to calculate %EE and %DL. 1160 
                          EE (%) = (
 Weight of VCM in micelles
Weight of VCM added
) ×  100           (3) 1161 
                         DL (%) = (
Weight of VCM in micelles
Total weight of micelles
) ×  100            (4) 1162 
4.5.5 In vitro drug release  1163 
The diffusion technique using a dialysis tube (MWCO 14,000 Da) was used to investigate the in vitro VCM 1164 
release behavior from VCM-loaded pH-responsive LPHNPs was investigated using 36. Briefly, dialysis 1165 
tubes of specified pore size were loaded with 2 ml of the formulations (blank and drug-loaded), sealed and 1166 
dialyzed against 40 ml of PBS at pH 7.4 and 6.0 at 37 °C in an incubator and maintained set at 100 rpm. 1167 
The released amount of VCM at different predetermined time intervals was determined with HPLC through 1168 
following a  previously reported procedure, conditions specified in section 2.3.3 37. The sink conditions 1169 
were maintained by adding an equivalent amount of fresh PBS after each sampling. All experiments were 1170 
performed in triplicate. 1171 
 1172 
4.5.6 Antibacterial Studies 1173 
4.5.6.1 In vitro antibacterial activity   1174 
VCM-loaded pH-responsive LPHNPs were evaluated for their antibacterial efficacy against S. aureus and 1175 
MRSA at pH 7.4 and pH 6.0 using a broth dilution method38. The cell culturing and broth dilution method 1176 
was done following a previously described procedure39. The bacterial cell culture (S. aureus and MRSA) 1177 
were grown in Mueller-Hilton Broth (MHB) for 24 h at 37 °C in a Labcon 3081 (USA) shaking incubator 1178 
set at 100 rpm. Using appropriate dilutions, 0.5 McFarland standard (1.5x108 CFU)/ml) was achieved by 1179 
diluting the cell culture with sterile distilled water and measured using a DEN-1B suspension McFarland 1180 
densitometer (Latvia). This concentration (1.5 × 108 CFU)/ml) was further diluted to a concentration of 5 × 1181 
105 colony forming units (CFU)/ml necessary for this study. Serial dilutions using bare VCM and VCM-1182 
loaded LPHNPs formulations (VCM_HS15_LPHNPs and VCM_RH40_LPHNPs) were prepared in HMB 1183 
broth adjusted to 7.4 and 6.0 pH levels and incubated with bacterial culture a shaking incubator set at 37 1184 
°C, 100 rpm for 24 h. After that, at predetermined time intervals (24, 48, 72 h), 5 μl of the sample mixture 1185 
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was spotted on Mueller-Hinton (MHA) plates and the minimum sample concentration at which no bacterial 1186 
growth was observed and recorded as the minimum inhibitory concentration (MIC). All experiments for 1187 
this study, including VCM-free LPHNPs (negative control), VCM-loaded LPHNPs and bare VCM (positive 1188 
control), were performed in triplicate. 1189 
 1190 
4.6 Results and Discussion 1191 
4.6.1 Synthesis of fatty acid-based zwitterionic DMGSAD Lipid 1192 
Seven synthetic steps were followed to successfully synthesise the zwitterionic DMGSAD Lipid, as shown 1193 
in Scheme 1 (above). The first step is the boc protection reaction of serinol to obtain compound 2, which 1194 
was confirmed by both 1H NMR and 13C NMR. A singlet peak that integrates to 9 protons at chemical shift 1195 
δ 1.33 ppm using proton NMR was identified as protons belonging to the tert-butyl group confirming the 1196 
formation of compound 2. Using EDC/DMAP coupling chemistry, compound 3 was synthesized from 1197 
compound 2 via an esterification reaction. The proton peaks at chemical shifts δ 0.83 (multiplet), δ 1.26 1198 
(multiplet), δ 1.64 (multiplet), δ 2.23 (multiplet) were identified as corresponding to the aliphatic chain of 1199 
stearic acid coupled to compound 2. Boc deprotection reaction using 25 % TFA was used to obtain 1200 
compound 4 from compound 3. The obtained compound after purification was elucidated using 1H NMR, 1201 
which showed the disappearance of isobutane peaks at δ 1.38 ppm and at δ 28.4 ppm in 13C NMR, 1202 
confirming a successful deprotection reaction.  1203 
4.6.2 In Vitro Cytotoxicity  1204 
The cytotoxicity effect associated with DMGSAD Lipid was evaluated using an MTT assay as described 1205 
in literature40. Briefly, different sample (DMGSAD Lipid) concentrations ranging from 20 – 100 µg/ml 1206 
were tested against three different cell lines (MCF-7, HeLa and HEK 293) and the results are represented 1207 
in Fig 1. The cell viability is measured in terms of the total activity of mitochondrion of a living cell 1208 
population in converting MTT into formazan crystals after being treated with a potential toxicant. After 1209 
incubation for 24 h, DMGSAD Lipid displayed a cell viability between 93.65 - 81.28%, 99.75 - 75.51 % 1210 
and 82.53 – 75.14 % for HEK 293, MCF-7 and HeLa cells, respectively. Even though cell viability was 1211 
reduced to about 75 % at the concentration of the lipid higher than 80 µg/ml. According to literature reports, 1212 
materials with cell viability greater than 75 % can be considered as less toxic and biosafe for biological 1213 
application41, 42. Therefore, these results of the MTT test proved that the cell viability was not compromised 1214 
with cell viability >75 % with respect to an increase in the concentration of the tested potential toxicant at 1215 
different concentrations tested. Therefore, the non-toxic nature of our material indicates its suitability for 1216 




Fig. 1: Percentage cell viability of human cells (HeLa, MCF-7 and HEK 293) after treatment with 1219 
DMGSAD.  1220 
4.6.3 Preparation and Characterization of VCM-Loaded LPHNPs 1221 
4.6.3.1 Size, Surface charge, Entrapment efficiency and Morphology  1222 
The LPHNPs were formulated via a slightly modified solvent evaporation method39, 43. Preliminary studies 1223 
were performed to obtain an optimal formulation. Different types of surfactants were screened at a fixed 1224 
concentration to identify the most stable formulation of LPHNPs with desirable physicochemical 1225 
characteristics. The polymeric surfactants used were Cremophor RH 40, Lutrol® F 68, Solutol HS 15 and 1226 
Poloxamer 407 as shown in Table 1. The prepared LPHNPs were characterized for pH-responsiveness and 1227 
other physicochemical characteristics by dispersion in different buffer solutions (pH 7.4 and 6.0). Among 1228 
the surfactants screened, Cremophor RH 40 and Solutol HS 15 stabilized formulations displayed the best 1229 
results in terms of particle size, PDI and ZP. The optimized formulations were given code names based on 1230 
the surfactant used, Cremophor RH 40 as RH40_VCM_LPHNPs and Solutol HS 15 as 1231 
SH15_VCM_LPHNPs. Both formulations demonstrated pH-responsiveness through a change in size, PDI 1232 
and ZP with respect to change in pH from 7.4 to 6.0. The size and ZP of RH40_VCM_LPHNPs changed 1233 
from 64.05 ± 0.64 to 113.6 ± 0.20 nm and from 0.55 ± 0.14 to 9.44 ± 0.33 Vm at pH 7.4 and 6.0, 1234 
respectively. Whereas for SH15_VCM_LPHNPs, only change in ZP from -1.55 ± 0.184 Vm to 9.83 ± 0.52 1235 
Vm was observed at pH 7.4 and 6.0, respectively. A change in particle size in response to acidic conditions 1236 
is an indication of rearrangement or swelling of the particles, which is necessary for leakage and high 1237 
localization of the drug at the site of infection. A change in surface charge can be associated with the 1238 
presence of tertiary amines from dimethylglycine head groups of the lipids. The tertiary amines will remain 1239 
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neutral at physiological pH and undergo protonation at acidic pH contributing towards the overall positive 1240 
surface charge of the particle. 1241 
Additionally, surface charge switching is also vital in making the system more hydrophilic to potentiate 1242 
fusion with the lipid-based membrane of the bacterial. It also facilitates the release of higher quantities of 1243 
the drug through repulsion force within the lipid membrane of the delivery system at the infection sites 1244 
(Mura et al., 2013). Lastly, it enables the carrier to bind easily to the negatively charged bacterial cells, 1245 
allowing for high drug localization for better therapeutic outcomes. Morphological analysis using TEM 1246 
showed that LPHNPs were discrete and had an almost spherical shape as shown in Fig 2 C and D. Both 1247 
formulations had a relatively high VCM encapsulation efficiency as reported in Table 2. 1248 
Table 1: Screening of surfactants to identify a stable pH-responsive formulation. 1249 
pH 6.0 pH 7.4 Surfactants 
ZP (mV) PDI Size (nm)  ZP (mV) PDI Size (nm) 
7.61±0.25 0.473±0.003 60.56±0.15 -2.76±0.064 0.257±0.024 141.9± 0.64 Kolliphor® RH 40 
6.82±1.13 0.119±0.003 34.46±0.24 -11.9±0.85 0.128±0.005 35.83±0.098 Solutol SH15 
22.0±1.20 0.307±0.38 134.4±0.14 5.64±0.49 0.322±0.010 183.9±3.18 Kolliphor® P188 
17.0±0.071 0.373±0.006 161.9±0.64 1.67±0.064 0.400±0.014 270.5±0.35 Poloxamer 407 
 1250 
Table 2: Effect of pH on size, PDI, ZP and %EE of VCM-LPHNPs  1251 
 pH 6.0 pH 7.4 Surfactants 
%EE ZP (mV) PDI Size (nm)  ZP (mV) PDI Size (nm)  
43.31 ±1.85 9.44±0.33 0.384±0.033 113.6±0.20 0.55±0.14 0.277±0.057 64.05± 2.64 Kolliphor® RH 40 







Fig. 2: A: Histogram showing size distribution by intensity; B; Optimized formulation at pH 7.4 and 6.0, 1256 
C; LPHNPs population and D Magnified TEM images displaying morphology of LPHNPs. 1257 
4.6.4 In vitro drug release profiles and drug release kinetics 1258 
The efficiency of stimuli (pH)-responsive delivery systems stems from their ability to improve targeted 1259 
drug release while avoiding premature drug release and promoting high localization of the drug at the 1260 
targeted site. The system undergoes conformational changes that promote drug release at high 1261 
concentrations at the targeted site in response to specific stimuli and thus, improving the therapeutic drug 1262 
efficacy over traditional therapies. Therefore, for this study, VCM-loaded pH-responsive LPHNPs 1263 
(RH40_VCM_LPHNPs and SH15_VCM_LPHNPs) were prepared and their pH-responsiveness was 1264 
investigated using different PBS solutions (pH 7.4 and 6.0), and was compared with bare VCM solution in 1265 
the same release conditions throughout 48 h as shown in Fig 3. The phosphate buffer pH 7.4 and 6.0 were 1266 
used to simulate the normal physiological and the acidic bacterial infected environment, respectively. As 1267 
shown in Fig 3 A and B, the drug release ratio at both pH conditions (7.4 and 6.0) for bare VCM solution 1268 
was almost complete (~90%) within the first 8 h. 1269 
In contrast, both formulations (RH40_VCM_LPHNPs and SH15_VCM_LPHNPs) at both pH levels 1270 
demonstrated a slow and prolonged VCM release with the cumulative percentage release of about 50 % 1271 
within the first 8 h. As shown in Fig 3 C, both formulations demonstrated a similar drug release profile at 1272 
pH 7.4 and 6.0 within the first 8 h. After 8 h, there was a increase in VCM release ~85 % at pH 6.0 as 1273 
137 
 
compared to ~60 % at pH 7.4 for both formulations in 24 h. The initial release profile within the first 8 h at 1274 
both pH levels could be attributed to VCM localized on the surface of the LPHNPs due to the presence of 1275 
dimethylglycine head groups causing surface electrostatic attachment of the drug. After this hour, the 1276 
increased drug release at pH 6.0 could be due to the pH triggered VCM release via ionization of tertiary 1277 
amines from dimethylglycine head groups. At pH 7.4, the tertiary amine remains unionized, exhibiting a 1278 
minimum swelling and retaining most of its entrapped drug. Whereas, at pH 6, due to ionization, a maximal 1279 
swelling is expected due to the electrostatic repulsion causing deformation or destabilization of LPHNPs. 1280 
Thus, more drug is released at pH 6.0 than at 7.4. The minimal swelling of LPHNPs at 7.4 can help reduce 1281 
premature release or loss of the drug to the nonspecific site. In contrast, the maximum swelling of LPHNPs 1282 
at acid pH (infection site) may contribute to a high concentration of the drug release at the targeted site for 1283 
better therapeutic outcomes. Also, the ionization of the dimethylglycine head groups induces an overall 1284 
positive charge on the surface of the LPHNPs. This positive charge enhances its binding affinity to the 1285 
negatively charged bacterial cell wall via electrostatic binding, promoting high drug localization at the 1286 




Fig. 3: Effect of pH on drug release profiles of (A and B) bare VCM, RH40_VCM_LPHNPs and 1289 
SH15_VCM_LPHNPs at pH 7.4 and (C) RH40_VCM_LPHNPs and SH15_VCM_LPHNPs at pH 7.4 and 1290 
6.0 respectively (n=3). 1291 
Table 3: Release Kinetics Data of SH15_VCM_LPHNPs from different models. 1292 
 pH 7.4  pH 6.0 
Model  R2 RMSE β/n- value R2 RMSE β/n- value 
Zero order  -1.2246 29.7315   -0.2475 32.0605  
First order  0.4334 15.0099   0.9705 4.9016  
Higuchi 0.4646 14.5662   0.8218 12.0861  
Korsmeyer-Peppas 0.9967 0.9755 n = 0.488  0.9964 1.1701 n = 0.529 
Hixson-Crowell 0.2086 17.7366   0.8544 10.8837  
Weibull 0.9908 1.6871 β = 0.614  0.9902 1.9292 β = 0.676 
 1293 
Table 4: Release Kinetics Data of RH40_VCM_LPHNPs from Different Models 1294 
 pH 7.4  pH 6.0 
Model  R2 RMSE β/n- value R2 RMSE β/n- value 
Zero order  -0.5449 26.8112   -0.3610 24.6736  
First order  0.6790 12.0755   0.7130 11.3267  
Higuchi 0.7123 11.5503   0.7955 9.5545  
Korsmeyer-Peppas 0.9576 4.1306 n = 0.398  0.9848 2.3475 n = 0.9848 
Hixson-Crowell 0.5487 14.3842   0.6052 13.2868  
Weibull 0.9811 2.7567 β = 0.541  0.9909 1.8089 β = 0.583 
 1295 
The release kinetics study using various mathematical models to further understand the release mechanism 1296 
of the formulation at both pH 7.4 and 6.0 was performed (Table 3 and 4). The mathematical models of 1297 
interest used include Zero order, First order, Higuchi, Korsmeyer-Peppas, Hixon-Crowell, and Weibull. 1298 
The best fit model to describe the release mechanism was selected based on the model with the highest 1299 
correlation coefficient (R2) closer to 1 and the lowest root mean-square error (RMSE). The VCM release 1300 
behavior from SH15_VCM_LPHNPs was found to follow the Korsmeyer-Peppas model with an “n” 1301 
exponent value of 0.488 and 0.529 at pH 7.4 and 6.0, respectively. The “n” value below 0.5 at pH 7.4 1302 
indicates that the Fickian mechanism governed the drug release pattern of the formulation, which is mainly 1303 
the diffusion mechanism. At pH 6.0, the release behavior was found to be non-Fickian with an “n” value 1304 
above 0.5. This was an indication that at pH 6.0, there was more than one release mechanism involved apart 1305 
from diffusion.  1306 
The VCM release behavior from RH40_VCM_LPHNPs was also investigated and the Weibull model was 1307 
found to be the best fit as it had the highest R2 value closer to 1 and the lowest RMSE. The VCM release 1308 
mechanism can be further understood using the β value, which describes the shape of the dissolution curve 1309 
139 
 
progression. The calculated β value for our formulation was within the range of 0.75 < β < 1, indicating 1310 
that more than one release mechanism was involved. Apart from diffusion-controlled release, a pH-1311 
controlled release contributed to the release mechanism (combined release mechanism) and the shape of 1312 
the dissolution profile of the formulation. This suggested that the incorporation of pH-responsive 1313 
zwitterionic lipids does influence a high rate of drug release and release patterns in response to reduced pH. 1314 
4.6.5 In vitro antibacterial studies  1315 
4.6.5.1 In vitro antibacterial activity 1316 
Table 5 summarizes the in vitro antibacterial activity of bare VCM, VCM-loaded LPHNPs and blank 1317 
LPHNPs. The efficacy of the formulations, in comparison with the bare drug, was tested using the broth 1318 
dilution method to determine the MIC of the formulation at pH 7.4 and 6.0. In this study, pH 7.4 represent 1319 
physiological conditions, whereas pH 6.0 (slightly acidic) represents the bacterially infected site. LPHNPs 1320 
showed enhanced antibacterial activity against both S. aureus and MRSA at pH 7.4 and 6.0 when compared 1321 
with bare VCM. According to the literature, there is high interaction of the nanosized delivery system with 1322 
the bacteria due to their large surface area, thus enhancing the activity of LPHNPs when compared to bare 1323 
VCM. The nanosized delivery systems can also accumulate inter- and intracellularly through binding onto 1324 
or penetrating the bacterial cell membrane. Therefore, it allows for high localization of the drug at the 1325 
infection site, enhancing and restoring the therapeutic outcome of the drug delivered.  1326 
 1327 
The MIC values of bare VCM at pH 6.0 against both S. aureus and MRSA were 2-folds higher when 1328 
compared to pH 7.4. The loss of activity at acidic pH could be due to the chemical degradation of VCM by 1329 
the acidic environment, reducing the effective drug concentration to treat the bacteria. The formulations 1330 
(VCM_RH40_LPHNPs and VCM_SH15_LPHNPs) showed a prolonged activity throughout 72 h and this 1331 
can be correlated to a prolonged and sustained VCM release profile from the formulations. Effective 1332 
concentration over a prolonged time can be achieved through a sustained release mechanism, thus inducing 1333 
an enhanced therapeutic effect over a long period, which, therefore, can help reduce the frequency of 1334 
administration and subsequent toxic side effects. The formulations demonstrated an enhanced antibacterial 1335 
activity for 72 h when compared to bare VCM, which was significantly losing activity over time. 1336 
 1337 
Furthermore, the efficacy of the formulations was tested at pH 7.4 and 6.0 to evaluate their pH-1338 
responsiveness against S. aureus and MRSA. The MIC of the formulation at both pH levels against S. 1339 
aureus was similar, whereas, against MRSA, the MIC for both formulations was eight folds better at pH 1340 
6.0 when compared to pH 7.4. Under acidic conditions (pH 6.0), the LPHNPs undergo surface charge 1341 
switching to positive as a result of protonation of the dimethylglycine head group. According to literature, 1342 
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the cationic surface charged nanoparticles interact or selectively bind to the negatively charged bacterial 1343 
membrane. This could lead to an enhanced antibacterial activity through target drug delivery and high 1344 
localization of the drug at the infection site. Therefore, targeting the bacterial infection site by pH-1345 
responsive nanosystems could be a promising alternative treatment for enhancing antimicrobial outcome 1346 
and reducing the development of bacterial resistance. Whilst the VCM-Loaded LPHNPs can improve 1347 
activity of VCM, there was no pH-responsive improvement against S. aureus. This is contrary to MRSA, 1348 
which showed enhanced antibacterial activity with respect to change in pH. According to the literature, the 1349 
MIC for VCM against S. aureus is considered as susceptible if it is ≤ 2 µg/ml and resistant if it is > 8 1350 
µg/ml44. Due to high sensitivity of S. aureus to VCM under normal conditions, the slight change in VCM 1351 
concentration due to pH responsive system may not show difference in MIC values. On the other hand, the 1352 
low sensitivity of MRSA to VCM due to the modified cell wall may lead to a measurable change in MIC 1353 
values as a result of change in the levels of VCM due to pH responsive system. Hence against MRSA there 1354 
was enhanced activity with respect to change in pH. 1355 
 1356 
Table 5: MIC Values of Bare VCM, Blank LPHNPs, and VCM-Loaded LPHNPs at pH 7.4 and 6.0 at 1357 
different time intervals against S. aureus and MRSA 1358 
In vitro antibacterial activity at pH 7.4 
Time (h) 24 48 72 24 48 72 
S. aureus (MIC μg/ml) MRSA (MIC μg/ml) 
Bare VCM 1.95 3.9 3.9 3.9 7.8 15 
VCM_RH40_LPHNPs 0.97 1.95 1.95 3.9 3.9 7.8 
VCM_SH15_LPHNPs 1.95 1.95 1.95 3.9 3.9 3.9 
Blank_RH40_LPHNPs NA NA NA NA NA NA 
Blank_SH15_LPHNPs NA NA NA NA NA NA 
In vitro antibacterial activity at pH 6.0 
Time (h) 24 48 72 24 48 72 
S. aureus (MIC μg/ml) MRSA (MIC μg/ml) 
Bare VCM 3.9 3.9 7.8 7.8 15 15 
VCM_RH40_LPHNPs 0.97 1.95 1.95 0.48 0.97 0.97 
VCM_SH15_LPHNPs 1.95 1.95 1.95 0.48 0.97 1.95 
Blank_RH40_LPHNPs NA NA NA NA NA NA 
Blank_SH15_LPHNPs NA NA NA NA NA NA 
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NA = No Activity 1359 
 1360 
4.7 Conclusion 1361 
In addressing the global challenge of antibiotic resistance, novel biomaterials have been used in the 1362 
formulation of stimuli-responsive delivery systems to improve the efficacy of the existing antibiotics. In 1363 
this regard, a novel fatty acid-based zwitterionic lipid was successfully synthesized and its potential to 1364 
prepare VCM-loaded pH-responsive lipid polymer hybrid nanoparticles was explored. The biocompatibility 1365 
studies showed that zwitterionic DMGSAD-lipid is non-toxic for pharmaceutical and biomedical 1366 
applications. Stable LPHNPs were formulated with desired size, PDI, ZP and %EE. The pH-responsiveness 1367 
of LPHNPs was demonstrated by the change in surface charge and with higher VCM release at pH 6.0 1368 
when compared to pH 7.4. The in vitro antibacterial activity of the VCM_LPHNPs against MRSA at pH 1369 
6.0 was better than the antibacterial activity of VCM_LPHNPs and bare VCM at pH 7.4. Our findings 1370 
suggest that VCM_LPHNPs formulations provide a promising and rational strategy for stable and efficient 1371 
delivery of VCM to the site of infection characterized by low pH. This can potentially overcome the current 1372 
public health issues of antimicrobial drug resistance 1373 
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CHAPTER 5, 1513 
CO-AUTHORED PAPERS 1514 
5.1 Introduction  1515 
In addition to the first authored experimental papers in Chapters, 2, 3 and 4 focusing on aims 1, 2 1516 
and 3, I have also been involved in other papers within our group as a Ph.D. student. As these 1517 
papers also focused on the broad aim of this PhD project to improve treatment of bacterial 1518 
infections, these papers have been included in the thesis. This chapter therefore includes one 1519 
published experimental paper and one review article in an ISI International Journals: Colloids and 1520 
Surfaces B: Biointerfaces (Impact Factor = 3.973) and WIREs Nanomedicine & 1521 
Nanobiotechnology (Impact Factor = 7.689). 1522 
  1523 
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5.2 Co-authored paper 1 1524 
Self-assembled oleylamine grafted hyaluronic acid polymersomes for delivery of 1525 
vancomycin against methicillin resistant Staphylococcus aureus (MRSA) 1526 
Walvekar, Pavan, Ramesh Gannimani, Mohammed Salih, Sifiso Makhathini, Chunderika 1527 
Mocktar, and Thirumala Govender. Colloids and Surfaces B: Biointerfaces. 2019 Oct 1528 
1;182:110388. (Appendix II) 1529 
5.2.1 Abstract  1530 
MRSA infections are a major global healthcare problem associated with high morbidity and 1531 
mortality. The application of novel materials in antibiotic delivery has efficiently contributed to 1532 
the treatment of MRSA infections. The study aimed to develop novel hyaluronic acid oleyl amine 1533 
(HA-OLA) conjugates with 25-50% degrees of conjugation, for application as a nano-drug carrier 1534 
with inherent antibacterial activity. The biosafety of synthesized novel HA-OLA conjugates was 1535 
confirmed by in vitro cytotoxicity assay. The drug loading ability of HA-OLA conjugates was 1536 
confirmed by 26.1-43.12% of vancomycin (VCM) encapsulation in self-assembled polymersomes. 1537 
These polymersomes were dispersed in nano-sized range (196.1-360.9 nm) with a negative zeta 1538 
potential. Vancomycin loaded polymersomes were to found have spherical and bilayered 1539 
morphology. The VCM loaded polymersomes displayed sustained drug release for 72 h. In vitro 1540 
studies showed moderate antibacterial activity for HA-OLA conjugates against both S. aureus and 1541 
MRSA with minimum inhibitory concentration (MIC) of 500 μg/mL. The VCM loaded HA-OLA 1542 
polymersomes displayed four-fold lower MIC (1.9 μg/mL) than free VCM (7.8 μg/mL) against 1543 
MRSA. Furthermore, synergism was observed for VCM and HA-OLA against MRSA. Flow 1544 
cytometry showed 1.8-fold higher MRSA cell death in the population for VCM loaded 1545 
polymersomes relative to free drug, at concentration of 1.95 μg/mL. Bacterial cell morphology 1546 
showed that the drug loaded polymersomes had stronger impact on MRSA membrane, compared 1547 
to free VCM. These findings suggest that, HA-OLA conjugates are promising nano-carriers to 1548 
function as antibiotic delivery vehicles for the treatment of bacterial/MRSA infections. 1549 
  1550 
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5.3 Co-authored paper 2 1551 
Intrinsic Stimuli-Responsive Nanocarriers for Smart Drug Delivery of Antibacterial 1552 
Agents – An In-Depth Review of the Last Two Decades 1553 
Nikita Devnarain, Nawras Osman, Victoria Fasiku, Sifiso Makathini, Mohammed Salih, Usri 1554 
Ibrahim and Thirumala Govender. (2020). WIREs Nanomedicine & Nanobiotechnology. 1555 
Manuscript ID: NANOMED-651 (In Press). 1556 
5.3.1 Abstract  1557 
Antibiotic resistance due to suboptimal targeting and inconsistent antibiotic release at bacterial 1558 
infection sites has driven the formulation of stimuli-responsive nanocarriers for antibacterial 1559 
therapy. Unlike conventional nanocarriers, stimuli-responsive nanocarriers have the ability to 1560 
specifically enhance targeting and drug release profiles. There has been a significant escalation in 1561 
the design and development of novel nanomaterials worldwide; in particular, intrinsic stimuli-1562 
responsive antibiotic nanocarriers, due to their enhanced activity, improved targeted delivery and 1563 
superior potential for bacterial penetration and eradication. Herein, we provide an extensive and 1564 
critical review of pH-, enzyme-, redox- and ionic microenvironment-responsive nanocarriers that 1565 
have been reported in literature to date, with an emphasis on the mechanisms of drug release, the 1566 
nanomaterials used, the nanosystems constructed and the antibacterial efficacy of the nanocarriers. 1567 
The review also highlights further avenues of research for optimising their potential and 1568 
commercialisation. This review confirms the potential of intrinsic stimuli-responsive nanocarriers 1569 
for enhanced drug delivery and antibacterial killing.  1570 
 1571 
  1572 
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CHAPTER 6. 1573 
CONCLUSION: 1574 
6.1 General conclusions  1575 
One of the greatest challenges facing modern medicine is the common occurrence of antibiotic-1576 
resistant bacterial pathogens, which have reached an alarming level throughout the world, with 1577 
available treatment options gradually becoming ineffective to treat multi-drug resistant bacteria. 1578 
The nano-drug delivery approach has been recognized as one of the most promising strategy to 1579 
improve clinical failures of conventional antibiotic therapies by demonstrating considerable 1580 
potential in restoring the effectiveness of existing antibiotics against bacterial infections. Hence, 1581 
there is a high demand for advanced biomaterials to design novel drug delivery systems that can 1582 
improve pharmacokinetic properties of drugs, contribute to enhance their antibacterial efficacy and 1583 
to counteract AMR development. Therefore, the broad aim of this study was to design and 1584 
synthesize pH-responsive fatty acid-based lipid materials, as well as explore their potential for the 1585 
preparation of novel lipid-based pH-responsive delivery systems to treat S. aureus and MRSA 1586 
infections. The specific research aims of this study were therefore, to: (1) synthesize four novel 1587 
two chain fatty acid-based lipids (FAL) and employ them to deliver VCM via pH-responsive 1588 
liposomes against S. aureus and MRSA infections; (2) synthesize novel biocompatible pH-1589 
responsive oleic acid-based dendritic lipid amphiphile and explore their potential to deliver VCM 1590 
via pH-responsive micelles against S. aureus and MRSA infections, and (3) to synthesise novel 1591 
fatty acid-based bi-tailed pH-responsive zwitterionic DMGSAD-lipid and explore their potential 1592 
to deliver VCM via pH-responsive LPHNPs against S. aureus and MRSA infections. 1593 
The main conclusions generated from the research data are summarised below: 1594 
Aim 1  1595 
• Four novel pH-sensitive two chain fatty acid-based lipid derivatives (stearic, oleic, linoleic, 1596 
and linolenic acid derivatives) were successfully synthesized, and their structures were 1597 
confirmed using FT-IR, 1H and 13C NMR and HRMS. 1598 
▪ Di -Stearoyl Amino Propionic acid tert-butyl Ester (DSAPE) 1599 
▪ Di - Oleoyl Amino Propionic acid tert-butyl Ester (DOAPE) 1600 
▪ Di- Linoleoyl Amino Propionic acid tert-butyl Ester (DLAPE) 1601 
▪ Di- LinoLenoyl Amino Propionic acid tert-butyl Ester (DLLAPE) 1602 
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• The cytotoxicity study using MTT assay on three different mammalian cell lines i.e., 1603 
adenocarcinoma alveolar basal epithelial cells (A549), liver hepatocellular carcinoma 1604 
(HepG2) cell lines and human breast adenocarcinoma (MCF7), showed that the 1605 
synthesized lipids were biosafe.  1606 
• The synthesized four lipids were used in the formulation of VCM-loaded pH-responsive 1607 
liposomes. The formulated liposomes were stable with mean vesicle diameters and PDI of 1608 
between 86.28 ± 11.76 to 282 ± 31.58 nm and 0.161 ± 0.003 to 0.151 ± 0.016 to 0.204 ± 1609 
0.014 at different pHs, respectively. The ZP values were negative at physiological pH (7.4) 1610 
and shifted towards positivity with a decrease in pH. The %EE and loading capacity were 1611 
in the range of 29.86 ± 4.5% and 44.27 ± 9.2%, respectively. The VCM release increased 1612 
and was more sustained at acidic pH than at the physiological pH. 1613 
• Enhanced antibacterial activity at pH 6.0 was observed for the DOAPA-VAN-Lipo and 1614 
DLAPA-VAN-Lipo formulations. Flow cytometry studies indicated a high killing rate of 1615 
MRSA cells using DOAPA-VAN-Lipo (71.98%) and DLAPA-VAN-Lipo (73.32%) at the 1616 
MIC of 1.59 µg/ml. In vivo studies showed reduced MRSA recovered from mice treated 1617 
with formulations by 4- and 2-folds lower than bare VAN-treated mice, respectively. 1618 
Aim 2  1619 
• Novel pH-responsive oleic acid-based dendritic lipid amphiphile (OLA-SPDA) was 1620 
successfully synthesized and structurally confirmed using FT-IR and 1H and 13C NMR. 1621 
• Cytotoxicity studies performed using an MTT assay on three mammalian cell lines, HEK-1622 
293, human liver hepatocellular carcinoma (HEP G2) and adenocarcinoma human alveolar 1623 
basal epithelial (A549) revealed that the synthesized OLA-SPDA lipid is biosafe. 1624 
• pH-responsive oleic acid-based dendritic lipid amphiphile self-assembled into stable 1625 
micelles with particle size, PDI, ZP and %EE of 84.16 ± 0.184 nm, 0.199 ± 0.011 and -1626 
42.6 ± 1.98 and 78.80 ± 3.26%, respectively. The micelles demonstrated pH-1627 
responsiveness with an increase in particle size to 141.1 ± 0.070 nm and a much faster 1628 
release profile at pH 6.0, as compared to pH 7.4 (84.16 ± 0.18 nm). The in vitro VCM 1629 
release from micelles was sustained compared to free VCM. 1630 
• The MIC of VCM-OLA-SPDA-micelle against MRSA was 8-fold lower compared to bare 1631 
VCM, and the formulation had a 4-fold lower MIC at pH 6.0 when compared to the 1632 
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formulation’s MIC at pH 7.4. MRSA viability assay showed the micelles had a percentage 1633 
killing of 93.39% when compared bare VCM (58.21%) at the same MIC (0.98 µg/ml). In 1634 
vivo mice (BALB/c) skin infection models showed an 8-fold reduction in MRSA burden 1635 
after treatment with VCM-OLA-SPDA-micelles when compared with bare VCM. 1636 
Aim 3 1637 
• The successful synthesis of novel fatty acid-based bi-tailed pH-responsive zwitterionic 1638 
DMGSAD-lipid was confirmed using FT-IR and 1H and 13C NMR. 1639 
• The cytotoxicity studies performed using an MTT assay on three mammalian cell lines, 1640 
cervical cancer cell lines (HeLa), human breast adenocarcinoma (MCF-7) and human 1641 
embryonic kidney cells 293 (HEK 293) confirmed the synthesized DMGSAD-lipid to be 1642 
biosafe for in vivo application. 1643 
• Screening of surfactant revealed that using RH40 and HS15 gave the optimal formulation 1644 
of LPHNPs. 1645 
• The optimize formulations RH40_VCM_LPHNPs and SH15_VCM_LPHNPs showed pH-1646 
responsiveness through a significant change in surface charge from 0.55 ± 0.14Vm to 9.44 1647 
± 0.33 Vm and from -1.55 ± 0.184 to 9.83 ± 0.52 Vm at 7.4 and 6.0, respectively.  1648 
• The in vitro VCM release from LPHNPs was sustained compared to free VCM. 1649 
• The antibacterial efficacy of VCM loaded LPHNPs was 8 fold better at pH 6.0 when 1650 
compared to pH 7.4. 1651 
The findings of this study, therefore, confirmed that the synthesized novel lipids were biosafe for 1652 
biomedical applications. These lipids displayed great potential in the formulation of lipid-based 1653 
nano-carriers to encapsulate antibiotics (VCM) and treat S. aureus and MRSA infections more 1654 
efficiently than the free drug under acidic conditions. In addition to their ability to encapsulate 1655 
therapeutic agents, these novel materials also hold great potential in delivering any drug class for 1656 
the treatment of a variety of infections characterized by acidic conditions. The additional 1657 
experimental paper presented in Chapter 5 as a co-author, confirmed the potential of a novel self-1658 
assembled polymeric conjugate (HA-OLA) for the treatment of bacterial infections. Also, the 1659 
review article in Chapter 5 elucidates the potential of different intrinsic stimuli-responsive 1660 
nanocarriers for the treatment of bacterial infections.   1661 
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6.2 Significance of the findings in the study  1662 
The newly synthesized materials and designed nano-formulations, VCM-loaded pH-responsive 1663 
liposome, micelles and LPHNPs were successfully employed to address the limitations associated 1664 
with conventional dosage forms of antibiotics and antibacterial resistance. The significance of the 1665 
findings in this study include the following: 1666 
New pharmaceutical products: This study has generated new pharmaceutical materials, i.e., two 1667 
chain fatty acid-based lipid derivatives (DSAPE, DOAPE, DLAPE and DLLAPE), OLA-SPDA 1668 
and fatty acid-based bi-tailed DMGSAD-lipid. This will expand the range of the available 1669 
pharmaceutical excipients for preparing new medicines, which can stimulate local pharmaceutical 1670 
industries to manufacture superior cost-effective medicines 1671 
Improved patient therapy and disease treatment: The newly designed VCM-loaded pH-1672 
responsive liposome, micelles and LPHNPs nanosystems were formulated successfully with 1673 
improved antibacterial efficacy against S. aureus and MRSA infections. These novel nano-systems 1674 
lowered the MIC of the loaded drugs significantly and can effectively control the infection with 1675 
reduced dosing frequency without affecting therapeutic outcomes at low pH conditions. These 1676 
findings, therefore, prove the potential of these novel lipid nano-systems in improving patient 1677 
therapy and treatment of bacterial infections, and thereby ultimately improving the quality of 1678 
patients’ lives as well as save lives.  1679 
Creation of new knowledge to the scientific community: The various studies and their findings 1680 
have contributed to the pharmaceutical sciences knowledge database in several ways. These 1681 
include the following: 1682 
• New synthetic pathways, characterization and determination of the toxicity profiles of 1683 
novel two chain fatty acid-based lipid derivatives (DSAPE, DOAPE, DLAPE and 1684 
DLLAPE), OLA-SPDA and DMGSAD-lipid were developed. The in vitro and in vivo 1685 
evaluation of drug-loaded nano-systems can add to the conception of new knowledge. 1686 
• Formulation and process parameters of VCM-loaded pH-responsive liposomes, VCM-1687 




• By combining novel materials having intrinsic antibacterial activity and an antibiotic, a 1690 
strategy for achieving synergistic antibacterial activity in nano-vesicular form was 1691 
described. 1692 
• For all the pH-responsive formulations, VCM-loaded liposome, VCM-OLA-SPDA-1693 
micelles and VCM-LPHNPs, there was a correlation of results generated from the 1694 
antimicrobial activity study through in vitro MIC determination and in vivo antibacterial 1695 
mice infection models of the developed novel nano-drug delivery system. 1696 
Stimulation of new research: The research findings of the various studies and the successful 1697 
development of VCM-loaded pH-responsive liposomes, micelles and LPHNPs can stimulate new 1698 
research areas, including the following: 1699 
• The newly synthesized novel two chain fatty acid-based lipid derivatives (DSAPE, 1700 
DOAPE, DLAPE and DLLAPE), OLA-SPDA lipid and DMGSAD-lipid can be utilized 1701 
for delivering other classes of drugs to treat various disease conditions, such as cancer, 1702 
HIV/AIDS, fungal infections, gene therapy-related diseases and metabolic diseases. 1703 
• Besides bacterial infections, pH-responsive liposomes, OLA-SPDA-micelles and LPHNPs 1704 
can also assist to treat other diseases that are associated with low pH conditions, such as 1705 
tumors  1706 
• Delivery of antibiotics using an antibacterial nano-carrier can contribute to combination 1707 
therapy in combating bacterial infections more effectively. 1708 
6.3 Recommendations for future studies 1709 
Although VCM-loaded pH-responsive liposomes, VCM-OLA-SPDA-micelles, VCM-LPHNPs 1710 
displayed great prospects as novel nano-drug delivery systems to eradicate the problem of bacterial 1711 
resistance, additional studies are necessary to further explore and improve their potential to ensure 1712 
eventual regulatory approval for patient use. The following studies are proposed: 1713 
• In the case of VCM-loaded pH-responsive liposomes, molecular dynamic (MD) 1714 
simulations could be performed to show the binding affinity of the positively charged 1715 
liposome surface to a negatively charged bacterial membranes. 1716 
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• The successfully developed liposome, micelles and LPHNPs for VCM delivery can be 1717 
loaded with different classes of antibiotics and tested against various bacterial strains to 1718 
evaluate their synergism and advantages over different antibiotics. 1719 
• Simultaneous delivery of multiple antibiotics from these nano-systems can be explored to 1720 
achieve enhanced and synergistic activities. 1721 
• Encapsulation of multiple hydrophilic as well as hydrophobic drugs in these vesicular 1722 
nano-systems can be explored. 1723 
• Application of these lipids as surfactants to stabilize other nanoparticulated systems such 1724 
as SLNs, PLNs etc., can be studied. 1725 
• Further studies including cytotoxicity studies using macrophages and other cell lines is 1726 
recommended 1727 
• In vivo intravenous infection model, bioavailability and pharmacokinetic studies followed 1728 
by clinical trials on both the developed nano-systems could be performed to achieve 1729 
approval for market introduction. 1730 
• In vivo acute, intermediate and long-term toxicity study models can be performed to 1731 
determine the full toxicological profile of the material and the formulations reported in this 1732 
study. 1733 
• Antibacterial testing using VRSA could be performed to evaluate the enhanced efficacy of 1734 
our novel nanomaterials. 1735 
• A method for the bulk production of the nano-systems presented in this study could be 1736 
developed to enable their applications for pharmaceutical industries. 1737 
 1738 
6.4 Conclusion 1739 
The findings of this study therefore specifically demonstrate the potential of the newly developed 1740 
pH-responsive liposomes, OLA-SPDA-micelles and LPHNPs as nano-carriers having inherent 1741 
antibacterial activity as well as their drug delivery potential, for improving the treatment of S. 1742 
aureus and MRSA infections. This current research has therefore made significant contributions 1743 
to nano-based approaches to overcome limitations of current/conventional dosage forms. The 1744 
study further directed a way towards the synthesis of novel pH-responsive lipid materials to 1745 
develop multifunctional nano-systems to treat bacterial infections characterized by low pH 1746 
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conditions. The understanding of novel antibacterial materials and nanotechnology to address the 1747 
current global antibiotic drug therapy crisis will be dependent on future intensive and 1748 
multidisciplinary research. This strategic approach will play a vital role in improving the treatment 1749 
of bacterial infections as well as other diseases that are associated with bacterial infections, thereby 1750 
saving lives and improving the quality of lives of communities. 1751 
 1752 
 1753 
  1754 
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